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ABSTRACT
Classical swine fever (CSF) is a devastating disease that poses one of the greatest 
risks to the swine industry worldwide. Existing live attenuated CSF virus (CSFV) 
vaccines, such as the C-strain, provide a rapid onset of complete protection, but their 
application is limited due to an inability to discriminate infected amongst vaccinated 
animals. Many studies have aimed to develop marker sub-unit vaccines, but they 
frequently fail to show an appropriate level of efficacy for use under emergency 
outbreak conditions. An understanding of the immunological basis of rapid 
protection afforded by C-strain vaccine would aid the development of the next 
generation of marker CSFV vaccines. The first part of the study explored the 
interaction of porcine natural killer (NK) cells and yÔ-T cells with CSFV. Results 
suggest that is unlikely that these cells directly contribute to the cellular effector 
mechanisms induced by live attenuated CSFV, but rather they are modulated by the 
type I interferon (IFN) response triggered by CSFV infected plasmacytoid dendritic 
cells. Secondly, T cell responses following vaccination and subsequent challenge 
infections with virulent CSFV were characterised. The CD3’*’CD4'CD8^^^ T cell 
population was the first and major source of CSFV-specific IFN-y and these cells 
were further characterised as CD107a^CD44^‘^ CD62L', expressing variable levels of 
CD25 and CD27 and subpopulations eo-expressed tumor necrosis factor alpha (TNF- 
a) and interleukin 2 (IL-2). Finally, the specificity of virus-specific CDS T cells was 
investigated by screening a peptide library spanning the CSFV C-strain vaccine 
polyprotein to identify and characterise CDS T cell epitopes. The results revealed 
immunodominanee in the CDS T cell response against CSFV, with antigen- 
specifieity dependent on major histocompatibility complex class I (MHC-I)
haplotype. It is hoped that the data generated by this study will inform on-going 
efforts to develop a safe and effective marker vaccine to improve the control of CSF.
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CHAPTER 1. INTRODUCTION
23
1.1 CLASSICAL SWINE FEVER
Classical swine fever (CSF), formerly called hog cholera, is a contagious and 
often fatal disease of domestic pigs and wild boars. It is economically one of the 
most important viral infectious diseases of domestic pigs and is classified as a 
notifiable disease of The World Organisation for Animal Health (OIE). Classical 
swine fever outbreaks can cause huge economic damage and impair national and 
international trade of pigs and pig products (Dong and Chen, 2007; Moennig, 2000). 
Only some member states of the EU, Australia, Canada, New Zealand and the United 
States of America have succeeded in eradicating this virus, while CSF is endemic in 
South East Asia, Latin America and the former Union of Soviet Socialist Republics 
(USSR). Recently, outbreaks emerged in South Africa (2005), Lithuania (2009 and 
2011) and Latvia (2012) (Dong and Chen, 2007; OIE 2013). The distribution of CSF 
from January 2012 to January 2013 is illustrated in Figure 1.1.
/ ' 4 M D O I E  O  ; 0  I Ï  I
I I No inform ation  
m  Never reported 
m i l  Not reported in th is  period 
m i  Suspected
Clinical D isease  
m i , ^ i . s  ea s e'l i m itS f to ^ 'n  e"o r mSreTzones 
-Current d is e a s e  event
Figure 1.1 Worldwide distribution of CSF from January 2012 to January 2013.
Figure taken from http://web.oie.int (disease and distribution maps).
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The etiological agent of CSF is the classical swine fever virus (CSFV), a member of 
the Pestivirus genus within the Flaviviridae family (Thiel et al., 1991). Natural hosts 
of CSFV are members of the family Suidae, with both domestic pigs and European 
wild boars fully susceptible to CSFV infection. As such, endemic infection in wild 
boar populations represents an important virus reservoir that poses a constant threat 
to domestic pigs (Laddomada, 2000). CSFV infection occurs via the oro-nasal route, 
through direct or indirect contact with infected pigs or by the consumption of 
contaminated feed, e.g. swill. In areas with a high density of pigs, virus spreads 
easily between neighbouring pig holdings (Fritzemeieij et al, 2000). Disease 
transmission via the semen of infected boars may also occur (Floegel et al, 2000).
Typically the incubation period for CSF is 7-10 days, however under field 
conditions symptoms may only become evident 2-4 weeks after virus introduction. 
The severity of clinical signs depends on the age of the animal and the virulence of 
the virus strain. In older breeding pigs the course of the infection is often mild or 
subclinical, whereas, piglets up to 12 weeks of age most often display an acute form 
of CSF (Moennig et al, 2003). CSF is characterized by pyrexia, which can exceed 
39.5°C in adults and 40°C in piglets. Other early signs include anorexia, lethargy, 
conjunctivitis, enlarged and discoloured lymph nodes, respiratory signs and 
constipation followed by diarrhoea. Neurological signs are also frequently seen, such 
as staggering gait with weakness of hind legs, in-coordination of movement and 
convulsions. The typical haemorrhages of the skin are usually observed on the ear, 
tail, abdomen and the inner side of the limbs during the second and third week after 
infection up until death. In the acute course of the disease, death occurs 2-3 weeks 
after infection (Moennig, 2000). Leukopenia and immunosuppression are often
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caused by CSFV and lead to secondary infections. In the chronic form of CSF, the 
initial signs are similar to acute infection but later predominantly non-specific signs 
are observed, e.g. intermittent fever, chronic enteritis and wasting. Animals may 
survive for 2-3 months before they die (Moennig et al, 2003). The virus is shed fi*om 
the infected animal in saliva, urine and faeces (Laevens et al, 1999).
CSFV is able to cross the placenta of pregnant animals and can infect 
foetuses during all stages of pregnancy. The outcome of transplacental infection of 
foetuses differs depending on the time of gestation and the virulence of the strain. 
Infection during early pregnancy may result in abortion, stillbirth, mummification 
and malformations, that will lead to a reduction in the fertility index in the holding 
(Moennig, 2000). Infection of sows fi*om about 50-70 days of pregnancy can lead to 
the ‘late onset CSF’. Infection before the onset of immune competence, which is 
estimated at 70 days gestation, results in the birth of persistently viraemic piglets, 
which may be clinically normal at birth and survive for several months. After birth 
they may show some clinical signs, such as poor growth, wasting and occasionally 
congenital tremor. These piglets at the time of infection are not immunocompetent 
and recognise CSFV as a “self’ antigen, so do not mount an adaptive immune 
response against the pathogen and shed the virus for 6-12 months before dying. This 
situation is comparable to cattle persistently infected with the related pestivirus 
bovine viral diarrhoea virus (BVDV), which are the primary reservoir for BVDV 
infection in cattle herds (Moennig et a l, 2003).
Different pathological findings can be observed in CSF infected animals. In 
the early phases of ontogenesis, the virus affects organ differentiation and leads to 
malformations. In postnatal infections, lesions are generally caused by thrombosis
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and/or endothelial damage, inducing haemorrhagic diathesis and petechial bleeding. 
Pathological changes are most often observed in lymph nodes, spleen and kidneys, 
with lymph nodes becoming swollen, oedematous and haemorrhagic. Different sizes 
of haemorrhages, from petechiae to ecchymosis may be observed in the kidney. 
Petechiae can also be found in the urinary bladder, larynx, epiglottis and heart and 
may be widespread over the serosae. Bronchopneumonia is another common feature 
and in a high proportion of fatal cases non-suppurative encephalitis is a consistent 
■finding, probably due to secondary infections (Moennig, 2000).
1.2 CLASSICAL SWINE FEVER VIRUS
CSFV belongs to the genus Pestivirus, together with BVDV and border 
disease virus (BDV) of cattle and sheep, respectively (Francki et a l, 1991). CSFV is 
a small (40-60 nm in diameter) enveloped positive stranded RNA virus (Thiel et al,
1991). In cell culture, most CSFV strains and isolates are non-cytopathic and do not 
induce apparent changes in infected host cells (Moennig et al., 2003). The major 
target cells for CSFV in vivo are endothelial cells, leukocytes and some epithelial 
cells, like the tonsillar crypt epithelial cells (Moennig et al, 2000).
The CSFV genome is 12.3 kilobases (kb) in length and possesses a non-capped 5’ 
untranslated region (UTR), a large single open reading frame (ORF) and a 3’ UTR 
without a poly(A) tail. The ORF serves as messenger RNA (mRNA) for the synthesis 
of a single polyprotein of about 3900 amino-acids, which is cleaved by host cellular 
and viral proteases during and after its translation. CSFV has four structural proteins 
(the core protein C and envelope glycoproteins El and E2) and eight non- 
structural proteins (Npro, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) (Thiel et
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al., 1991, Rumenapf et al., 1993). The genome and proteome organization of the 
virus structure are illustrated in Figure 1.2.
CSFV genome:
1RES Polyprotein open-reading frame
CSFV proteins: 
I
■ D D
Npro I Core E""' El E2 
I
Non I 
Structural | Structural
D □
p7 NS2 NS3 NS4A NS4B NS5A NS5B
Non structural
Figure 1.2 The genome and proteome organisation of CSFV. The genome 
encodes a single polyprotein which is cleaved by host and viral proteases to produce 
12 proteins. The location of structural and non-structural proteins is indicated.
Like other pestiviruses, CSFV entry into a host cell is a process characterized 
by attachment of virions to receptor molecules (which remain to be identified), 
internalization and membrane fusion. After entry, the virus replicates in the cytosol 
and CSFV RNA can be detected from 4 to 6 hours after infection (Rumenapf and 
Thiel, 2008). Viral protein synthesis is initiated in a cap-independent manner by an 
internal ribosome entry site (1RES), located in the 5' UTR, which directly binds the 
40S ribosomal subunit without the requirement for a translation initiation factor 
(Pestova et al, 1998). New viruses are assembled in intracellular vesicles, located on 
membranes of the endoplasmic reticulum, and are released by exocytosis (Rumenapf 
and Thiel, 2008).
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Npro is the first protein translated fi*om the genome and is a 23 kiloDalton 
(kDa) autoprotease, which rapidly cleaves itself from the downstream core protein 
(Thiel et al., 1991). Npro contributes to CSFV evasion of the host innate immune 
response by preventing double-stranded RNA-induced apoptosis (Johns et a l, 2010) 
and counteracts type I interferon (IFN) induction by blocking interferon regulatory 
factor (IRF) 3 activity (Ruggli et al., 2005, La Rocca er al, 2005).
The core protein is thought to be involved in the cycle of the virus, due to its 
interaction with IQGAPl, a pivotal element in cytoskeleton regulation (Gladue et al, 
2011). Recently, it has been shown that this protein is not essential for virus 
propagation in vitro, but is important for its virulence in vivo (Riedel et al., 2012).
The three envelope proteins (E"^ % El and E2) are processed from a precursor 
E012 protein in an ordered fashion (Rumenapf et al, 1993). El and E2 are anchored 
to the envelope by their carboxyl termini, with E™^ loosely associated with the 
envelope. E“ ® and E2 reside on the outer surface of CSFV virions and are involved in 
attachment to susceptible cells and viral entry. Weiland et al. (1999) showed that the 
glycoprotein E™^ is located at the surface of infected cells. E™® is essential for virus 
propagation and represents a structural component of the pestivirus particle and a 
target for non-neutralizing antibodies. E™^ is a unique pestivirus glycoprotein, not 
found in other Flaviviruses, and exhibits RNase activity. This ability to catalyze the 
degradation of RNA into smaller components probably has a role in viral 
pathogenesis, since Meyers et al (1999) showed that mutations abrogating the 
RNase activity of E™^ led to virus attenuation. E™ i^s a heavily glycosylated protein 
and Sainz et al. (2008) reported that modification of one of its glycosylation sites can 
attenuate virulence of CSFV in swine. Alteration of the N-linked glycosylation of the
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other structural proteins, El and E2, also leads to an attenuation of the virulent CSFV 
strain Brescia (Femandez-Sainz et al, 2009, Risatti et al, 2007). The glycoprotein 
E2 is the most immunogenic protein of CSFV and most neutralizing antibodies are 
directed to it (Weiland et a l, 1990). E2 is also a major CSFV virulence determinant 
and Risatti et a l (2005) showed that the replacement of the E2 gene in the h i^ ly  
pathogenic strain Brescia with the E2 gene from the vaccine C-strain resulted in 
significant attenuation in vivo. In 2007, Risatti et al mapped the amino acids 
mediating this attenuation by constructing a series of Brescia viruses containing 
defined amino acid substitutions from the C-strain E2 sequence. Attenuation was 
observed when at least 12 amino-acid substitutions were introduced near the 
carboxyl terminus of E2 glycoprotein (Risatti et al, 2007). P7 is a small protein, 
which exists in two forms (E2-p7 and p7) and has an apparent molecular mass of 6 to 
7 kDa. Both forms of p7 are found in CSFV infected cells, however neither is 
detectable in mature virions (Elbers et a l, 1996). Recently, Gladue et a l (2012) 
demonstrated that p7 is a viroporin, with the pore-forming functionality residing in 
the carboxyl half of the protein, and showed it is required for CSFV virulence in 
swine and is critical for virus production in cell culture (Gladue et al, 2012).
Little is known about the role of the non-structural protein NS2, although it 
was recently reported that NS2 is able to activate the nuclear transcription factor 
kappa B (NF-kB), which promotes interleukin (IL)-8 expression and up-regulation of 
the anti-apoptotic protein Bcl-2 (Tang et al, 2011). These results suggest that NS2 
may be involved in the inflammatory response induced by CSFV infection and 
protection against host-cell apoptosis. The non-structural protein NS3 has a RNA 
helicase domain, which can promote IRES-mediated and cellular translation (Xiao ét
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al., 2008). This protein is highly conserved among pestiviruses and induces non­
virus-neutralising antibody responses. NS3 is also a potent T cell antigen, inducing 
lymphoproliferation, IFN-y production and cytotoxic T cell (CTL) responses (Rau et 
al., 2006). NS3 also possesses a proteinase domain whose catalytic activity is 
required for processing at non-structural protein cleavage sites NS3/NS4A, 
NS4A/NS4B, NS4B/NS5A and NS5A/NS5B. The NS4A protein is also thought to 
contribute to down-stream cleavage at the NS4B/5A and NS5A/5B sites (Xu et al.,
1997). The NS4B protein contains a putative Toll/interleukin-1 receptor (TIR)-like 
domain which may contribute to immune evasion (Femandez-Sainz et a\., 2010). 
TIR domains participate in the signal transduction of Toll-like receptors (TLRs), 
which are a large family of proteins that play essential roles in recognizing microbial 
components and activating the innate immune system (Kawai et ah, 2009). 
Femandez-Sainz et al. (2010) showed that mutations in this TIR-like domain led to 
an enhancement of transcriptional activation of TLR-7-induced genes, particularly 
IL-6, in swine macrophages and attenuation of CSFV in swine. These results suggest 
that NS4B interferes with TLR-7 activity during CSFV infection and this contributes 
to immune evasion (Femandez-Sainz et al., 2010). •
It has been recently reported that NS4B is involved in viral RNA replication 
and probably acts synergistically with E2 to influence viral replication efficacy in 
vitro and CSFV pathogenicity m vivo (Tamura et al., 2012). Little is known about the 
functions of NS5A and NS5B. It has been reported recently that both NS5A and 
NS5B interact with the 5’UTR, modulating CSFV replication (Sheng et al., 2012). 
NS5A is also able to decrease CSFV IRES-mediated translation in a dose-dependent 
manner (Xiao et al., 2009) and this effect is suppressed by NS5B, through a NS5A-
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NS5B interaction (Sheng et al., 2012). These two proteins might have an important 
role in the CSFV life cycle, regulating the level of viral translation and replication 
(Sheng fl/., 2012).
Phylogenetic analysis of CSFV strains originating from different continents allowed 
the division of CSFV into three genetic groups with several subgroups: 1.1, 1.2, 1.3; 
2.1, 2.2, 2.3; 3.1, 3.2, 3.3, 3.4 (Baton et al, 2000). Three regions of the CSFV 
genome, located on the 5’UTR, E2 and NS5B, were used to discriminate between 
isolates and to segregate viruses into genetic groups (Baton et al, 2000). All CSF 
virus isolates detected in the EU since the 1990s belonged to the group 2, which is 
further divided into different subgroups: 2.1, 2.2 or 2.3. These isolates were clearly 
distinct from earlier CSF reference viruses, which belonged to group 1. Group 1 
appears to be circulating only in Russia and isolates belonging to group 3 occur only 
in Asia (Moennig fl/., 2003).
1.3 VACCINATION AND CONTROL OF CLASSICAL SWINE FEVER
In 1904, the causative agent of CSF was proved to be a virus but not a bacterium 
(Schweinitz et al, 1904), which led to development of the first-generation vaccines, 
consisting of virus and serum. In. 1936, a vaccine was produced by inactivating 
CSFV virions from the blood of infected pigs using crystal-violet. Unfortunately, 
these early vaccines showed poor safety and efficacy (Saulmon, 1973) and in the 
1940s experiments were undertaken to attenuate CSFV by adapting it to rabbits 
(Moennig, 2000). From 1954-1955, Zhou and colleagues successfully prepared a 
stable lapinized CSFV, by attenuating the virulent Shimen strain by 214 passages
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through rabbits. After a further 266 passages, the strain was made available for 
commercial use. Since 1957, this lapinized strain has been widely used in the 
mainland of China and was called the Chinese vaccine or C-strain (Dong and Chen, 
2007). Scientists also attempted to attenuate CSFV by serial passages through cell 
culture at low temperature (29-30°C), developing the Thiverval strain from the 
virulent Alfort strain and the Japanese guinea-pig exaltation-negative (GPE ) strain 
from the virulent strain ALD. With this method the virus lost its virulence, but not its 
ability to replicate and trigger the immune system. At present, the routinely used 
CSF vaccines are all live attenuated vaccines, including C-strain, GPE', Thiverval 
and their derivative strains (van Oirschot, 2003). It is generally accepted that C-strain 
is very safe for pigs of any age or breed. It was shown that no vertical transmission 
occurred after inoculation of pregnant sows with C-strain and immunization of sows 
of 1 to 3 months into pregnancy did not result in stillbirths or abortions (Qiu et al., 
1999, Wang et al., 1996). Studies have shown that there is very little likelihood for 
C-strain to revert to virulence, even if it is subject to serial passage in pigs (Wang et 
al., 1996). Many researchers have shown the protective efficacy of C-strain to be 
near 100% in a variety of different challenge models (Qui et al., 2006). As a 
consequence, C-strain vaccines are used in many endemic countries and play an 
important role in controlling CSF epidemics in domestic pigs (Dong and Chen, 
2007). It has been suggested that it could be the vaccine of choice for an emergency 
vaccination protocol, as it can rapidly stop the spread of the field virus (van Oirschot, 
2003, Graham et al., 2012a). However, the antibody response induced by C-strain 
vaccines is indistinguishable from that of infected or convalescent animals. The 
inability to use serological methods to discriminate vaccinated from field virus-
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infected animals is a major disadvantage to their use to control CSF outbreaks in 
non-endemic countries (Moennig, 2000). In many CSF endemic countries, such as 
India and Russia, prophylactic C-strain vaccination is still carried out to avoid/reduce 
economic losses (Paton et al, 2003).
From the epidemiological point of view, persistent problems in some European 
Union (EU) Member States have been due to endemic infection of CSF virus in wild 
boar populations. The infection has spread sporadically to domestic pigs either by 
direct contact or through unregulated swill feeding (Edwards et a l, 2000). Swill 
feeding is another important epidemiological factor, and has been responsible for the 
introduction of CSF into previously disease-free areas. Swill can include CSFV 
infected meat and the virus has the ability to survive in a variety of meat products 
(Weiland et al, 1999). Legislation requires that swill should be cooked before 
feeding to swine (Edwards et a l, 2000). Cooking or pasteurizing pig meat inactivates 
CSFV and studies have shown meat to be non-infectious after treatment at either 
65°C for 30 minutes or 71°C for as little as 1 minute (Helwig et a l, 1966; Terpstra et 
al, 1976). The structure and density of pig populations have a considerable influence 
on the control of CSF. In recent years high pig concentrations have built up in 
several regions of Europe and the probability of spreading the disease after a primary 
outbreak in those areas is much higher than in areas with lower pig densities. 
Outbreaks in areas with high pig densities often lead to extensive epidemics with 
most severe economic losses, like the disastrous 1997/1998 epidemic in the 
Netherlands (Paton et al, 2003). That epizootic, with 429 outbreaks, was controlled 
after 14 months without vaccination, but its direct costs, excluding export losses, 
were estimated at United Stated Dollars (US$) 2 billion (Terpstra et a l, 2000).
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In the case of CSF outbreaks in domestic pig populations, a strict stamping 
out strategy without prophylactic vaccination is applied within the EU, with killing 
of affected herds and those in proximity. The EU aims to completely eradicate CSF 
in Europe and the legislative control for the disease was first introduced in 1980 and, 
with some amendments, is still in force today (Edwards et al., 2000). During the 
1980s, the Member States moved from a diversity of national control policies 
towards a common, community wide approach based on the cessation of vaccination, 
notification of outbreaks, harmonized control measures, uniform diagnostic 
procedures, contingency plans, establishment of epidemiological units and financial 
support. The control zones around an outbreak are based on geographical and 
epidemiological principles, and take no account of national boundaries between the 
member states (European Union, 1980, Edwards et ah, 2000). Although emergency 
vaccination was not prohibited by the EU Council Directive 80/217/EEC, it has 
rarely been applied in EU, because of the severe economic consequences. According 
to this directive and its amendments, in case of an emergency vaccination, vaccinated 
pigs must not be traded and their products are not allowed to enter international trade 
(except for heat-treated meat) (van Oirschot, 2003).
The incidence of CSF in the EU has, become very low raising the prospect of 
elimination. Nevertheless, the virus has been periodically reintroduced in the EU, 
with outbreaks of CSF in wild boar and domestic pigs including in Austria (1995), 
Belgium (1997), Germany (1995-1998), Italy (1995-1998), Spain (1997-1998), the 
Netherlands (1997-1998) (Edwards et al., 2000), the United Kingdom (UK) (2000) 
(Gibbens et al, 2000), Lithuania (2009 and 2011) and Latvia (2012) (OIE 2013). 
Once an outbreak becomes an extensive epizootic, the costs of control rise and
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imposing strict control measures becomes increasingly difficult (Edwards et ah, 
2000). For example, during the outbreak of the 1997/1998 in the Netherlands, 1300 
herds were slaughtered pre-emptively and 8,830,536 uninfected pigs were killed for 
welfare reasons caused by the movement ban (Stageman et al., 2000).
In conclusion, the stamping-out policy to control CSF outbreaks may be very 
expensive due to the large numbers of animals have to be pre-empitvely culled in 
order to minimize the spread of virus, or, culled for welfare reasons during the 
imposition of animal movement bans (Greiser-Wilke and Moenning, 2004). Public 
resistance against drastic measures such as destroying thousands to millions of 
healthy pigs is also growing. As a consequence, the use of emergency vaccination 
will become more likely in the near future (van Oirschot, 2003). To 
prevent/minimise virus spread and to protect neighbouring herds (Risatti et al, 
2007). To address this, significant efforts have been made towards the development 
of marker vaccines and the corresponding diagnostic tests that allow the 
differentiation of infected from vaccinated animals (DIVA) (Greiser-Wilke and 
Moenning, 2004).
1.4 CSFV MARKER VACCINES
A marker or DIVA vaccine may possess at least one antigenic protein or 
epitope less than the field virus, ‘negatively marked’, or carry a unique antigenic 
sequence absent from field virus, ‘positively marked’ (van Oirschot, 2003). 
Emergency vaccination with a marker vaccine and a corresponding serological 
diagnostic test is Ian effective strategy for reducing the size of an epidemic and would 
be a better alternative than a vaccination policy using conventional live attenuated
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vaccines (Greiser-Wilke and Moenning, 2004). A candidate marker vaccine should 
meet a series of minimal demands including: not having any side effects to 
immunized animals; not representing a potential danger to immunized animals or 
animals of different species after possible genetic recombination; being stable, cheap 
and easy to produce under standardized protocols; inducing a quick onset of a long 
and solid immunity; inducing a broad immunity against all virus variants; conferring 
protection that prevents a “carrier” state; preventing both vertical and horizontal 
transmission of the virus; and having a highly sensitive and specific differentiating 
diagnostic test (Dong and Chen, 2007).
The differentiating diagnostic test discriminates between vaccinated and 
infected animals by measuring antibodies against a protein that is absent or present in 
the marker vaccine (Dong and Chen, 2007). Since the early 1990s, many attempts 
have been made to develop new marker vaccines against CSFV and various 
strategies and methods have been studied, such as recombinant chimeric vaccines, 
recombinant deletion vaccines, DNA vaccines, subunit protein vaccines and peptide 
vaccines (Beer et al., 2007).
1.4.1 Live viral vector vaccines
To create a recombinant chimeric viral vaccine, some attenuated viruses, 
harmless to the host, are used as delivery vectors for foreign target genes that allow 
expression of the immunogenic antigen within the cells of the vaccinated host. With 
such systems, it is relatively easy to differentiate the antibody pattern of infected and 
vaccinated animals with an ELISA (Beer et al., 2007). Both vaccinia virus, 
pseudorabies virus (PRV), porcine and human adenovirus were used as vectors in
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which CSFV genes were inserted (Rumenapf et al, 1991, Peeters et a l, 1997, 
Hammond et al, 2000, Sun et al, 2012). The suitability of these recombinant viruses 
to provide rapid protection, as would be required in an outbreak setting, is yet to be 
evaluated. A promising approach has been to use BVDV strains as potential live 
vectors for a CSFV marker vaccine. Two chimeric pestiviruses were constructed: 
CP7_E2alf and CP7_E2gif, where the E2 coding region of strain CP7 (a 
cytopathogenic BVDV strain avirulent for pigs) was replaced by that of CSFV strain 
Alfort 187 or BDV strain Gifhom, respectively (Reimann et a l, 2004, Rasmussen 
al, 2005). Both chimeric strains were innocuous for pigs and a single vaccination 
was sufficient to achieve complete protection from lethal challenge and prevent 
horizontal transmission (Reimann et a l, 2004, Rasmussen et a l, 2005). Recently, it 
has been reported that CP7_E2alf is able to provide clinical protection against 
challenge with virulent CSFV Koslov in piglets with maternally derived C-strain 
antibodies (Rangelova et a l, 2012). This recombinant vaccine is also able to protect 
pigs against CSFV challenge from only 7 days after vaccination, preventing the 
development of CSFV clinical signs and virus transmission to contact pigs, so it 
appears at present to be the most promising CSFV DIVA vaccine candidate (Eblè et 
al, 2012). The only disadvantage of CP7_E2alf is that it might revert to virulent 
viruses or show negative features, such as changes in tissue or species tropism (Beer 
et a l, 2007). Possible recombination with BVDV wild strains could lead to the 
development of disease in cattle.
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1.4.2 Recombinant deletion vaccines
The partial or complete deletion of a gene can lead to the creation of a marker 
vaccine, which is normally more attenuated than the parental strain. Different 
proteins of CSFV were analysed as targets to develop deletion vaccines. Only the 
deletion of E2 or NS3 can induce an antibody pattern distinct from that of the 
field virus and E^ ® and E2, which are the major immunogens of CSFV, are the better 
analysed targets to develop a CSFV recombinant deletion vaccine (Dong and Chen, 
2007). Several E™^ and E2 deletion mutants were constructed, but these vaccines 
were unable to provide rapid protection (Widjojoatmodjo et al., 2000, van Gennip et 
al. 2002, Frey et al, 2006).
Substitution of E“ ® or E2 genes is another strategy to develop CSFV negative 
marker vaccine, van Geppin et al. (2000) constructed two chimeric CSF viruses 
(Flc9 and Flcll), based on an infectious complementary DNA (cDNA) copy of the 
CSFV C-strain. They replaced the antigenic region encoding sequences E2 (Flc9) or 
E™® (Flcll) gene with the analogous sequences from the genotype 2 BVDV strain 
5250. These strains were genetically stable and induced the production of antibodies 
specific for the respective BVDV antigens, which failed to recognise the CSFV 
antigens, even after repeated vaccination. Moreover, these strains induced complete 
protection against a lethal CSFV challenge even 1-2 weeks after vaccination (van 
Geppin et a l, 2000, de Smith et al, 2001). A disadvantage of these marker vaccines 
is that pre-existing antibodies against BVDV E2 or E™® in pigs may disturb the 
immunization with Flc9 or Flcl 1 (Dong and Chen, 2007).
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1.4.3 DNA vaccines
DNA vaccines are generally considered safer than live attenuated vaccines, 
because there are no risks of possible recombination with the field virus. Only the 
most immunogenic protein of the pathogen is inserted into the plasmid vector, so all 
the candidate DNA vaccines against CSFV were aimed at inducing cellular and 
antibody responses against E2 (Beer et al., 2007). Initially the cDNA of the E2 
glycoprotein was cloned into the plasmid vector pCI (Andrew et al., 2000). Later, in 
order to enhance the immunogenicity of E2-based DNA vaccines, genes coding for 
porcine IL-12 or IL-18 or CD40 ligand (CD 154) were included in these recombinant 
vaccines (Wienhold et al., 2005). In other studies the E2 glycoprotein was cloned 
into the plasmid pcDNAS.l and this DNA vaccine was able to elicit both T cell 
responses and neutralizing antibodies (Ganges et al., 2005, Tarradas et al, 2010). 
However, high doses and multiple vaccinations were necessary to gain satisfactory 
protection and this is a limit for their use in emergency vaccination programs 
(Andrew et al, 2000, Wienhold et al, 2005, Tarradas et al, 2010).
1.4.4 Subunit vaccines
A subunit vaccine is usually composed of only one purified or recombinantly 
expressed antigenic protein fi-om the pathogen. A vaccine based on baculovirus 
expressed E”®^ was shown to confer minimal protection (Moormann et al., 1996). In 
contrast, baculovirus expressed E2 glycoprotein was shown to be a potent 
immunogen by different groups and this formed the basis of two licensed vaccines: 
BAYOVAC® CSF Marker manufactured by Bayer and Porcilis®Pesti manufactured 
by Intervet (Greiser-Wilke and Moennig, 2004). Unfortunately, these vaccines are
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able to prevent virus transmission only from 10 days (BAYOVAC®) or 14 days post­
vaccination (Porcilis®Pesti), whereas the C-strain vaccine induces clinical protection 
less than one week after vaccination (Bouma et al, 2000; Dewulf et a l, 2004; 
Graham et al, 2012a). This drawback will complicate the possible use of these 
subunit vaccines in emergency vaccination programs. In an attempt to enhance the 
onset of protective efficacy of a subunit E2 vaccine, Toledo et al (2010) evaluated 
the immunogenicity and efficacy of subunit E2 vaccine co-adminstered with 
recombinant porcine IFN-a. This cytokine, in addition to having a direct anti-CSFV 
effect, plays a role in the development of adaptive immune response by stimulating 
maturation of dendritic cells and acting as a survival factor for activated T cells, 
which play an important role in protection against CSFV. Animals vaccinated with 
E2 antigen alone showed a partial protection against CSFV when the challenge was 
performed 7 days after vaccination, whereas pigs immunized with the co-formulation 
containing both E2 and IFN-a were fully protected against a challenge performed 7 
days later. Such a subunit vaccine formulation may be useful under outbreak 
conditions due to its ability to confer rapid protection (Toledo et a l, 2010).
1.4.5 Peptide vaccines
If delivered with the appropriate formulation/adjuvant, synthetic peptides are 
able to elicit a high titer of peptide-specific neutralizing antibodies, which are 
produced soon after immunization (Dong and Chen, 2007). Multimerization is an 
effective strategy to increase the immunological response to peptides. The creation of 
complexes of two or more peptides held together by non covalent bonds can enhance 
peptide presentation and result in an increase activation of the host immune system
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(Tam et al, 1988). Dong et al. (2005) produced a multi-peptide-vaccine (MPV) 
against CSFV, where five overlapping peptides from B/C units of E2 from CSFV 
strain Shimen were linked to bovine serum albumin (BSA) and absorbed into 
aluminium adjuvant. This vaccine conferred full protection to immunized pigs and 
the specific antibody levels that developed after vaccination allowed the 
discrimination between vaccinated and infected animals. However multiple 
vaccinations were performed in order to achieve protection, limiting the use of this 
vaccine in emergency vaccination programmes (Dong et al, 2005). Both neutralizing 
antibody epitopes and T-cell epitopes are promising components for candidate 
peptide vaccine against CSFV, so Monso et al. (2011) constructed a CSFV 
dendrimeric peptide, where they integrated B and T antigenic sites located on E2 and 
NS3 of CSFV and this construct induced the production of both neutralizing 
antibodies and IFN-y producing cells (Monso et a l, 2011). Recently Tarradas et al. 
(2012) showed that a dendrimetric construct including both a T cell epitope (located 
on NS3) and B cell epitopes induced a higher level of protection than the 
dendrimetric systems incorjporating only B cell epitopes However, only partial 
protection against experimental infection was achieved with this construct (Tarradas 
et al., 2012). To date, peptide vaccines are not suitable promising CSFV vaccine 
candidates.
From these many different approaches to CSFV DIVA vaccine development, it 
appears that the chimeric pestivirus CP7_E2Alf is the most promising candidate by 
virtue of its ability to rapidly confer complete protection. However, there are safety 
concerns over this genetically modified virus. Another concern pertains to its
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reliance on detection of Ems antibodies for DIVA discrimination. Unfortunately, the 
antibody response to the E™® protein in vaccinated and subsequently infected animals 
is much lower than that induced against the E2 protein and tests to detect this low 
level of E™® are not yet sensitive or specific enough (Schroeder et a l, 2012). 
Therefore, there is merit in continuing to explore new avenues towards the 
development of a CSFV DIVA vaccine.
1.5 IMMUNOLOGY OF CSF
As described above, the lapinized C-strain vaccine has contributed greatly to 
the control of CSF by right of its desirable safety and efficacy (Qui et al, 2006). The 
major disadvantage of this live-attenuated vaccine is that it poses problems in 
discriminating infected among vaccinated animals and this limits its application in 
non-endemic regions. Nevertheless, it is important to analyze the immunological 
mechanisms that underlie immunity to CSFV and the rapid protection afforded by C- 
strain vaccines since this information is important in underpinning efforts to develop 
the next generation of CSFV vaccines.
1.5.1 CSFV and Innate Immunity
CSFV infection displays a variety of effects on innate immune cells. 
Monocytes are the major targets for CSFV infection in the peripheral blood, although 
in later stages infection of granulocytes has also been observed (Summerfield et al,-
1998). As stated above, viral up-take involves binding to receptors (Rumenapf and 
Thiel, 2008). The related pestivirus BVDV binds to the receptor CD46, which 
promotes entry of the virus (Krey et a l, 2006), but currently no information is 
available for CSFV.
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CSFV has developed several strategies to evade the host innate immune 
system. As described above, the nonstructural protein Npro prevents double-stranded 
RNA-mediated apoptosis in infected cells (Ruggli et ah, 2005). Infected monocytes 
are prevented from undergoing programmed cell death, so they are probably 
responsible for the dissemination of the infection through the host. Instead, CSFV 
induces apoptosis, indirectly, of uninfected bystander cells, with consequent 
development of leukopenia (Summerfield et al., 1998). The mechanisms behind 
CSFV induced apoptosis are still not well defined. It has been reported that the 
glycoprotein E™® can induce lymphocyte apoptosis (Bruschke et al., 1997), but 
another study suggested that the high levels of IFN-a, detectable after infection with 
virulent CSFV strains, are responsible to apoptosis of bystander cells (Renson et al., 
2010). Renson er al. (2010) reported that virulent CSFV strains up-regulate 
apoptosis-related IFN stimulated genes (ISG) in lymphocytes, with differences 
between highly and moderately virulent strains. Another study showed that the 
induction of the tumor necrosis factor-alpha-related apoptosis-inducing ligand 
(TRAIL) by CSFV infected dendritic cells (DCs) is linked to CSFV induced 
lymphopenia (Durand et al., 2009). Severity of leukopenia varies according to the 
strain virulence and depletion of T and B lymphocytes is induced rapidly, detectable 
even before the onset of viraemia (Summerfield et al.., 2001). No leukopenia can be 
detected after vaccination with the C-strain (Graham et al, 2010), suggesting that 
leukopenia is probably a strategy to promote CSFV survival in the host and the live 
attenuated vaccine has lost this ability.
CSFV is able to replicate in dendritic cells (DCs), which are professional 
antigen-presenting cells (APCs) that play an important role in the induction of
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adaptive immune responses, by processing antigens, expressing lymphocyte co­
stimulatory molecules, migrating to lymphoid organs and secreting cytokines 
(Banchereau et al, 1988). DCs can broadly be divided into two subpopulations: 
conventional or myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), the latter 
specialized in rapidly secreting large amounts of type I interferon following viral 
stimulation (Liu, 2005). Both subsets are susceptible to CSFV infection, they mature 
and are activated upon infection, as demonstrated by up-regulation of co-stimulatory 
molecules CD80/86 and secretion of cytokines (Jamin et al., 2009). IFN-a 
production by infected mDC is inhibited by the blocking of IRF3 by Npro (Ruggli et 
al., 2005, La Rocca et al., 2005). CSFV, however, is not able to inhibit virus induced 
IFN-a production by infected pDCs, due to the lower interference by Npro with 
IRF7, more prominent in pDCs (Fiebach et al., 2008). Moreover, it has been recently 
been shown that interaction of CSFV-infected cells with bystander uninfected pDCs 
induces greater IFN-a production compared to direct infection of pDCs (Python et 
al., 2013). It has been proposed that the exacerbated pDC-derived IFN-a response is 
responsible for the apoptosis of bystander lymphocytes, through up-regulation of 
their apoptosis-related IFN stimulated genes (ISG) (Renson et al., 2010).
Little is known about the effect of CSFV on natural killer (NK) and yô-T 
cells, which are two major lymphocyte populations of the innate immune system. NK 
cells have the ability to attack pathogen-infected and malignant cells and to produce 
immunostimulatory cytokines such as IFN-y (Gemer et al., 2009). These cells are 
triggered to kill or ignore cells (cancer cells and virus-infected cells) depending on a 
balance of inhibitory and activating signals received through ligands on potential 
targets. Although some viruses can directly trigger NK cells, like influenza virus
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through the hemaggluinin-NKp46 receptor binding (Mandelboim et al, 2001) or 
murine cytomegalovirus via the m l57 glycoprotein-Ly49 receptor interaction (Smith 
et al, 2002), activation of these cells by most pathogens is led by accessory cells, 
which release cytokines and provide contact-dependent signals to NK cells (Newman 
et al, 2007). Mature mDCs are a major source of IL-12, which increases NK 
cytotoxicity and production of cytokines such as TNF-a and IFN-y (Trichieri, 2003), 
and are able to release IL-15, which has a critical role in NK cell survival, expansion 
and function (Fehniger and Caligiuri, 2001). The cross-talk between NK cells and 
DCs is bidirectional and activated NK cells can further maturate DCs, enhancing 
their ability to stimulate T cell responses (Gerosa et al, 2002).
yô-T cells represent another significant lymphocyte population originally 
defined as effector lymphocytes of the innate immune system but now being 
regarded, like NK-cells, as also playing an important role in the activation and 
regulation of immune responses. yô-T cells express a subtype of T cell receptor 
(TcR) different from the conventional ap TcR and display characteristics of both T 
cells and cells of the innate immune system. They recognize conserved non-peptide 
antigens that are up-regulated by stressed cells, by both TcR and non-TcR molecules, 
such as TLRs and NK receptors (NKRs). Like NK cells, the balance between 
activating and inhibitory signals regulates the yô-T cell response (Bonneville et al, 
2010). yô-T cells show several different functions, because they are involved in 
different immunological processes. They are able to release perforin and granzymes 
and kill infected or malignant cells (Dieli et a l, 2001). Moreover, these cells can 
produce cytokines, such as IFN-y and TNF-a, involved in the protection against 
viruses and other intracellular pathogens, or cytokines that contribute to the
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protection against extracellular parasites (IL-4, IL-5 and IL-13), extracellular bacteria 
(IL-17) and also immunosuppressive cytokines (Transforming Growth Factor (TGF)- 
p and IL-10) (Bonneville et al., 2010). Activation of yô-T cell responses may 
therefore be direct or indirect, mediated by the interaction with APCs, such as DCs, 
through release of pro-inflammatory cytokines and expression of ligands for yô TcR 
and NKRs (Devilder et al., 2009). In turn, IFN-y produced by yô-T cells enhances 
IL-12 production by DCs, which can then promote the development of type-I ap T 
cells (Devilder et al., 2009). Moreover, in humans it has been shown that these cells 
not only interplay with APCs, such as DCs, but also display characteristics of 
professional antigen presenting cells themselves (Brandes et al, 2005). In swine, yô- 
T cells act both as cytotoxic cells and professional APCs. They can express CD8a 
and major histocompatibility complex (MHC) class II molecules, which in swine 
seem to be correlated with T cell activation (Gemer et al, 2009). These cells 
represent the major T cell subpopulation within peripheral blood particularly in 
young pigs. Their percentage decreases with age but they remain in circulation in 
large numbers (Yang fl/., 1996).
Currently, no information is available on the role of NK and yô-T cells in the 
immune response against CSFV, so this study aimed to characterise the interaction of 
these cells with CSFV and the results are described in Chapter 3 of this thesis.
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1.5.2 CSFV and Adaptive Immunity
Antibody Responses
Vaccination with C-strain vaccines induces the production of virus- 
neutralizing antibodies, which usually appear about two weeks after vaccination and 
levels increase until at least 4-12 weeks (Terpstra et a l, 1990). As previously stated, 
antibodies are directed against the envelope proteins E™®, E2 and the non-structural 
protein NS3 (Beer et al., 2007). Both immunoglobulin M (IgM) and G (IgG) 
antibody are produced against CSFV, and as expected E2-specific IgM antibody can 
be detected earlier than specific IgG antibody (Li et al, 2013). Piglets bom firom 
non-immune sows can be vaccinated fi*om two weeks of age and it has been shown 
that neutralising antibodies can persist in these animals until the age of slaughter. 
The presence of matemal antibodies at the time of vaccination, however, interferes 
with the development of a protective antibody response (Terpstra and Tielen, 1976), 
probably because the vaccine is neutralised by the matemally-derived antibodies 
before the development of a protective immune response. Terpstra and Wensvoorf 
(1988) observed a relationship between vaccine-induced antibody titres against 
CSFV and protection against vims dissemination, excretion, transmission, disease 
and death in a study where antibody titres were measured by the neutralisation 
peroxidase-linked assay (NPLA). This is a test with high capacity in large scale 
surveys for the detection of neutralizing antibody against CSFV (Terpstra et al., 
1984). The correlation between vaccine-induced antibody titres against CSFV and 
protection against vims was observed when challenges were not performed early 
after vaccination. From an epidemiological point of view, the authors observed that, 
using the NPLA, titres lower than 32 were inadequate to protect against CSFV
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challenge (Terpstra and Wehsvoort, 1988). There are different data regarding the 
persistence of neutralising antibodies in vaccinated pigs. While neutralising 
antibodies against CSFV can persist for many years after a single vaccination, they 
also wane and disappear in some pigs. Terpstra and Tielen (1976) observed that most 
of the sows vaccinated once 1-3 years earlier were not able to respond with an 
increase in antibody titre after a second vaccination (Terpstra and Tielen, 1976). 
Some sows that had been vaccinated 6 years earlier had no or very low neutralising 
antibody titres, but did not show any signs of disease after challenge. These data 
suggest that other immunological mechanisms, such as T cell responses, are also 
involved in protection against CSF following C-strain vaccination (van Oirschot, 
2003).
T cell Responses
T lymphocytes play a central role in the antigen-specific immune response 
against various pathogens. Porcine T cells can be broadly divided into a number of 
subpopulations, including yô-T cells (previously described in 1.5.1), MHC class I 
restricted cytotoxic CD8  ^T cells, MHC class II restricted CD4^ T-helper cells and 
regulatory T cells (Gemer et al, 2009).
CD 8^  T cells contribute to resistance against intracellular infections with certain 
viral, protozoan, and bacterial pathogens. Although they are known primarily for 
their capacity to kill pathogen-infected, transformed, or allogeneic cells, they 
elaborate a variety of effector mechanisms with the potential to defend against 
infection. They recognise class I MHC-assoelated peptides, which are usually 
derived from cytosolic, endogenously synthesized proteins. CD4^ T cells play a
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major role in instigating and shaping adaptive immune responses. They recognize 
class II MHC-associated peptides, which derived mainly from endocytosed proteins 
(Abbas and Lichtman, 2005). Recognition of peptide-MHC complexes by the TCR is 
the first signal for activation and provides specificity to the subsequent T cell 
response. CD4 and CDS bind the non-polymorphic regions of MHO molecules and 
transduce signals that, together with signals delivered by the TCR complex, initiate T 
cells activation. Important for the activation of T cells is the engagement of 
molecules (e.g. CD28) on the T cell by co-stimulatory molecules expressed by 
mature mDCs {e.g. CD80 and CD86), and costimulatory signals provided by 
cytokines. In the absence of co-stimulation, T-cell receptor signalling alone results in 
anergy, a form of non-responsiveness (Abbas and Lichtman, 2005). Helper T cells 
(TH) are CD4^ T lymphocytes that aid in cell- and antibody-mediated immune 
responses. Once activated, TH cells proliferate and secrete cytokines and 
differentiate into one of several subtypes, the main represented by type 1 (THl) and 
type 2 (TH2) T helper cells. THl are involved in protection against intracellular 
pathogens and they provide signals to maximize the killing efficacy of macrophages 
and the proliferation of CD8  ^ T cells. The latter promote the stimulation of the 
humoral immune system, stimulating B-cells into proliferation, increasing the 
production of neutralizing antibodies and promoting B-cell antibody class switching 
to IgE (Mosmann et al., 1986). Porcine regulatory T cells have a phenotype similar to 
that of mouse and humans: CD4^CD25^Foxp3^. These cells can suppress 
proliferation of other T cells and produce IL-10 (Gemer et al, 2009). Pigs display a 
high percentage of extra-thymic double positive CD4^CD8^. These cells are 
considered to be activated or memory TH cells as they differ from CD4^CD8" T cells
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in their ability to respond to recall antigen in a secondary immune response 
(Saalmuller fl/., 1999).
Protection against CSF has been observed before the appearance of a humoral 
response (Dewulf et al., 2004), but not before IFN-y secreting cells are evident in 
peripheral blood, suggesting that cellular immunity is responsible for the rapid 
protection conferred by the C-strain vaccine (Suradhat et al., 2001). Different studies 
have suggested that C-strain virus is a potent inducer of a type-1 T cell response and 
IFN-y responses are a good indicator in cell-mediated responses to virus infection in 
pigs. Suradhat et al. (2005) analysed the kinetics of IFN-y production in lymphocyte 
subpopulations after vaccination with C-strain and showed that CD4^CD8^ T cells 
were the major producers of this cytokine. They observed that after exposure to 
virulent CSFV there was an increase in the number of IFN-y producing cells in both 
vaccinated and unvaccinated animals. In unvaccinated pigs both CD4^CD8^ (mature 
TH cells) and CD4'CD8^ (cytotoxic T cells) contributed to IFN-y production, while 
CD4'CD8^ T cells were the major IFN-y producers in the vaccinated group, 
suggesting that different immunological events occur after vaccination or challenge 
with virulent CSFV strain. Graham et al. (2012a) reported that only vaccinated pigs 
displayed virus-specific IFN-y responses, detected from day 8 post-vaccination, 
whereas unvaccinated challenge control animals failed to mount a detectable 
response. In accordance with Suradhat Qt al. (2005), they reported that both antigen- 
experienced CD4 (CD4^CD8^) and cytotoxic CD 8 (CD4"CD8^) T cells were 
identified as the cellular source of IFN-y (Graham et al, 2012b). In another study, 
Graham et al (2010) also observed that the C-strain, but not the virulent strain 
UK20007.1, induced cell-mediated immune responses against CSFV. They observed
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that C-strain vaccination enhanced the development of IFN-y responses, which 
peaked at day 9 and remained elevated until the end of the experiment (day 21). In 
contrast, infection of unvaccinated animals with the virulent CSFV strain failed to 
generate a detectable IFN-y response, whereas cultures from these pigs showed 
increased levels of pro-inflammatory cytokines, such as TNF-a, IL-lp and IL-6. 
These pro-inflammatory cytokine responses may reflect a pathological pro- 
inflammatory cascade initiated in vivo following the dissemination of CSFV 
(Graham et al., 2010). Overall, there is a need to better identify the cellular source of 
CSFV-specific IFN-y and to characterize the cellular immune response against CSF. 
Studies on the related pestivirus BVDV showed that both CD4 and CDS T cell 
responses are evoked, with the former producing IL-4 and the latter IFN-y, 
suggestive that the major role for CD4 T cells is to mediate help for the induction of 
B cell antibody responses (Rhodes et al, 1999). Monoclonal antibody mediated cell 
depletion studies have shown that CD4 T cell depletion increased the duration of 
virus shedding, while CDS and yô T cell depletion had little effect, demonstrating the 
importance of CD4 T helper cells in mediating immunity to BVDV (Howard et al,
1992). However, the possible role of depletion of other CD4^ populations such as 
plasmacytoid dendritic cells was not addressed.
The correlation of IFN-y production in vaccinated pigs with markers of T cell 
activation was assessed only by Suradhat et al, who reported that the production of 
this cytokine was not tightly associated to the surface expression of the T cell 
activation marker CD25 (Suradhat et al, 2005). It has been reported that IFN-y 
exerts direct anti-viral effects on CSFV in vitro (Graham et al, 2012b) and that there 
is a close temporal correlation between the induction of CSFV-specific T cell IFN-y
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responses and rapid protection induced by a C-strain vaccine (Graham et a l, 2012a). 
Moreover, vaccine induced CSFV-specific T cells have been shown to have 
cytotoxic activity against infected cells, with specificity mapped to structural and 
non-structural proteins. Several studies were performed in order to identify targets of 
the T cell response. A MHC class I-restricted T cell epitope was identified on the 
cleavage site between NS3 and NS4a (ENALLVALF) (Pauly et al, 1995). The 
authors initially used target cells infected with recombinant vaccinia viruses 
expressing individual CSFV proteins, in order to identify proteins targets of the 
virus-specific T cell response. Later, using synthetic peptides, they identified the T 
cell epitope target of the CTL response (Pauly et al, 1995). Armengol et al (2002) 
identified another peptide recognized by CTL, KHKVRNEVMVHWFDD, located 
on NS2-NS3, using overlapping synthetic pentadecamers. The identified 
pentatecamer induced IFN-y release and was able to trigger a peptide-specific 
cytotoxic response (Armengol et al, 2002). Cytotoxic T cell epitopes were also 
identified on the glycoprotein E2. Ceppi et al (2005) transfected APCs with mRNA 
encoding this structural protein and they detected an E2-specific IFN-y and cytotoxic 
response in CSFV immunized pigs (Ceppi et a l, 2005). Unfortunately, most of these 
studies utilized inbred homozygous pigs so were focused on a single haplotype and 
the phenotype of the responding T cells/MHC restriction was not or only partially 
characterized (Pouly et al, 1995; Ceppi et al, 2005; Armengol et al, 2002).
Although recent research has provided new insight into the contribution of 
the cellular response in protection against CSFV, there is a need for further 
characterizion of this response. In summary, monocytes and other cells of the 
myeloid lineage are the major targets for CSFV infection and the virus prevents these
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cells from apoptosis. DCs are also susceptible to infection and the different DC 
subsets (mDCs and pDCs) respond with secretion of different cytokines to CSFV. 
The exacerbated pDC-derived IFN-a response may play an important role in the 
development of leukopenia after infection with virulent CSFV strains. A better 
characterization of the response of mDCs and pDCs to CSFV would help to 
understand how the disease develops after infection with virulent CSFV strains and 
how protective immune responses are induced by infection with the C-strain 
vaccine. The role of NK and yô-T cells in the immune response against CSFV has 
not been defined, instead several studies suggest that both CD4 and CDS T cell 
responses are evoked after vaccination with the C-strain vaccine and few MHC class
I-restricted T cell epitopes have been identified. However, the cell populations 
responsible for the release of CSFV-specific IFN-y, associated to the rapid protection 
conferred by the C-strain vaccination, have to be functionally and phenotypically 
defined and the viral targets of the IFN-y response has to be properly identified and 
characterised.
1.6 AIMS, HYPOTHESIS AND OBJECTIVES
There is a need to develop alternative strategies to improve the control of CSF 
outbreaks and minimize the need for mass culling. Live attenuated CSF vaccines 
provide a rapid onset of complete protection but pose problems in discriminating 
infected from vaccinated animals, and existing marker vaccines do not provide a 
suitable efficacy for use under emergency outbreak conditions. An imporved 
understanding of the immune mechanisms underlying the rapid protection afforded 
by C-strain vaccines will generate information to aid the development of the next
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generation of CSFV vaccines. Since C-strain vaccines provide complete protection 
before the appearance of neutralising antibody responses this study aimed to further 
characterize the host cellular responses triggered by this vaccine. The hypothesis that 
vaccination with C-strain CSFV induces IFN-y and cytotoxic responses, targeting 
both structural and non-structural components of the virus, which mediate rapid 
protection against CSFV, was investigated through the following three objectives:
1. To determine the interaction of C-strain and virulent CSFV with NK and yô-T 
cells (Chapter 3).
2. To conduct a detailed characterisation of C-strain induced CSFV-specific T 
cell responses (Chapter 4).
3. To identify and characterize the antigen specificity of the CSFV-T cell 
response (Chapter 5).
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CHAPTER 2. MATERIALS AND METHODS
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2.1 ETHICS STATEMENT
All animal work was approved by the Animal Health and Veterinary Laboratories 
Agency Ethics Committee and all procedures were conducted in accordance with the 
UK Animals (Scientific Procedures) Act 1986 under project licence permit numbers 
PPL 70/6559 and 70/7403. To minimise animal suffering, careful completion of 
clinical score sheets and regular observation were conducted. This informed 
euthanasia decisions based on a humane endpoint, which was pre-defined as either a 
total clinical score > 15 or a temperature > 41°C and more than 2 individual clinical 
scores reaching a value of 3. None of the animals in these experiments experienced 
clinical signs necessitating euthanasia. All animals were euthanized on pre­
determined days by either intramuscular administration of Ketamine/Rompun 
sedative followed by intravenous administration of 2 0 % sodium pentobarbitone 
solution or by electrical stunning followed by exsanguination.
2.2 SOURCE AND PREPARATION OF VIRUS STOCKS
A commercially available live attenuated C-strain CSFV (AC Riemser 
Schweinepestvakzine, Riemser Arzneimittel AG, Riems, Germany), the highly 
virulent CSFV strains Alfort 187 (AHVLA CSF reference laboratory virus archive, 
Addlestone, UK) and Brescia (kindly provided by Dr Alexandra Meindl-Bohmer, 
University of Veterinary Medicine, Hannover, Germany) and the moderately virulent 
UK2000/7.1 (a genotype 2.1 isolate the UK CSF outbreak in 2000) (Sandvik et al, 
2000) and CBR/93 (a genotype 3.3 isolate kindly provided by S. Parchariyanon) 
(Parchariyanon et al, 2000) strains were propagated in vitro by inoculation of sub­
confluent monolayers of a porcine kidney cell line (PK15). PK15 cells were
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maintained in Eagle’s Minimum Essential Medium (E-MEM) (Life Technologies, 
Paisley, UK) supplemented with 100 lU/ml penicillin, 100 pg/ml streptomycin (Life 
technologies. Paisley, UK) and 10% foetal bovine serum (FBS) (Autogen Bioclear, 
Caine, UK). After 4 days, the supernatant was collected and pooled with a freeze- 
thawed cell lysate. The resultant pool was clarified by centrifugation at 524 x g for 
10 minutes, aliquoted and stored at -80°C. Virus titres were obtained by serial 
dilution of the virus suspension on PK15 cells followed by immunoperoxidase 
staining to identify infection rates as previously described (Drew, 2008). Mock virus 
supernatant was prepared in an identical manner from uninfected PK15 cells.
2.3 SYNTHETIC CSFV PEPTIDES
A synthetic overlapping peptide library was designed, which comprised 
pentadecamer (15mer) peptides off-set by four residues. The peptide sequences were 
designed using the predicted polyprotein of CSFV C-strain Riems (GenBank 
accession number AY259122.1). The synthesized library of 945 peptides (JPT 
Peptide Technologies, Berlin, Germany) were reconstituted in sterile 40% 
acetonitrile (Sigma-Aldrich, Poole, UK) with O.IM N-2-Hydroxyethylpiperazine-N'-
2-Ethanesulfonic Acid (HEPES) (Life technologies. Paisley, UK) at a concentration 
of 1 mg/ml. For initial screening, peptides were combined into pools representing the 
structural and non-structural proteins of CSFV and diluted in Roswell Park Memorial 
Institute (RPMI)-1640 medium supplemented with 10% FBS, 100 U/ml penicillin 
and 100 pg/ml streptomycin (complete RPMI; cRPMI) and used at a final total 
peptide concentration of 1 pg/ml, unless otherwise stated. In order to identify the 
antigenic peptides from positive pools, a two-way matrix system was adopted to
58
screen peptides representing the non-structural proteins: NS5A, NS3, NS2 and the 
structural protein E2. The matrix pools were designed so that each peptide was 
uniquely present in 2 different pools. The 121 NS5A peptides were prepared in 22 
matrix peptide pools (A-V), the 110 NS2 peptides in 21 matrix peptide pools (A-U), 
the 168 NS3 peptides 26 matrix peptide pools (A-Z) and the 90 E2 peptides 19 
matrix peptide pools (A-S). After identification of the antigenic pentadecamers, 
truncated 8-11  mers of consensus antigenic sequences were designed, synthesised 
(JPT Peptide Technologies, Berlin, Germany), reconstituted and prepared as 
described above.
2.4 VACCINATION AND CHALLENGE OF PIGS WITH CSFV
In the first experiment (Experiment 1), 42 Large White/Landrace cross-breed pigs, 8 - 
10 weeks of age, were randomly assigned to four groups. The numbers of animals 
per group, the treatments administered and days that the animals were sampled and 
responses analysed are summarised in Table 1. Five days prior to challenge, animals 
in Groups 1 (n=6 ) and 2 (n=12) were inoculated intranasally with 10^  50% tissue 
culture infective dose (TCID50) of C-strain CSFV (1 ml divided equally between 
each nostril and administered using a mucosal atomization device MAD-300, Wolfe 
Tory Medical, USA). Group 3 animals (n=12) were inoculated with 2 ml of 
reconstituted vaccine into the brachiocephalous muscle (as recommended by the 
manufacturer, RiemserArzneimittel AG) and Group 4 (n=12) were intranasally 
inoculated with 1 ml of mock virus supernatant as described for Groups 1 and 2. On 
day 0 post-challenge. Groups 2-4 were inoculated intranasally with 10^  TCID50 of 
CSFV Brescia strain as described above and Group 1 received a similar inoculation
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of mock virus supernatant. On days -2 and 0 post-challenge, three animals were 
euthanized from Groups 2-4 and on days 2 and 5 post-challenge three animals were 
euthanized from all four groups and blood samples collected for analysis of CSFV- 
specific T cell responses.
Table 2.1 Experimental design of first CSFV vaccination/challenge experiment.
Experimental group
Days post-challenge
-5 - 2 0 3 5
1. Vaccine (i.n.) only 
(n=6 )
Vaccinated 
C-strain 10^  
TCID50 i.n.
Mock challenge 
i.n.
Phï/bleed
(n=3)
PM/bleed
(n=3)
2. Vaccine (i.n.) & 
challenge (n=1 2 )
PM/bleed 
(n=3) .
Challenge 
CSFV Brescia 
1 0  ^TCID50 i.n. 
PM/bleed (n=3)
3. Vaccine (i.m.) & 
challenge (n=1 2 )
Vaccinated 
C-strain 10^  
TCID50 i.m.
4. Challenge only 
(n=1 2 )
Mock
vaccination
i.n.
A second experiment (Experiment 2) utilized 11 Large White/Landrace pigs, 6  
months of age. Eight animals, designated AN5, AN7, AN8 , AN9, AN 10, ANll,  
AN 12, AN13, were vaccinated 5 days before challenge (day -5) by intramuscular 
inoculation with 10^  TCID50 of C-strain CSFV and challenged at day 0 and day 28 by 
intranasal inoculation of 10^  and 10^  TCID50 of CSFV Brescia, respectively, as 
described above. Three negative control animals received similar inoculations of 
mock virus supernatant on each occasion.
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Cryopreserved samples from a third previously conducted animal experiment 
(Experiment 3) were used, the experimental design/procedures of which were 
described previously (Graham et ah, 2010). In brief, 6 Large White/Landrace cross 
male pigs, 8-10 weeks of age were utilized. Four pigs were inoculated with 2 ml (100 
protective dose 50% (PD50) of the reconstituted C-strain vaccine into the 
brachiocephalous muscle (as recommended by the manufacturer, 
RiemserArzneimittel AG) and two unvaccinated pigs were used as negative controls 
and housed in a separated pen.
Cryopreserved retrospective samples from another experiment (Experiment 4) 
previously described (Graham et al, 2012a) were utilised to assess recognition of the 
identified T cell epitopes by additional C-strain vaccinated pigs. In brief. Large 
White/Landrace cross male pigs, 9 weeks of age, were vaccinated intramuscularly 
with 2 ml of reconstituted C-strain vaccine and after 3 or 5 days were challenged by 
intranasal inoculation of CSFV UK2000/7.1 or CBR/93 strains, with 10"^ '^  or 10^  ^
TCID50 respectively, as described above.
2.5 MONITORING OF VACCINATED AND CHALLENGED PIGS
2.5.1 Clinical parameters
Animals were inspected by AHVLA Animal Service Unit staff twice daily (am and 
pm) and 9 parameters relevant for indication of CSF (liveliness, body tension, body 
shape, breathing, walking, skin, eye/conjunctiva, appetite/leftover at feedings, 
defecation) were examined and scored as 0 (normal), 1 (slightly altered), 2  (distinct 
clinical signs), 3 (CSF symptoms), as previously described (Everett et a l, 2010). A 
total clinical score for each animal was assigned twice daily and temperatures were
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monitored by rectal thermometer readings and recorded once daily. For Experiment 
1, temperature and clinical score monitoring commenced on day -11 relative to 
challenge until the termination of the experiment (day 5 post-challenge) and for 
Experiment 2 they were monitored for 7 days before and after each of the CSFV 
Brescia inoculations.
2.5.2 Haematological parameters
Peripheral blood leukocytes were enumerated using flow cytometry (Everett et al., 
2010). In brief, 50pl Ethylenediaminetetraacetic Acid (EDTA) blood was incubated 
with 5pi of mouse anti-porcine CD45-FITC monoclonal antibody (mAb) (K252-1E4, 
AbD Serotec, Oxford, UK), as reported in Table 2, for 10 minutes at room 
temperature (RT) in the dark. 945pi of FACS Lysing solution (BD Biosciences, 
Oxford, UK) was added for 10 minutes at RT to lyse erythrocytes and fix leukocytes. 
Cell counts were obtained on a volumetric flow cytometer (MACSQuant Analyzer, 
Miltenyi Biotec, Gerisch Gladbach, Germany) by gating FITC positive events and 
leukocyte counts per pl/blood were obtained by multiplying the leukocyte density by 
the dilution factor (x 2 0 ).
2.5.3 Virological parameters
Total RNA was extracted from EDTA blood using the QIAamp Viral RNA mini 
extraction kit, according to the manufacturer’s protocols (Qiagen, Crawley, UK). 
CSFV viral copy numbers were assessed by quantitative reverse transcription PCR 
(RT-PCR), using the One-Step Superscript III Platinum kit (Life Technologies, 
Paisley, UK; Everett et al., 2010). Primers CSFIOO-F and CSF192-R were used at a
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concentration of 600 nM and the F AM-labelled CSF probe (Hoffinann et al., 2005) 
were used at 200 nM. The viral genome copy number was determined by comparison 
to a ten-fold serial dilution of a standard, which consisted of RNA transcribed from 
plasmid pCRXLV234-6, containing the 5’UTR of CSFV strain Alfort 187 (Everett et 
al, 2 0 1 0 ).
2.6 ISOLATION AND CRYOPRESERVATION OF PORCINE CELLS 
FROM BLOOD AND LYMPHOID TISSUES
2.6.1 Peripheral blood mononuclear ceils
Peripheral blood mononuclear cells (PBMC) were prepared by diluting 20 ml of 
heparinised blood in 10 ml of phosphate buffered saline (PBS) (Life Technologies, 
Paisley, UK), layering over 20 ml of Ficoll (Ficoll-Paque™ PLUS, GE Healthcare, 
Uppsala, Sweden) and centrifuged at 1455 x g for 30 minutes at room temperature 
(RT), without braking, in a rotating bucket centrifuge (Beckman Coulter, High 
Wycombe, UK). PBMC were aspirated from the plasma-Ficoll interface and washed 
three times in PBS by centrifugation at 930 x g for 5 minutes at 4°C. PBMC were re­
suspended in cRPMI and cell density was determined by analyzing 50 pi of cell 
suspension using a volumetric flow cytometer (Miltenyi Biotec, Bisley, UK) and 
gating on events with typical forward scatter (ESC) and side scatter (SSC) for 
PBMC. Cells were cryopreserved for later analyses as follows: PBMC were adjusted 
to a density 1-2x10^ cells/ml, re-suspended in cold (4°C) 10% dimethylsulfoxide 
(DMSO) (Sigma, Poole, UK) in FBS and transferred to pre-cooled (4°C) labelled 
cryotubes. These tubes were immediately transferred to a pre-cooled (4°C) Cryo 1°C 
Freezing Container (Nalgene, Fisher Scientific, Loughborough, UK) containing 250
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ml of 100% isopropyl alcohol (4°C), which was placed in a -80°C freezer for a 
minimum of 4 hours to a maximum of 24 hours. Cryotubes were then transferred to a 
liquid nitrogen storage container.
For subsequent analysis, cells were rapidly thawed in a 37°C water bath and washed 
in pre-warmed cRPMI. Cells densities were determined as described above, adjusted 
to 1x10  ^cells/ml and 100 pi transferred to wells of a 96 well round bottom microtitre 
plate (Costar, Fisher Scientific, Loughborough, UK) to perform flow cytometric 
analysis.
2.6.2 Tonsil and lymph node cells
Tonsils and medial and lateral retropharyngeal lymph nodes were dissected from pigs 
post-mortem. Lymphoid tissues, first separated from connective and epithelial 
tissues, were placed in a small volume of Hank's Balanced Salt Solution (HBSS) 
(Life Technologies, Paisley, UK) supplemented with 100 lU/ml penicillin and 100 
mg/ml streptomycin and chopped into fine pieces with sterile pointed scissors. 
Tissues were transferred to a 100 pm cell strainer (BD Biosciences, Oxford, UK) 
inserted in a 50 ml collection tube. A plunger from a 5 ml syringe was used to disrupt 
the tissues and HBSS was passed regularly through the cell strainer and the process 
continued until only connective tissue remained in the cell strainer. Cells were 
washed twice in HBSS and re-suspended in cRPMI. Cell numbers were determined 
using a MACSQuant Analyzer flow cytometer (Miltenyi Biotec, Gerisch Gladbach, 
Germany) and gating on events with typical forward scatter (FSC) and side scatter 
(SSC) for lymphocytes. Cells were adjusted to a density l-2xl0^cells/ml and
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cryopreserved as described in 2.6.1. For subsequent analysis, cryopreserved cells 
were revived as described in 2 .6 .1 .
2.7 QUANTIFICATION OF CSFV RNA IN TONSILS AND 
RETROPHARINGEAL LYMPH NODES
This analysis was kindly performed by Dr. Pedro Sanchez-Cordon and Dr. Felicity 
Haines, Department of Virology, AHVLA, New Haw, UK. To quantify CSFV RNA 
in tonsils and retropharyngeal lymph nodes, RNA was extracted from tissue 
homogenates. Briefly, ~200mg of tissue was homogenised in 4ml RTL buffer 
(Qiagen, Crawley, UK) using the Precellys® 24-Dual Tissue Homogeniser 
(Precellys, Stretton Scientific Ltd, Stretton, UK), 2 x 30 secs cycles at 6,000rpm. 
Tissue homogenates were clarified by centrifugation for 10 minutes at 1,000 x g  and 
RNA extracted using the RNEasy Maxi kit with the additional DNase treatment as 
per manufacturer’s instructions (Qiagen, Crawley, UK). CSFV RNA was quantified 
by qRT-PCR as described (Everett et al., 2010) and normalised to 18s RNA using 
the Eukaryotic 18S rRNA Endogenous Control (Life Technologies, Paisley, UK).
2.8 DETECTION OF TYPE I INTERFERON IN THE SERA OF 
VACCINATED AND CHALLENGED PIGS
Venous blood was collected in Serum Separation Tubes (BD Biosciences) and serum 
collected by centrifugation at 1500 x g for 10 minutes and stored at -80°C until 
analyzed. Type I IFN activity was determined using an Mx/chloramphenicol 
acetyltransferase (CAT) reporter gene assay originally developed for the 
quantification of bovine IFN-a/p (Fray et al, 2001). Serum samples were diluted to
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2 0 % (v/v) in serum-free tissue-culture medium and added to the reporter bovine 
kidney cells line MDBK-t2 for 24 hours. A titration of recombinant porcine IFN-a 
(R&D Systems, Abingdon, UK) was added as a standard. Lysates were prepared 
from the cultures and CAT enzyme was measured by ELISA (Roche, Welwyn 
Garden City, UK), according to manufacturer’s instructions. In brief, MDBK cells 
were washed and lysed by addition of a lysis buffer for 30 minutes at RT. After 
centrifugation (1500 x g for 5 minutes), clarified lysates were transferred to a pre­
coated ELISA plate and incubated for 1 hour at RT. Wells were washed and anti- 
CAT -DIGOXIGENIN (anti-CAT-DIG) was added and incubated for 1 hour at RT, 
then, after washing, anti-DIG-peroxidase (ANTI-DIG-POD) was added to the wells. 
After 1 hour of incubation, wells were washed and POD substrate was added and 
incubated at RT for 30 minutes. Absorbance was read using a FLUOstar OPTIMA 
microplate reader (BMG Labtech, Aylesbury, UK).
In bovine it has been shown that MDBK-t2 cells are able to detect also bovine type 
III IFNs (Dr. Bryan Charleston, Pirbright Institute, personal communication). 
However, no information are currently available on their ability to detect porcine 
type III IFNs.
2.9 ENRICHMENT OF PORCINE LEUKOCYTE SUBSETS USING 
MAGNETIC BEAD BASED AND FLOW CYTOMETRIC CELL SORTING
Heparinised venous blood was collected and PBMC were prepared as described in 
2.6.1. All the subsequent washes used centrifugation at 930 x g for 5 minutes, using a 
rotating bucket centrifuge.
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2.9.1 Dendritic cell enrichment
Porcine blood DC populations were enriched by two rounds of magnetic cell 
separation (CD 14 depletion and CD 172a enrichment) and purified populations 
isolated by subsequent flow cytometric sorting: PBMC were re-suspended in mouse 
anti-human CD 14 coated microbeads (10 pl/lO^cells, Miltenyi Biotec, Bisley, UK) 
and incubated at RT for 10 minutes. After two washes with 50 ml of PBS 
supplemented with 2% FBS, cells were re-suspended in PBS supplemented with 2% 
FBS and 5mM EDTA (MACS buffer; 1 ml/2.5xl0^ cells), passed through a cell 
strainer to eliminate clumps and applied to a MACS LD column on a QuadroMACS 
unit (Miltenyi Biotec, Bisley, UK). The column flow-through (CD 14" cells) and two 
washes of 3 ml MACS buffer were collected and washed in PBS with 2% FBS. 
Cells were then labelled with mouse anti-porcine CD 172a (74-22-15A, Washington 
State University Monoclonal Antibody Center (WSUMAC), Pullman, USA; 2 
pl/lO^cells) at RT for 10 minutes. Cells were washed, incubated with rat anti-mouse 
IgG-coated microbeads (10 pl/10^ cells, Miltenyi Biotec, Bisley, UK) and incubated 
at RT for 10 minutes. After a further two washes with 50 ml of PBS 2% FBS, 
CD172a+ cells were enriched using LS columns as described by the manufacturer 
(Miltenyi Biotec, Bisley, UK). To assess the purity of enriched DCs or to purify 
myeloid (mDCs) and plasmacytoid (pDCs) DCs, cells were labelled with mouse anti- 
porcine CD4-PerCP-Cy5.5 (74-12-4, BD Biosciences, Oxford, UK) and a lineage 
cocktail of mouse IgGl mAbs against porcine CD3 (8E6 , WSUMAC, Pullman, 
USA), CD8a (PT3613, WSUMAC, Pullman, USA) and CD21 (B-Ly4, BD 
Biosciences, Oxford, UK), followed by labelling with APC conjugated rat anti­
mouse IgGl antibody (X56, BD Biosciences, Oxford, UK). Details of all the
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antibodies used to stain surface markers are reported in Table 2.2. Purification of 
mDCs and pDCs was kindly performed by Dr. Jane Edwards, Virology Department, 
AHVLA, New Haw, UK. For sorting, cells were washed, resuspended at a density of 
10^  cells/ml in cRPMI and lineage CD4" mDCs and lineage CD4^ pDCs were sorted 
using a MoFlo Astrios Cell Sorter (Beckman Coulter, High Wycombe, UK) at the 
AHVAL Central Flow Cytometry Facility, New Haw, UK. After sorting, the purity 
and numbers of sorted populations was determined by flow cytometry. Cell densities 
were adjusted to 2x10^ cells/ml in cRPMI and transferred at 50pl/well to a round- 
bottom 96 well plate.
2.9.2 Monocyte enrichment
Porcine monocytes were enriched by positive magnetic sorting of PBMC labelled 
with mouse anti-human CD14 coated microbeads (10 pl/lO^cells, Miltenyi Biotec, 
Bisley, UK) and collection of the positive fraction following separation on a LS 
column. Cells were washed with 50 ml of PBS 2% FBS, cell density was adjusted to 
2x10^ in cRPMI and cells were added 100 pl/well to a round-bottom 96 well plate.
2.9.3 yô-T cell enrichment
Porcine yô-T cells were enriched by positive magnetic sorting of PBMC labelled 
with mouse anti-porcine mAb against TcRl-N4 delta chain (PGBL22A, WSUMAC, 
Pullman, USA; 10 pl/10^ cells), followed by rat anti-mouse IgG-coated microbeads 
and collection of the positive fi*action following separation on a LS column. Cells 
were washed with 50 ml of PBS 2% FBS, cell density was adjusted to 2x10^ or 4x10^ 
cells/ml and cells were added at 100 or 50 pl/well to a round-bottom 96-well plate.
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To assess purity, an aliquot of cells was stained with the mouse anti-porcine TcRl- 
N4 mAh conjugated to Zenon® Alexa Fluor® 405 as described by the manufacturer 
(Life technologies. Paisley, UK) and analysed by flow cytometry.
2.9.4 Natural Killer cell enrichment
Since there is no single discriminatory marker that identifies all porcine NK cells, 
CD3'CD8a^ NK cells were isolated by two rounds of magnetic sorting. PBMC were 
first depleted of T cells by incubating with a mouse anti-porcine CD3 mAb 
(BB238E6, Cambridge Bioscience, Cambridge, UK), followed by rat anti-mouse 
IgG-coated microbeads and collection of the flow-through and washes on an LD 
column as described above. The CD3 negative fraction was labelled with a mouse 
anti-pig CD8a (PT36B, WSUMAC, Pullman, USA) and after incubating with rat 
anti-mouse IgG-coated microbeads were enriched using an LS column. After sorting, 
the cell density was adjusted to 2x10^ or 4x10^ cells/ml and 100 or 50 pl/well 
transferred to wells of a round-bottom 96-well plate and purity was assessed after 
staining an aliquot with mouse anti-pig CD8a-PE (76-2-11, BD Biosciences, Oxford, 
UK) and anti-CD3-APC (BB238E68C8, BD Biosciences, Oxford, UK). Details of all 
the antibodies used to stain surface markers are reported in Table 2.2.
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2.10 IN VITRO CULTURE OF PBMC, DCS, MONOCYTES, NK AND yô-T 
CELLS WITH CSFV, CSFV PEPTIDES AND RECOMBINANT PORCINE 
CYTOKINES
2.10.1 Stimulation of PBMC with CSFV or CSFV derived peptides
Both freshly isolated and previously cryopreserved PBMC were used in experiments. 
Cell densities were calculated using flow cytometry as described in 2.6.1 and 
adjusted to 1x10  ^cells/ml and lOOpl transferred to wells of a 96-well round-bottom 
microtitre plate (Costar, Fisher Scientific, Loughborough, UK).
PBMC were stimulated with 100 pi of CSFV Alfort 187 strain at a multiplicity of 
infection (MOI) of 1 or with 100 pi of peptide pools or individual peptides at 1 
pg/ml, unless otherwise stated. Mock-virus infected PK15 supernatants/cRPMI 
medium and Concanavalin A (ConA, Sigma-Aldrich, Poole, UK) at 10 pg/ml were 
used as negative and positive controls, respectively. Cells were incubated at 37°C for 
two hours (peptide stimulation) or overnight (virus stimulation) and then Brefeldin A 
(GolgiPlug, BD Biosciences, Oxford, UK) was added (0.2 pl/well) and cells were 
further incubated overnight (peptide stimulation) or for 6 hours (virus stimulation). 
To detect cytotoxic degranulation, mouse anti-porcine CD 107a-Alexa Fluor 647 or 
mouse IgGl isotype control-Alexa Fluor 647 mAbs (both AbD Serotec, Oxford, UK; 
10 pl/well; Table 2.3) and monensin (Golgi Stop, BD Bioscience, Oxford, UK; 0.2 
pl/well) were added in conjunction with Brefeldin A. After Brefeldin A incubation, 
flow cytofluorometric analyses were performed, as described in 2 .1 0 .
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2.10.2 Culture of DCs, monocytes, NK and yô-T cells with CSFV and porcine 
cytokines
Enriched NK cells or yô-T cells (2x10^ cells/well) alone or co-cultures with enriched 
or purified DC populations (1x10^ cells/well), were cultured with CSFV C-strain or 
Brescia (100 pl/well). For experiments involving only enriched NK/yÔ-T cells a MOI 
of 1 was used, whereas an MOI of 0.66 was used for DC co-culture experiments. In 
one defined experiment, an MOI of 3 was used. In defined experiments, cells were 
cultured in the presence of recombinant porcine cytokines: cytokines: IL-12 (100 
ng/ml) and IL-18 (100 ng/ml), IFN-a (4000 or 2000 or 1000 U/ml) and/or TNF-a 
(800 or 400 or 200 pg/ml) (all R&D Systems, Abingdon, UK). In all experiments, 
mock virus supernatant or medium was used as a negative control. Cultures were 
incubated for 24-48 hours, at 37°C in a 5% C02 humidified atmosphere. After 24 
hours of culture, cells were re-suspended and centrifuged at 930 x g for 2 minutes, 
the supernatants were collected and stored at -80°C until analyzed.
2.11 ASSESSMENT OF CYTOKINE PRODUCTION FROM NK, yô-T AND 
DC CELL CULTURES
2.11.1 Cytokine Array ELISA
The quantitative measurement of cytokines (IL-ip, IL-2, IL-4, IL-6 , IL-8 , IL-10 and 
TNF-a) in cell culture supernatants was kindly performed by Dr. Jane Edwards, 
Virology Department, AHVLA, New Haw, UK, using a CiraTM Porcine Cytokine 1 
Array ELISA (Aushon, Billerica, USA), according to manufacturer’s instructions. 
Briefly, defi*osted cell culture supernatants were diluted 1:2 and added to the wells. 
After 3 hours incubation, wells were washed and biotinylated antibody reagent was
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added to the wells and incubated for 30 minutes. Wells were washed and 
streptavidin-horseradish peroxidise (HRP) reagent was added to the wells. After 30 
minutes of incubation, SuperSignal® substrate was added and luminescence was 
read within 1-10 minutes on a CCD camera (Aushon, Billerica, USA). All 
incubations were made at RT.
2.11.2 Cytokine ELIS As
IFN-y and IL-12 were quantified in culture supernatants using ELIS As (Porcine IFN- 
gamma Quantikine ELISA kit and IL-12 DuoSet, both R&D Systems, Abingdon, 
UK), according to manufacturer’s instructions. Briefly, cell culture supernatants were 
added to the wells and after 2  hours of incubation wells were washed and polyclonal 
biotinylated mouse anti-porcine IFN-y or IL-12 antibody was added. After 1 or 2 
hours of incubation, respectively, wells were washed and Streptavidin-HRP was 
added and incubated for 30 or 20 minutes, respectively. Wells were washed and 
tetramethylbenzidine (TMB) substrate solution was added, incubated for 20 minutes 
in the dark and the reaction stopped by addition of 2N H2SO4. Absorbance was read 
using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK). All 
incubations were made at RT.
2.11.3 Type I Interferon bioassay
Type I IFN activity was determined using an Mx/CAT reporter gene assay, by 
adding dilutions of culture supernatants to reporter bovine kidney cells (MDBK-t2) 
for 24 hours. Procedures are described in 2.8 and absorbance was read using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK).
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2.11.4 IFN-y ELISpot Assay
Ninety six-well ELISpot plates (Multiscreen-IP Filter Plates; Millipore, Watford, 
UK) were prepared by pre-wetting each well with 15 pi of 35% ethanol for 1 minute 
then washed three times with sterile PBS. The capture antibody (mouse anti-porcine 
IFN-y mAb, P2G10, BD Biosciences, Oxford, UK), prepared at 0.5 pg/ml in PBS, 
was added at 50 pl/well and plates incubated at 4°C overnight. Capture antibody was 
then decanted and plates washed three times with un-supplemented RPMI-1640 
medium. Plates were blocked by addition of 200 pl/well cRPMI and incubation for at 
least 1 hour at 37°C. Freshly isolated PBMC were suspended at 5xl0^/ml in cRPMI 
and 100 pi of cells was added to each well. CSFV Alfort 187 strain was diluted in 
cRPMI and added at a multiplicity of infection (MOI) of 1. Concanavalin A (ConA, 
Sigma-Aldrich, Poole, UK) at 10 pg/ml and mock-infected PK-15 cell cryolysate 
supernatant were used as positive and negative controls, respectively. All conditions 
were tested in triplicate and plates were incubated at 37°C in a 5% C02 humidified 
atmosphere for 18 hours. Well contents were discarded and 100 pi of cold water was 
added to each well and incubated for 5 minutes. Wells were then washed five times 
with PBS with 0.05% Tween 20 (wash buffer). Biotinylated mouse anti-porcine IFN- 
y mAb (P2C11, BD Biosciences, Oxford, UK) was diluted to 0.167 pg/ml in PBS, 
0.05% Tween 20, 1% FBS and added 50 pl/well. Plates were then incubated at 4°C 
overnight. Plates were washed 3 times with wash buffer and incubated with 
Streptavidin-HRP (R&D Systems, Abingdon, UK; 0.5 pg/ml, 50 pl/well) for 1 hour 
at 37°C. Plates were washed five times and lOOpl/well 5-bromo-4-chloro-3-indolyl- 
phosphate (BCIP)/ nitro blue tétrazolium (NBT) substrate (R&D Systems, Abingdon,
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UK; lOOpl/well) was added and incubated at RT in the dark until spots became 
visible, typically 1 5 - 6 0  minutes. The substrate was then discarded and the plates 
washed extensively with water and left to dry in the dark. Spots were visualized 
using an automated ELISpot reader (Autolmmun Diagnostika, Strassberg, Germany).
2.12 MULTI-PARAMETER CYTOFLUOROMETRIC ANALYSIS OF PBMC, 
NK AND yô-T CELLS
Cells from both in vitro and ex-vivo experiments were harvested and washed in 
sterile PBS (Life technologies. Paisley, UK). To assess viability, cells were stained 
with Near Infra-Red Fixable Live/Dead Viability Dye (Life technologies. Paisley, 
UK) for 30 minutes at 4°C and then washed twice with PBS supplemented with 2% 
FBS and 0.09% sodium azide (FACS buffer).
2.12.1 Cell surface marker staining
Cells were stained for 10 min at RT with the following mAbs: MHC class II DR- 
FITC (2E9/13, AbD Serotec, Oxford, UK), CD8a-PE (76-2-11, BD Biosciences, 
Oxford, UK), CD4-PerCP-Cy5.5 (74-12-4, BD Biosciences, Oxford, UK), CD3-APC 
(BB238E68C8, BD Biosciences, Oxford, UK), CD3 (BB238E6, Cambridge 
Bioscience, Cambridge, UK) and TcRl-N4 (PGBL22A, WSUMAC, Pullman, USA) 
CD25 (K231.3B2, AbD Serotec, Oxford, UK), CD27 (b30c7, kindly provided by Dr 
Wilhelm Gemer, University of Veterinary Medicine, Vienna, Austria; Reutner et a l,
I
2012), CD44-eFluor450 (IM7, eBioscience, Hatfield, UK) and CD62L (CC32, AbD 
Serotec, Oxford, UK), as described in Table 2.2. Un-conjugated anti-CD3 and anti- 
TcRl-N4 mAbs were labelled using Zenon Alexa Fluor 647 or Zenon Alexa Fluor
74
405 mouse IgGl labelling kits, according to manufacturer’s instructions (Life 
Technologies, Paisley, UK). Cells were then washed twice with FACS buffer. 
Staining with CD25, CD27 and CD62L mAbs was visualized by incubation of cells 
with AFC-conjugated rat anti-mouse IgGl (X56, BD Biosciences, Oxford, UK) for 
10 minutes and then washed twice with FACS buffer. Irrelevant isotype control 
mAh was used for MHC class II DR-FITC: IgG2b isotype control-FITC (AbD 
Serotec, Oxford, UK), as described in Table 2.2. The antibodies used to gate the 
different lymphocyte populations (CD8a, CD4, CDS and TcRl) and surface markers 
(CD25, CD44, CD62L) were compared to the corresponding isotype controls, as 
reported in Table 2.2, on initial stock of PBMC to exclude non-specific binding 
(Figure 2.1).
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Figure 2.1 Comparison of surface antibody staining to their corresponding 
isotype controls. PBMC were stained with the antibodies or their corresponding 
isotype controls or were unstained, then flow cytometric analysis were performed.
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2.12.2 Intracellular marker staining
Surface stained cells were fixed using CellFIX (BD Biosciences) for 10 min at RT 
and then analyzed or were fixed and permeabilised using CytoFix/CytoPerm 
Solution (BD Bioscience) for 20 minutes at 4°C. After two washes in BD 
PermAVash Buffer (BD Biosciences), cells were incubated with mAbs at RT. for 10 
minutes in the dark. mAbs used for intracellular staining were: anti-human perforin- 
FITC (yG9, BD Biosciences, Oxford, UK), anti-CSFV E2 mAh (WH303, Cell and 
Tissue Culture Unit, AHVLA, New Haw, UK), anti-IFN-y-FITC or -Alexa Fluor 
647 (CC302, AbD Serotec, Oxford, UK), anti-TNF-a-Pacific Blue (MAbll, 
Cambridge Bioscience, Cambridge, UK) and anti-IL-2 (A150D 3F1, Life 
technologies. Paisley, UK), as described in Table 2.3. Anti-IL-2 was labelled using 
Zenon Alexa Fluor 647 mouse IgG2a labelling kit (Life Technologies, Paisley, UK). 
Staining with anti-CSFV E2 mAh was visualized by subsequent staining with rat 
anti-mouse IgGl-APC (X56, BD Biosciences, Oxford, UK). Irrelevant isotype 
control mAh was used to control staining for perforin, CSFY E2 and IFN-y mAbs, as 
described in Table 2.3. TNF-a and IL-2 staining was compared to that of the 
corresponding isotype controls, as reported in Table 2.3, on pokeweed mitogen 
(PWM; 1 pg/ml) stimulated PBMC, in order to exclude non-specific binding (Figure 
2 J ^
Cells were given two final washes in BD PermAVash buffer and re-suspended in 
FACS buffer prior to flow cytometric analysis. All the washes used centrifugation at 
930 X g for 2 minutes and cells were analyzed on a MACSQuant Analyzer (Miltenyi 
Biotec) or CyAn ADP (Beckman Coulter) flow cytometers.
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Figure 2.2 Comparison of intracellular anti-cytokine mAb straining to their 
corresponding isotype controls. PBMC were stimulated with pokeweed mitogen 
(PWM; Ipg/ml) and stained with anti-cytokine antibodies or their corresponding 
isotype controls or were unstained and then flow cytometric analysis was performed.
2.12.3 Flow Cytometric Gating Strategies
Sorted NK/yÔ-T cells were analysed by gating on viable cells (Live/Dead Fixable 
Dead Cell Stain negative) in the lymphocyte population, then the two different 
populations were gated upon and their levels of surface/intracellular parameters 
assessed. Gates were set using the corresponding isotype/unstained controls. The 
number of live sorted NK/yô-T cells acquired for analysis was at least 50,000 events. 
To analyse unsorted cells, analyses were made by exclusion of doublets, followed by 
gating on viable cells (Live/Dead Fixable Dead Cell Stain negative) in the 
lymphocyte population, and defined lymphocyte subpopulations were then gated
80
upon and their expression of cytokines assessed. Gates were set using the 
corresponding isotype/unstained controls and values were corrected by subtraction of 
the % positive events in the biological negative control (mock-virus supernatant 
stimulated or unstimulated cultures). The number of singlet live lymphocytes 
acquired for analysis ranged from 200,000 -  400,000 events.
To determine the absolute numbers of IFN-y producing cells, the PBMC density in 
peripheral blood was assessed by CD45-FITC staining as described above except 
with the exclusion of granulocytes, which were distinguished by their high forward 
and side scatter characteristics. This value was then used to convert the percent of 
IFN-y secreting cells within the viable PBMC gate to a cell density/pl blood.
2.13 SEQUENCE ANALYSIS OF T CELL ANTIGENIC 
PEPTIDES/EPITOPES
The sequences of the identified T cell antigenic regions/epitopes were aligned against 
the fiill-genome sequences of 15 CSFV isolates (GenBank accession numbers shown 
in parentheses): Genotype 1.1 Alfort 187 (X87939), KC Vaccine (AF099102), ALD 
(D49532), GPE- (D49533), Alfort A19 (U90951), cF114 (AF333000), Riems 
(U45477), Shimen (AF092448), Koslov (HM237795), SWH (DQ127910), Brescia 
(AF091661); Genotype 2.1 Penevezys (HQ148063); Genotype 2.3 Borken 
(GU233731) and Alfort Tübingen (AAA43844); Genotype 3.4 94.4/IL/94/TWN 
(AY646427.1); the BVDV reference strain NADL (AJ133738) and BDV reference 
strain BD31 (U70263), using the Clustal W algorithm on MegAlign (DNAStar 
Lasergene 9 Core Suite, Madison, WI, USA).
The sequences of the identified T cell antigenic regions/epitopes were also aligned 
against the corresponding sequences of the CSFV isolates UK2000/7.1 (genotype
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2.1) and CBR/93 (genotype 3.3). These sequences were not available on GenBank 
and so were generated as follows: RNA from CSFV UK2000/7.1 and CBR/93 was 
extracted from virus suspensions and cDNA generated by reverse transcription as 
previously described (Everett et al, 2010). In brief, viral RNA was extracted from 
virus suspensions using ViralAmp RNA purification kit (Qiagen, Crawley, UK) and 
then was reverse transcribed: 4 pi RNA was added to a 9 pi reaction mix containing 
1 pi of deoxynucleotide triphosphates (dNTP) (10 mM of each dNTP, Promega, 
Southampton, UK), 1 pi of random primers (50 ng/ml, Promega, Southampton, UK), 
7 pi of water for prerincubation at 65°C for 5 minutes; this solution was then added 
to a second solution mix containing 4 pi 5x reverse transcriptase (RT) buffer, 1 pi 
dithiothreitol (DTT) (O.IM), 1 pi RNasin (40 U/pl), 1 pi Superscript III enzyme (200 
U/pl) (all Life Technologies, Paisley, UK) and incubated at 25°C for 5 minutes, 
50°C for 50 minutes, 70°C for 15 minutes; finally 1 pi of E. coli Rnase H (Life 
technologies, Paisley, UK) was added and the solution was further incubated at 37°C 
for 20 minutes. 5 pi of cDNA was used as template for PCR amplification with high 
fidelity Platinum Taq in a reaction mix containing: 1 pi dNTP (10 mM of each 
dNTP, Promega, Southampton, UK), 5 pi 5x PCR buffer, 1.5 pi MgS0 4  (50 mM), 
0.2 pi Platinum Taq (5 U/ml) (all Life Technologies, Paisley, UK) and 2 pi (20 pM) 
of each primer (Sigma-Aldrich, Poole, UK). The following primers were used to 
amplify the selected regions: Core-F-954 AGAGCATGAGAAGGACAGYA and 
Core-R-1211 GTGCCRTTGTCACTYAGGTT, E2-F-2397
GTGCAAGGTGTGRTATGGC and E2-R-3613
GTGTGGGTRATTAAGTTCCCTA, NS2-F-3840 TAGTAGTCGYYGTGATGTTR 
and NS2-R-4248 GCCCACATCGTAAAMACCA, NS3-F-5974
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AGGATAGGKGAGATGAAGG and NS3-R-6332
TTCATCTCCTCTACTGGTATC, NS5A-F-9278 ACTATGACTACAGGGGAG 
and NS5A-R-9857 GATATCTTTGTGGAGTCTGT. The following thermal profile 
was adopted: 94°C for 2 minutes, 40 x (94°C 30 seeonds; 53°C 30 seconds for E2/ 
49°C 30 seconds for core and NS3/ 46°C 30 seconds for NS2 and NS5A; 72°C 60 
seconds); 72°C 1 minute: 4°C. Sequencing reactions using purified amplicons were 
set up in both directions using a chain termination protocol based on fiuorochrome 
labelled dideoxynucleotides (Central Sequencing Unit, AHVLA, New Haw, UK) and 
assembled sequences were aligned with the matching antigenic peptide.
2.14 MHC CLASS I HAPLOTYPE DETERMINATION BY LOW- 
RESOLUTION PCR-BASED ANALYSIS
This analysis was kindly performed by Dr. Sabine Essler, Department of 
Pathobiology, Institute of Immunology, University of Veterinary Medicine Vienna, 
Austria. Pigs used in this study were genotyped for their swine leukocyte antigen 
(SLA) class I haplotypes. Genomic DNA was extracted from PBMC using a 
QIAamp DNA extraction mini kit, according to the manufacturer’s protocols 
(Qiagen, Crawley, UK) and then low-resolution (Lr) PCR screening assays 
(Sequence Specific Primed PCR; PCR-SSP) was run as previously described (Essler 
et al., 2013). In brief, this method is used to type alleles at the three classical SLA 
class I loci (SLA-1, SLA-3 and SLA-2) and relies on 47 discriminatory PCR primer 
pairs, which amplify products of 114-316 bp and are designed to amplify the SLA 
class I alleles by groups that have similar sequence motifs. All typing primers were 
previously validated and were optimized to be used at the same concentration (5 
pmol/each) and annealing temperature (65°C). Typing of each pig includes a
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negative control without DNA to check for reagent contamination, and is set up and 
electrophoresed in a standard 96-well format. Interpretation of the results is based on 
the presence of a smaller PCR product than the positive control in each lane (Ho et 
aA,2009).
2.15 DATA ANALYSIS AND STATISTICS
Graphical and statistical analyses were performed using GraphPad Prism 5.04 
(GraphPad Software Inc, La Jolla, USA). Data were represented as mean +/- standard 
deviation (SD) to indicate the uncertainty around the estimate of the group mean. In a 
defined experiment, the standard error of the mean (SEM) was used. Two tailed 
unpaired t-tests or one-way analysis of variance (ANOVA) followed by a 
Bonferroni’s post-hoc test or a Dunnetf s test were used and a p value < 0.05 was 
considered statistically significant.
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CHAPTER 3. CONTRIBUTION OF NK AND yô-T CELLS IN THE IMMUNE 
RESPONSE AGAINST CLASSICAL SWINE FEVER VIRUS
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3.1 INTRODUCTION
As stated in the introduction of this thesis, protection against CSF precedes the 
detection of a humoral response, but not IFN-y secreting cells in peripheral blood 
(Suradhat et al, 2001; Dewulf et a l, 2004) and studies have suggested that C-strain 
virus is a potent inducer of type-1 T cell responses, which may play a role in 
protection against CSF particularly in the absence of antibody responses (Sudharat et 
al 2005; Graham et al 2012a; Graham et al 2012b). Consequently, an improved 
understanding of the cellular immune mechanisms triggered by the C-strain vaccine 
would aid the development of the next generation of CSFV marker vaccines. 
Currently, little is known about the contribution of NK and yô-T cells in the cellular 
immune response against CSFV. Their activation/inhibition could be crucial given 
that swine possess only a small number of cytotoxic T-cells, but large numbers of 
lymphocytes with innate cytotoxic activity, especially yô-T cells (Denyer et al, 
2006). In young pigs, yô-T cells and NK cells represent approximately 50% and 10% 
of the total peripheral blood lymphocyte population, respectively, although their 
frequencies decrease with age (Denyer et al, 2006; Gemer et al, 2009).
NK cells are a type of lymphocyte of the innate immune system and are able to 
release cytokines and exhibit cytotoxic activity, offering an early response to virus- 
infected cells (Gemer et al, 2009). These cells are triggered to kill or ignore target 
cells depending on a balance of inhibitory and activating signals (Lanier, 2005) and 
many pathogens activate them through accessory cells, like DCs (Gerosa et al, 
2002). While little is known about the contribution of NK cells in the response to 
CSFV, several studies have reported the effects of the related Flavivims, hepatitis C 
vims (HCV), on human NK cells. NK cell activity can be directly inhibited by the 
HCV core (Herzer et al, 2003) and E2 stmctural proteins (Crotta et a l, 2002). The
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HCV non-structural protein, NS5A, is able to impair NK cell activity indirectly, by 
inducing monocytes to secrete cytokines which result in the down-regulation of 
NKG2D (activating receptor) expression on NK cells (Sene et al, 2010). This 
inhibition of NK cells, which occurs early in infection, would allow the HCV to 
establish a replicative advantage prior to the induction of the specific immune 
response and would also destroy the NK-DC cross-talk, impairing DC-mediated 
priming of CD8^ CTL responses (Golden-Mason and Rosen, 2006). Although no 
data exist, it is tempting to speculate that CSFV may also employ mechanisms to 
evade the NK cell response and this may have been lost during the attenuation of the 
C-strain, allowing it to induce rapid protection well in advance of neutralising 
antibody responses.
yô-T cells represent another significant lymphocyte population of the innate 
immune system which, like NK-cells, play an important role in activating and 
shaping the adaptive immune response (Bonneville et al, 2010). These cells can be 
activated directly or indirectly, by the interaction with APCs, like DCs (Devilder et 
al, 2009). yô-T cell responses to CSFV have not been described. However in HCV 
patients, yô-T cells from the liver, but not from the blood, are able to be expanded in 
vitro after exposure to cytokines and it is thought that yô-T cells are activated 
through the cross-linking of CD81, which binds with high affinity the HCV structural 
protein E2 (Tseng et a l, 2001).
It may be hypothesised C-strain vaccination activates NK and yô-T cells resulting in 
their contribution to protection by exerting anti-viral effector functions. Similarly to 
HCV, evidence for such cellular activation .may only be observable at the local tissue 
level, which in the case of CSFV would be the tonsils and in the lymph nodes 
draining the oronasal cavity. This Chapter reports an investigation which aimed to
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address this hypothesis by studying the interaction of these two populations of the 
innate immune system with C-strain and virulent CSFV.
3.2 RESULTS 
3.2.1 Summary
The interaction of NK and yô-T cells with CSFV was investigated using both an in 
vitro and an ex-vivo approach. Initially, purified NK and yô-T cells were co-cultured 
in vitro with CSFV virions, using both the live attenuated C-strain vaccine and the 
virulent Brescia strain, and the direct effects on these populations were assessed. The 
cross-talk of DC populations with NK and yô-T cells in response to CSFV was next 
investigated. Naïve pigs were chosen to perform the in vitro experiments, to analyse 
the direct effect of the viruses on different cell populations. Expression of MHC class 
II (MHC-II), intracellular perforin levels and secretion of IFN-y were selected as 
parameters to analyse the phenotype of NK and yô-T cells, as suggested by a recent 
publication (Pintaric et al, 2008). Finally, these findings were extended to ex-vivo 
analyses of these cells in the tonsils and retro-pharyngeal lymph nodes from pigs 
vaccinated with C-strain and/or challenged with CSFV Brescia. ex-vivo approach 
was chosen to have a more precise picture of how CSFV triggers the immune 
response in these lymphoid tissues, which are the primary sites of CSFV infection 
and thus where innate immunity might play an important role. Type I IFN level in 
the sera were finally detected, in order to estimate the amount of this cytokine in 
tonsils/retropharyngeal lymph nodes.
3.2.2 In vitro analysis: interaction of NK and yô-T cells with CSFV
The direct effects of a live-attenuated C-strain and the virulent Brescia strain of 
CSFV were assessed on NK and yô-T cells in vitro. The recombinant porcine
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cytokines IL-12 and IL-18 were used as a positive control, due to their reported 
ability to activate porcine NK and yô-T cells, with consequent up-regulation of 
activation markers, increase in the intracellular levels of perforin and release of 
antiviral cytokines (Pintaric et ah, 2008). The gating strategy used to interrogate 
responses in NK and yô-T cells is displayed in Figures 3.1 and 3.2, respectively. 
Neither virus induced activation of either cell type as assessed by an increase in the 
proportion of cells expressing MHC class II (MHC-II) (marker of activation), 
intracellular perforin (marker of cytotoxic activity) or by the secretion of IFN-y 
(Figure 3.3). Furthermore it was found that both cell populations were resistant to in 
vitro infection by attenuated or virulent CSFV as assessed by intracellular staining 
for CSFV E2 protein (Figure 3.4).
To assess the indirect effect of CSFV on NK and yô-T cells, these cells were co­
cultured with CSFV and enriched blood DCs, which contained both pDCs and 
mDCs. As displayed in Figure 3.3, co-culture with DCs and either virus strain led to 
a significant increase in the proportion of both NK and yô-T cells expressing MHC- 
II, which was not associated with upregulation of perforin or stimulation of an IFN-y 
response.
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Figure 3.1 Flow cytometric gating strategy used to interrogate responses of 
enriched NK cells. Responses to CSFV were interrogated in live sorted NK cells. 
NK cells with typical FSC vs. SSC for PBMC (A), stained negative for LIVE/DEAD 
stain (B) and positive for CDS expression (C) were assessed for MHC class II 
expression (D) and intracellular levels of perforin (E). MHC class II and perforin 
gates were set using cells stained with corresponding isoptye control mAbs. 
Representative dot plots are shown.
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Figure 3.2 Flow cytometric gating strategy used to interrogate responses of 
enriched yô-T cells. Responses to CSFV were interrogated in live sorted yô-T 
eells. yô-T cells with typical FSC vs. SSC for PBMC (A), stained negative for 
LIVE/DEAD stain (B) and positive for yô-TcR expression (C) were assessed for 
MHC class II expression (D) and intracellular levels of perforin (E). MHC class II 
and perforin gates were set using cells stained with corresponding isoptye control 
mAbs. Representative dot plots are shown.
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Figure 3.3 Analysis of the direct and indirect effects of CSFV on NK and yô-T 
cells. NK and yô-T cells were co-cultured with CSFV (C-strain or Brescia), alone or 
with enriched blood DCs (mixed population of pDC and mDC), at a ratio 2:1, using 
an MOI of 1 or 0.66 respectively. Mock virus supernatant was used as a negative 
control. 24 hours after infection, cells were stained and analysed by flow cytometry, 
using the gating strategy illustrated in Figure 3.1 and 3.2, and the supernatant was 
collected to assess the level of secreted IFN-y. Surface expression of MHC II and 
intracellular levels of perforin were investigated in live NK cells (A) and yô-T cells
(B). Data represent the mean of 3 replicates + SD. On the far right of each panel, data 
represent the mean of the concentration of IFN-y in the culture supernatant + SD. 
Values for each group were compared to the corresponding un-stimulated control 
(mock alone or mock + DCs respectively), using a one-way ANOVA followed by a 
Dunnetf s Multiple Comparison Test; ***p<0.001, **p<0.01, *p<0.05.
20 -
NK cells y6-T cells m o n o cy te s
Figure 3.4 NK and yô-T cells are resistant to infection by CSFV in vitro. NK
cells, yô-T cells and monocytes were co-cultured with CSFV Brescia strain, using an 
MOI of 3. 48 hours after infection, cells were harvested and CSFV infection was 
assessed using flow cytometry.
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3.2.3 In vitro analysis: MHC II up-regulation on NK and yô-T cells co-cultured 
with CSFV and DCs
To determine whether the MHC-II up-regulation on NK/yô T eells was due to eell-to- 
cell contact with DCs or to soluble faetor/s released by DCs in response to CSFV 
infection, experiments were conducted using supernatants of DCs eo-cultured with 
CSFV. Enriched DCs were infected with C-strain or Brescia CSFV, or moek- 
infected, and after 24 hours their supernatants were harvested and stored at -80°C 
until use.
Culture of fireshly isolated NK and yÔ-T cells with supernatants from DCs infected 
with either strain, but not uninfected DC cultures, led to a significant increase in the 
proportion of NK/yô-T cells expressing MHC-II, suggesting that soluble factors 
released from the cells were responsible for the stimulatory effect (Figure 3.5).
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Figure 3.5 Effect of soluble factors released by DCs co-cultured with CSFV on 
the MHC II expression by NK and yô-T cells. NK and yô-T cells were co-cultured , 
with CSFV (C-strain or Brescia), or with supernatants from CSFV and enriched 
blood DC cultures. Mock was used as a negative control. Twenty four hours after 
culture, eells were harvested and the surface expression of MHC-II was investigated 
using flow cytometry. Data represent the mean of 3 replicates + SD. Values for each 
group were compared to the corresponding un-stimulated control (mock alone or 
mock + DC supernatant), using a one-way ANOVA followed by a Dunnetf s 
Multiple Comparison Test; ***p<0.001, **p<0.01.
In order to establish whether mDCs or pDCs were responsible for this partial 
activation, NK and yô-T cells were co-cultured with CSFV in the presence of sorted 
porcine blood mDCs or pDCs. As displayed in Figure 3.6, a significant increase in 
the cells expressing MHC-II was observed on the surface of both NK and ÿô-T cells
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when cultured with virus and pDCs, whereas culture with mDCs had no stimulatory 
effect, suggesting that soluble factors released by pDCs in response to CSFV induced 
MHC-II up-regulation on the surface of NK/yÔ-T eells.
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Figure 3.6 Effect of pDCs or mDCs on the MHC-II expression by NK and yô-T 
cells. NK and yô-T cells were co-cultured with CSFV (C-strain or Brescia), alone or 
with sorted pDCs or mDCs, at a ratio 2:1, using an MOI of 1 or 0.66 respectively. 
Mock was used as a negative control. 24 hours after infection, cells were harvested 
and the surface expression of MHC-II was investigated in live NK or yô-T cells, 
using flow cytometry. Data represent the mean of 3 replicates + SD. Values for each 
group were compared to the corresponding un-stimulated control (mock alone or 
mock + pDCs or mock + mDCs), using a one-way ANOVA followed by a Dunnetf s 
Multiple Comparison Test; ***p<0.001, *p<0.05.
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3.2.4 In vitro analysis: MHC-II up-regulation and cytokines derived from 
CSFV-pDC co-cultures
The eytokine profiles of supernatants from co-cultures of NK and yô-T cells with 
CSFV and mDCs/pDCs were assessed in an attempt to identify differentially 
expressed cytokines that may be responsible for the upregulation of MHC-II. No 
significant differences were observed in the levels of IL-ip, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-12 or IFN-y between mDC and pDC cultures (data not shown), while 
significantly higher levels of IFN-a and TNF-a were detected in pDC co-cultures 
compared those containing mDCs (Figure 3.7A and B). The type I IFN released by 
mDCs in response to CSFV was significantly less than pDCs (Fig 3.7B). To detect 
type I IFN, an Mx/CAT reporter gene assay was used. This assay has been shown to 
also detect bovine type III IFN (Dr. Bryan Charleston, Pirbright Institute, Personal 
Communication); however, no information exists as to whether this assay 
additionally detects porcine type III IFN.
Enriched NK and yô-T eells were therefore cultured with recombinant porcine IFN-a 
and TNF-a at concentrations comparable to those detected in CSFV-pDC culture 
supernatants, either individually or in combination, and effects on MHC-II 
expression assessed (Figure 3.7C). Stimulation with IFN-a (from 1000 U/ml) but not 
TNF-a induced a significant up-regulation of MHC-II on NK and yô-T cells and 
there was evidence for a further enhancement of MHC-II expression by yô-T cells 
when the two cytokines were combined.
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Figure 3.7 Effect of IFN-a and TNF-a on the MHC-II expression by NK and yô- 
T cells. Enriched NK and yô-T cells were co-cultured with attenuated C-strain or 
virulent Brescia strain CSFV alone or together with sorted pDCs or mDCs, at a ratio 
2:1. A mock virus-infected cryolysate supernatant was used as negative control. 
Twenty four hours post-culture, the levels of TNF-a (A) and type I IFN (B) in 
supernatants were analysed using a porcine cytokine array and Mx/CAT reporter 
gene assay, respectively. Enriched NK and yô-T cells were then cultured in cRPMI 
medium alone or in the presence of porcine recombinant IFN-a and/or TNF-a, at 
concentrations comparable to those detected in CSFV and pDC co-cultures, and the 
expression of MHC-II was assessed by flow cytometry after 24 hours (C). Data 
represent the mean of triplicate cultures + SD. Values for each group were compared 
to the corresponding un-stimulated control using a one-way ANOVA followed by a 
Dunnetf s Multiple Comparison Test; ***p<0.001, **p<0.01, *p<0.05.
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3.2.5 Ex-vivo analysis: role of NK and yô-T cells responses against CSFV in the 
tonsils and retro pharyngeal lymph nodes
Ex vivo experiments were performed in the context of C-strain CSFV vaccinated 
and/or Brescia challenge, in order to complement the in vitro results. An experiment 
was conducted where pigs were vaccinated with the C-strain virus and challenged 
five days later with the virulent Brescia strain. Two different routes of vaccine 
administration (i.n. or i.m.) were tested and a challenge control group was included 
in the study. Vaccinated animals were solidly protected from challenge, whereas 
unvaccinated challenge control pigs developed clinical signs of CSF, viraemia and 
leukopenia, as displayed in Figure 3.8.
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Figure 3.8 Outcome to challenge with virulent CSFV following vaccination with 
live attenuated C-strain CSFV. Five days after intranasal (i.n.) or intramuseular 
(i.m.) vaccination, animals were challenged by intranasal inoculation with CSFV 
Brescia strain. One additional group was vaccinated but not challenged and another 
one was challenged only. (A) Clinical signs of CSF were scored bi-daily, (B) viral 
RNA copy numbers in peripheral blood were determined by real-time RT-PCR and
(C) leukocyte counts assessed by volumetric flow cytometry. Results are expressed 
as the mean data for each group and error bars represent SD.
The phenotype of NK and yô-T cells was analysed in the tonsils and retro-pharyngeal 
lymph nodes (RP LN), which are the primary sites of CSFV infection and thus where 
innate immunity might play an important role. As before, flow cytometry was used to 
assess the surface expression of MHC-II and the intracellular levels of perforin in 
cells isolated from tissues on day -2, 0,2 and 5 post-challenge.
Differences between groups in terms of the up-regulation of MHC class II (Figure 
3.9) in the tonsils and RP LN were observed, while no significant differences were 
detected in the proportions of NK and yô-T cells expressing perforin in the tonsils
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(Figure 3.10). On the day of challenge (day 5 post-vaccination), there was some 
evidence of an up-regulation of MHC-II on yô-T cells in the draining lymph nodes 
from intranasally vaccinated animals, although more significant changes were 
observed five days post-challenge (Figure 3.9B). At this time point, there was a 
significantly greater proportion of MHC-II expressing NK and yÔ-T cells in both the 
tonsils and retro-pharyngeal lymph nodes of unvaccinated challenge control pigs 
compared to both vaccinated and challenged pigs and those which were vaccinated 
but unchallenged. Comparison of the viral loads in these tissues confirmed that the 
challenge control pigs had significantly higher amounts of viral RNA present on day 
5 post-challenge (Figure 3.11 A). Concomitant with the increased viral loads, it was 
also found that by day 5 post-challenge, unvaccinated challenge control pigs had 
high levels of type IIFN in the serum (Figure 3.1 IB).
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Figure 3.9 MHC-II expression on NK and yô-T cells 5 days after C-strain 
vaccination (day 0) and 5 days after CSFV Brescia challenge (day 5). Cells from 
tonsils and retro-pharyngeal lymph nodes were collected 5 days after vaccination and 
5 days after challenge and cryopreserved till analysis. MHC-II expression on NK and 
yô-T cells was assessed using flow cytometry. Panel A shows the gating strategy 
used to interrogate responses in live NK and yô-T cell populations. Representative 
data from a challenged only pig on day 5 are displayed. The two populations were 
distinguished using mAbs: yô-T cells (CD3^yô-TcR^) and NK cells (CD3'CD8^°^). 
Panel B and C shows the percentage of MHC-II expressing yô-T cells and NK cells 
in the tonsils and lymph nodes, 5 days after vaccination and 5 days after challenge, 
respectively. Data represent the mean of 9 replicates/group (triplicate samples for 3 
pigs) + SD. Statistical analysis were performed using using a one-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test; ***p<0.001, **p<0.01, 
*p<0.05.
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Figure 3.10 Proportions of NK and yô-T ceils expressing perforin in the tonsils 5 
days after C-strain vaccination (day 0) and 5 days after CSFV Brescia challenge 
(day 5). Cells from tonsils were collected 5 days after vaccination and 5 days after 
challenges and cryopreserved till analysis. Expression of perforin in NK and yô-T 
cells was assessed using flow cytometry. The two populations were gated as 
illustrated in Figure 3.9A. Graphs display the percentages of perforin^ NK cells and 
yô-T cells in the tonsils 5 days after vaccination and 5 days after challenge, 
respectively. Data represent the mean of 9 replicateS/group (triplicate samples for 3 
pigs) + SD. Statistical analysis were performed using using a one-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test; ***p<0.001, **p<0.01, 
*p<0.05.
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Figure 3.11 Quantification of CSFV loads in tonsils and retro-pharyngeal lymph 
nodes, and serum type I IFN levels following C-strain vaccination and/or 
virulent Brescia challenge. Sera, tonsils and retropharyngeal lymph nodes (RP LN) 
were collected longitudinally following C-strain vaccination and challenge 5 days 
later with CSFV Brescia strain. CSFV RNA loads were quantified by in the tissues 
by qRT-PCR (A) and levels of type I IFN in sera determined using a Mx/CAT 
reporter gene assay (B). Data represent the mean of triplicate cultures for 3 
pigs/group +/- SD. Statistical analysis was performed using a one-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test; ***p<0.001, **p<0.01.
3.3 DISCUSSION
3.3.1 Introduction
This study aimed to provide insight into the potential role of NK and yô-T cells in the 
immune response against CSFV, through a combination of in vitro experimentation, 
using sorted NK and yô-T cells from naïve pigs, and ex vivo analyses of key
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lymphoid tissues, from pigs vaccinated with live attenuated CSFV and/or challenged 
with virulent CSFV.
3.3.2 CSFV induced pDC derived type I IFN induces MHC-II up-regulation on
C
NK and yô-T cells in vitro
The data generated by this study suggests that neither NK nor yô-T cells appear to be 
appropriately activated for contribution to antiviral effector functions, but they are at 
least partially activated following stimulation with type I IFN produced by pDCs co­
cultured with CSFV. Co-culture of NK and yô-T cells with CSFV and pDCs, but not 
mDCs, led to an up-regulation of MHC-II on the surface of these cells, which was 
associated with hijgh levels of IFN-a released by pDCs. In response to infection, 
mDCs released significantly lower amounts of IFN-a compared to pDCs, which is 
most likely due to the inhibition of the type I IFN induction cascade by CSFV Npro- 
induced proteasomal degradation of interferon regulatory factor 3 (IRF3) (Bauhofer 
et al., 1986; Ruggli et al, 2005, La Rocca et al, 2005). By virtue of their utilisation 
of IRF7 instead of IRF3, pDCs possess a functional type I IFN response to CSFV 
infection, although it has been recently shown that Npro also interacts with IRF7 and 
reduces the capacity of pDC to produce IFN-a (Fiebach et al, 2008). In our 
experiments only 20-40 % of pDCs were infected after co-culture with CSFV (data 
not shown), so we are not able to determine if type I IFN was released by CSFV- 
infected and/or bystander uninfected pDCs. In fact, it has been recently reported that 
interaction of pDCs with CSFV-infected cells induces greater IFN-a production 
compared to direct infection of pDCs (Python et al, 2013). While IFN-a is the 
prototypic antiviral cytokine, it also plays an important immunoregulatory role 
enhancing both innate and adaptive immune responses (Colonna et al, 2004).
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Moreover it is well known that IFN-a can up-regulate MHC-II on professional 
APCs, although there are few reports demonstrating that it can induce expression on 
non-conventional APCs (Bukowski et al, 1986). For the first time, this study has 
shown this effect of IFN-a on two non-conventional APCs, NK and yô-T cells, in 
pigs.
3.3.3 High levels of type I IFN in pigs infected with virulent CSFV correlates 
with MHC-II upregulation by NK and yô-T cells in the tonsils and local lymph 
nodes.
The results of the ex vivo analysis showed that up-regulation of MHC class II on 
tonsillar and lymph node was associated with virulent Brescia infection and appeared 
to be inversely correlated to C-strain induced protection. Indeed the activated 
phenotype was observed in tissues with both the highest levels of CSFV infection 
and circulating type I IFN. It is likely that CSFV stimulation of pDCs is responsible 
for the latter, since it has been previously described that pDCs rapidly increase in 
numbers in tonsils following CSFV infection accompanied with high levels of IFN-a 
(Jamin et al, 2008). While there was little evidence for MHC-II upregulation 
associated with C strain infection in vivo, the results did show a C-strain induced 
response in vitro. This may be explained by the more limited replication of C-strain 
in vivo and/or a failure of pDCs to traffic to the tonsils resulting in the reduced type I 
IFN levels observed. Alternatively, it is possible that some form of immune 
regulation is triggered by C-strain infection, such as IL-10 induction, which may 
inhibit the pDC mediated type I IFN response (Ito et a l, 1999). Moreover, as stated 
above, it has been recently shown that interaction of pDCs with CSFV-infected cells 
induces greater IFN-a production compared to direct infection of pDCs (Python et
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al, 2013), therefore the ability of virulent CSFV strains to rapidly replicate in 
macrophages and mDCs may potentiate the IFN-a response by pDCs in lymphoid 
tissues. This exacerbated type I IFN response to CSFV, mediated by pDCs, has been 
hypothesised as a key driver of the pathogenesis of CSF including the hallmark trait 
of leukopenia (Renson et al, 2013; Summerfield et al, 2006). In fact, leukopenia 
was described in the challenged only group by day 3 post-challenge and it was 
correlated with the high level of IFN-a in the blood and with MHC-II up-regulation 
of NK/y6-T cells in the tonsils and lymph nodes.
3.3.4 Porcine yô-T cells and NK cells as non-conventional APCs
The increased expression of MHC-II on activated NK and yô-T cells raises the 
question of whether these cells acquire an antigen presenting cell function in 
response to CSFV infection, however, this was out of the scope of the present study. 
A previous study reported that porcine yô-T cells are able to acquire a phenotype 
similar to professional APCs after vaccination against foot-and-mouth disease 
(FMD) and these cells were able to process and present soluble antigen to CD4^ T 
cells, likely modulating the outcome of the adaptive immune response (Takamatzu et 
al, 2006). Human yô-T cells have also been described as gaining AFC function 
following contact with microbes, enabling them to induce conventional CD4^ and 
CD8^  T cell responses (Brandes et al, 2005). It has been suggested that yô-T cells 
act as APCs only in the initiation of pro-inflammatory immune responses and they 
are not able to substitute DCs in controlling self-tolerance and immune regulation 
(Brandes et al, 2005).
The ability of NK cells to express MHC-II after interaction with DCs has 
been previously described in mice. Nakayama et a l observed that NK acquisition of
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MHC-II was mediated by intercellular membrane transfer (or ‘cross-dressing’) from 
interacting DCs and that NK cells also acquired co-stimulatory molecules such as 
CD80 and CD86 from DCs (Nagamaka et al., 2011). However, in the present study it 
was observed that both recombinant cytokines and supernatants derived from CSFV 
and pDCs cultures induced up-regulation of MHC-II on NK cells, suggesting that 
this was a consequence of de novo expression of MHC-II by the NK cells rather than 
via ‘cross-dressing’ from DCs. Interestingly, MHC-II-dressed NK cells have been 
shown to inhibit DC-induced CD4^ T-cell responses via competitive antigen 
presentation (Nagamaka et al., 2011) and it remains to be determined whether the 
MHC-II^ NK cells observed here may inhibit or promote CSFV-specific T cell 
activation.
Despite significant upregulation of MHC-II, the apparent lack of activation of 
NK and yô-T cells enabling release of antiviral cytokines, like IFN-y, or perforin- 
mediated cytotoxic fiinction, raises the possibility that CSFV may be actively 
inhibiting this process. CSFV infection of blood-derived pDCs and mDCs induces 
maturation of these cells as assessed by an increase in co-stimulatory molecule 
expression (J. Edwards and S. Graham, unpublished data) and in addition to type I 
IFN DCs secrete a range of other cytokines, e.g. IL-2 and IL-12, with the capacity to 
activate NK and yô-T cells. Studies of HCV, another member of the Flaviviridae 
family, have shown that several viral proteins, core, E2 and NS5A, can either directly 
or indirectly, in the case of the latter, inhibit human NK cell activation (Herzer et al., 
2003; Crotta et al., 2002; Sene et al, 2010). Since NK cells may also play an, 
important role in the induction of T cell responses via a reciprocal activating cross­
talk with DCs, these inhibitory mechanisms may offer the virus a significant 
advantage in evading immune responses at several levels. However, since there was
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lack of complete activation of NK cells with both C-strain and virulent CSFV, it is 
unlikely that this could have a negative impact on T cell induction in vivo, since C- 
strain induces a virus-specific T cell response which is undetectable in virulent 
CSFV-infected animals (Graham et al, 2012a; Graham et al, 2012b; Graham et al, 
2010).
3.4 CONCLUSIONS
In summary, CSFV induced a partial activation of NK and yô-T cells, as 
characterised by MHC-II up-regulation, which appeared to be mediated by type I 
IFN produced by pDCs in response to CSFV in vitro and was most clearly observed 
ex-vivo in tissues with high viral loads and accompanying circulating type I IFN. 
These cells however failed to display anti-viral effector functions and it therefore 
appears unlikely that either population contributes directly to the rapid protection 
conferred by C-strain CSFV. Further studies should be conducted to determine 
whether MHC-II bearing NK and yô-T cells can function as APCs or rather might 
inhibit DC-induced T cell responses against CSFV, and, to assess whether CSFV can 
actively inhibit the activation of these cells.
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CHAPTER 4. ASSESSMENT OF THE PHENOTYPE AND 
FUNCTIONALITY OF PORCINE CDS T CELL RESPONSES FOLLOWING 
VACCINATION WITH LIVE ATTENUATED CLASSICAL SWINE FEVER 
VIRUS AND VIRULENT VIRUS CHALLENGE
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4.1 INTRODUCTION
Understanding of the immunological basis of the rapid protection afforded by live 
attenuated C-strain vaccines would aid the development of the next generation of 
marker CSFV vaccines by informing the selection of appropriate delivery 
systems/adjuvants to trigger protective responses. Since C-strain-induced protection 
precedes the appearance of neutralizing antibody (Suradhat et al., 2001) and it has 
been reported that there is a close temporal correlation between the induction of 
CSFV-specific T cell IFN-y responses and rapid protection induced by this live 
attenuated vaccine (Graham et al., 2012a), the objective of this part of the study was 
to conduct an in-depth characterization the T cell response elicited by C-strain 
vaccination.
In addition to the secretion of IFN-y, which has been shown to exert direct anti-viral 
effects on CSFV in vitro (Graham e/ al., 2012b), vaccine induced CSFV-specific T 
cells have also been shown to have the capacity to lyse infected cells with 
specificities mapped to the structural protein E2 and the non-structural protein NS3 
(Ceppi et al, 2005; Rau et a l, 2006; Pauly et al, 1995). Flow cytometric studies 
have identified both CD4 and CDS T cells as the cellular source of CSFV-specific 
IFN-y, with the latter co-expressing the cytolytic molecule perforin (Graham et al, 
2012b; Suradhat et al, 2005).
Further evidence for a protective role for T cells stems fi"om recent subunit vaccine 
studies which have shown that the protective capacity of a CSFV E2 DNA vaccine 
was associated with T cell IFN-y rather than neutralising antibody responses 
(Tarradas et al, 2010) and that inclusion of defined NS3 T cell epitopes improved
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the immunogenicity and the degree of protection afforded by a peptide based CSF 
vaccine (Tarradas et al, 2012).
The goal of an efficient vaccine is to generate memory CD4 and/or CDS T cells 
capable of recognizing and rapidly expanding to combat infection (Kaech et al,
2002). Whilst challenging, it has been proposed that the efficacy of T-cell-based 
vaccines could be improved by manipulating the generation and maintenance of 
distinct memory T cell subsets, which in recent years have been identified in humans 
and mice through the application of multiparameter flow cytometry (Thakur et al,
2012). The two main categories of memory T cells are classified as effector memory 
(T em) and central memory (T cm) (Sallusto et a l, 1992) and can be distinguished with 
the lymph node homing markers CD62L and CCR7, with CD62L^CCR7^ and 
CD62L'CCR7‘ cells representing the Tcm and Tem, respectively (Wiesel et a l, 2009). 
The adhesion molecules CD44 and GDI la are further used to differentiate naive 
from effector/memory CDS T cells (Wiesel et a l, 2009). Moreover, the simultaneous 
detection of cytokines {e.g. IFN-y, TNF-a, IL-2) and other effector 
molecules/markers {e.g. CD 107a mobilisation) has enabled assessment of T cell 
polyfunctionality and it has.been shown that T cells capable of exerting multiple 
functions may provide greater protective capacity (Larsen et al., 2012). Recent 
studies using such approaches have suggested that effector memory and/or 
polyfunctional CDS T cells play an important role in immunity to other viruses 
belonging to the family Flaviviridae, such as hepatitis C virus (HCV) (Bames et al, 
2012; Mikkelsen et a l, 2011 ; Urbani et a l, 2002) and yellow fever virus (YFV) 
(Akondy et a l, 2009).
To provide an improved understanding of the role that T cells may play in immunity 
to CSFV, this study deployed novel flow cytonietric antibody panels to quantitatively
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and qualitatively assess the T cell response induced following C-strain vaccination 
and subsequent CSFV challenge infection. It also assessed whether the T cell 
responses of vaccinated and challenged animals were sustained and/or readily 
recalled upon subsequent re-challenge infection and the impact this re-challenge had 
on their phenotype and function.
4.2 RESULTS
4.2.1 Summary
The rapid onset of protection conferred by the C-strain vaccine has previously been 
correlated to the induction of a broadly cross-reactive T cell IFN-y response (Graham 
et al, 2012a, Graham et al, 2012b). To characterize this early response, a first in 
vivo experiment was conducted where pigs were vaccinated with the C-strain vaccine 
and challenged after five days with the virulent Brescia strain. Using flow cytometry, 
the early source of CSFV-specific IFN-y was identified and this cell population was 
characterized for its ability to release another antiviral cytokine (TNF-a) and to 
degranulate upon antigen encounter. To assess the durability and recall of these 
responses, a second in vivo experiment was conducted where vaccinated animals 
were challenged with virulent CSFV after 5 and again after a fiirther 28 days. The 
reasoning behind the second challenge was to assess whether these responses were 
recalled/boosted upon re-exposure and the effects, if any, on the phenotype/function 
of CSFV-specific T cells. CSFV-specific IFN-y-producing cells were identified and 
their expression of surface markers (CD44, CD62L, CD25, CD27), and ability to 
release other cytokines (IL-2 and TNF-a) and to degranulate assessed. In order to 
analyse CSFV-specific IFN-y-secreting T cells in vaccinated pigs in the absence of
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challenge, cryopreserved samples from a third animal experiment were analysed 
(Graham et al., 2010). An ex-vivo approach was chosen to have a better picture of the 
immune response triggered by vaccination and to define the CSFV-specific IFN-y- 
producing cells correlated with rapid protection induced by C-strain vaccine. In vitro 
experiments were excluded due to the inability to detect CSFV-specific IFN-y after 
culturing PBMC from naïve pigs with this virus (data not shown). Flow cytometry 
was chosen because it allows a detailed characterisation of IFN-y releasing cells, 
impossible using other techniques like ELISA and ELISPOT.
4.2.2 CDS T cells are the principal source of virus-specific IFN-y after C-strain 
vaccination and challenge with virulent CSFV
The first in vivo experiment was performed in order to characterize the early cellular 
immune responses elicited by a live attenuated CSFV vaccine. Pigs were vaccinated 
with the C-strain vaccine and challenged after five days with the virulent Brescia 
strain. Vaccinated pigs were solidly protected against CSF. In contrast, unvaccinated 
challenge control pigs developed clinical signs of the disease, viraemia and 
leukopenia, as previously shown in Figure 3.7.
PBMC from vaccinated and challenge control pigs were collected longitudinally 
during the experiment, at day -2, 0, 3 and 5 post-challenge and cryopreserved. 
CSFV-specific IFN-y release from different lymphocyte populations was assessed 
using flow cytometry in order to identify the cellular source according to the gating 
strategy illustrated in Figure 4.1. The determination of the absolute numbers of IFN-y 
producing cells is also described in 2.12.3. As shown in Figure 4.2, CDS T cells, as 
defined by the CD3^CD4’CD8a^‘^  phenotype (Gemer et al., 2009), were identified 
as the main source of CSFV-specific IFN-y after vaccination with the C-strain virus.
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Neither CD4^CD8a' or CD4^CD8a^°^ T cells, which in swine have been proposed to 
represent naïve and activated/memory populations respectively (Gemer et al., 2009), 
showed a significant increase in CSFV-specific IFN-y"*" cells over the time-period 
analysed. CD3'CD8a"^ NK cells and CD8a °^'^ ‘^ T cells, which are mostly yô-T cells 
(Gemer et al., 2009), did not show significant IFN-y expression after vims 
stimulation at any of the time points examined. To exclude the possibility that CD8a^ 
yô-T cells falling within the CD3"^CD4'CD8a^‘^  ^gate were contributing to the IFN-y"*" 
cells detected, assays were performed with a pan-yô-T cell mAh and utilising PBMC 
firom 3 representative vaccinated and challenged pigs (Figure 4.3). Both challenged 
and unchallenged vaccinated animals, but not the challenge only pigs, displayed 
significant vims-specific CD8 T cell IFN-y responses from 8 days after vaccination 
(day 3 post-challenge) (p<0.05). Interestingly, CD8 T cells from vaccinated but 
unchallenged animals showed a higher frequency of IFN-y"* CD8 T cells compared to 
vaccinated and challenged animals at 8 days post-vaccination (p<0.05; Figure 4.2). 
The frequency of vims-specific CD8 T cells increased most markedly in the 
vaccinated and challenged pigs on day 5 post-challenge (10 days after vaccination), 
with the greatest number of cells being observed in those vaccinated intranasally 
(p<0.05).
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Figure 4.1 Gating strategy used in flow cytometric analysis of PBMC from 
vaccinated and challenged control pigs. The IFN-y response was interrogated in 
the singlet, live lymphocytes. Lymphocyte populations were defined as: CDS T cells 
(CD3*CD8a"'^CD4'), ‘memory’ CD4 T cells (CD3*CD8a‘°”CD4^), ‘naïve’ CD4 T 
cells (CD3+CD8aCD4"^), other T cells (CD3*CD8a‘°"'''CD4') and NK cells (CD3‘ 
CD8a CD4"). Finally, intracytoplasmic IFN-y expression was assessed in each 
population and compared to staining with an isotype control mAh. Panel B displays 
representative data of the expression of IFN-y versus CD8a on live singlet 
CD3^CD4 T cells after CSFV stimulation (pig 51, vaccine (i.n.)/challenge group, 
day 5 post-challenge).
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Figure 4.2 CD8 T cells are the principal source of CSFV-specific IFN-y following 
vaccination and challenge. At day -2, 0, 3 and 5 post-challenge, PBMC were 
stimulated in vitro with CSFV or mock virus supernatant and IFN-y expression was 
assessed by flow cytometry. Mean number of IFN-y producing cells/pl blood in 
response to CSFV stimulation for each lymphocyte population following mock- 
correction from three pigs/group/time-points is presented and error bars represent 
SD.
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Figure 4.3 Assessment of the contribution of yô-T cells to the ‘early’ CSFV- 
specific IFN-y responses. PBMC from three representative C-strain vaccinated pigs 
from different groups, cryopreserved at day 5 post-ehallenge were stimulated in vitro 
with CSFV or mock-virus supernatant and IFN-y production by cells expressing 
CD8a and/or TcR 6-ehain assessed by flow cytometry. Representative dot plots show 
the gating of live singlet CDSa^'TcR 5-chain’ CDS T cells and CDSa^ ’TcR 5-chain^ 
yô-T cells and subsequent assessment of IFN-y expression (A). Panel B shows the 
mean moek-eorreeted % IFN-y^ cells for each population. Means were calculated 
from 9 replicate cultures (triplicates for 3 pigs/group) +/- SD. Values were compared 
using a two-tailed un-paired t-test and significance is indicated by ***p<0.001.
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In order to fiirther characterize this early T cell response, the ability of the IFN-y 
expressing CDS T cells to degranulate and release other antiviral cytokines upon 
stimulation with CSFV was investigated. Since results showed that CSFV-specific 
IFN-y^ cells were located solely in the CD3^y5-TcR'CD4'CDSa^'^^ T cell population 
(Figures 4.2), subsequent stains were conducted with the omission of CD3 mAh and 
used only CD4 and CDSa mAbs to discriminate T cell populations. Translocation of 
lysosomal-associated membrane protein T (LAMP 1/CD 107a) to the cell membrane 
has been confirmed as a marker of cytotoxic degranulation by CDS T and NK cells 
(Betts et al, 2003). While CD 107a mobilisation has been reported as a marker for 
porcine NK cell degranulation (Toka et al, 2009), this is the first report of its 
application to assess porcine CDS T cell degranulation. PBMC isolated 5 days post­
challenge were stimulated with CSFV and analysed for their expression of IFN-y and 
CD 107a or TNF-a. More than 50% of IFN-y expressing CDS T cells fi*om all 
vaccinated animals expressed CD 107a on their surface, suggestive of cytotoxic 
activity against CSFV-infected antigen presenting cells (Figure 4.4A). Assessment of 
the co-expression of IFN-y and TNF-a by CDS T cells after virus stimulation showed 
individual variability between animals, but on average the majority of CSFV-specific 
CDS T cells expressed IFN-y and not TNF-a (Figure 4.4B). There were no 
significant differences in the proportions of TNF-a^IFN-y" or CD107a^IFN-y‘ CDS T 
cells between mock or CSFV stimulated conditions (Figure 4.4C).
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Figure 4.4 Functional and phenotypic characterization of ‘early’ CSFV-specific 
CDS T cells. Five days post-challenge, PBMC were stimulated in vitro with CSFV or 
mock virus supernatant and the expression of CD 107a, IFN-y and TNF-a by singlet, 
live CD8a^^^CD4' T cells was assessed by flow cytometry. The gating strategy was 
identical to the one illustrated in Figure 4.1, except with the exclusion of the CD3 
mAh. Representative dot plots show quadrant gates defining expression of IFN-y and 
CD107a (A), and IFN-y and TNF-a (B) by the live singlet CD8a“®^ CD4' T cell 
population. Data represent the mean of 6 replicates (2 replicates/pig/group) following 
subtraction of responses to mock-virus supernatant and error bars represent SD. Data 
for CD107a+lFN-y- and TNF-a+lFN-y live CD8a“*''CD4' cells in response to CSFV 
and mock-virus supernatant stimulation are presented in figure 4.4C. Values were 
compared using a two-tailed un-paired t-test and significance indicated by 
***p<0.001, **p<0.01, *p<0.05.
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4.2.3 CSFV C-strain induced CDS T cell responses are sustained and boosted 
upon later re-challenge infection
To further investigate the possible role for T cells in providing protection against 
CSFV, another experiment was conducted where C-strain vaccinated animals were 
challenged with Brescia strain after 5 days and then re-challenged with a 10-fold 
higher dose after 28 days. All animals were protected against both challenge 
infections with no clinical signs of CSF or reduction in leukocyte counts being 
observed (Figure 4.5).
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Figure 4.5 Outcome to challenge and re-challenge with virulent CSFV following 
vaccination with live attenuated C-strain vaccine. Five days after intramuscular 
(i.m.) vaccination, animals were challenged by intranasal inoculation with CSFV 
Brescia strain and re-challenge after 28 days with a higher dose of CSFV Brescia 
strain. Three negative control animals received similar inoculations of mock virus 
supernatant on each occasion. (A) Clinical signs of CSF were scored bi-daily and (B) 
leukocyte counts assessed by volumetric flow cytometry, 7 days before and after 
each of the CSFV Brescia inoculations. Results are expressed as the mean data for 
each group and error bars represent SD.
PBMC were collected longitudinally during the experiment and the CSFV-specific 
IFN-y response was again investigated ex vivo using flow cytometry (Figure 4.6). 
Significant virus-specific CD8 (CD3^CD4"CD8a '^^^) (Figure 4.6A) and memory
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CD4 (CD3^CD4^CD8a^°^) T cell responses (Figure 4.6B) were detected in 
vaccinated and challenged, but not control animals, from day 7 and 14 post­
challenge, respectively. No virus-specific IFN-y expression was detected in ‘naïve’ 
CD4 T cell (CD3^CD4 CD8a^^), CDSa}^^ '^ T cell or NK cell populations 
(representative data displayed in Figure 4.7). The contribution of yô-T cells was 
again directly assessed on three representative pigs using a TcR 8-chain mAh and no 
CSFV-specific increase in IFN-y^ yô-T cells were detected (Figure 4.7). The CD8 T 
cell response showed an initial peak on day 14 post-challenge, contracted to a degree 
and then peaked again 7 days after the second challenge infection (day 35) (Figure 
4.6A). The percentage of cells remaining in the contracted CSFV-specific CD8 T cell 
population following this second peak was similar to that observed after the first at 
-0.4%. Individual differences between animals were observed in the kinetics of the 
response, with pigs which showed the greatest peak in response to the first challenge 
infection displaying less evidence of a recall in response to the second challenge 
(data not shown). The kinetics of the memory CD4 T cell IFN-y response was largely 
similar to the CD8 response except that the frequency of cells was lower and was 
accompanied with an increase, albeit to lower levels, in the percentage of IFN-y 
expressing CD4 T cells in response to the mock virus supernatant, an effect not 
observed in the control animals despite these animals having been inoculated with 
this supernatant in place of the vaccine/challenge viruses. Subtraction of the response 
to mock-virus supernatant from the CSFV stimulated responses and conversion of 
this percentage to the number of IFN-y expressing cells per pi of blood clearly 
revealed that the CD8 T cell population was the major contributor to the CSFV- 
specific T cell response (Figure 4.6C).
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Figure 4.6 Vaccine-induced CD8 T cells display a sustained response and are 
boosted by re-challenge with virulent CSFV. PBMC from eight pigs vaccinated 
with C-strain CSFV and challenged with CSFV Brescia strain after 5 and a further 28 
days (Vaccinated/Challenged) and from unvaccinated/unchallenged pigs (control) 
were isolated on the indicated days and stimulated in vitro with CSFV or a mock 
virus supernatant. IFN-y expression by (A) CDS (CD3^CD4‘CD8a^ )^ and (B) 
memory CD4 (CD3^CD4^CD8a^°) T cells was assessed by flow cytometry using the 
gating strategy illustrated in Figure 4.1. (C) The absolute numbers of CSFV-specific 
CDS and ‘memory’ CD4 T cells were calculated from mock-corrected % IFN-y^ cells 
and absolute PBMC count data. The data represent the mean of 16 and 4 replicates 
for the vaccinated/challenged and control groups (2 replicates/pig/group), 
respectively, +/- SD (A, B) or standard error mean (SEM) (C). Mean values were 
compared using a two-tailed un-paired t-test and significance indicated by **p<0.01, 
*p<0.05.
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Figure 4.7 Assessment of the contribution of ‘naïve’ CD4 T ceils, NK cells and 
yô-T cells to CSFV-specific IFN-y responses at later time-points post-challenge.
PBMC from six pigs vaccinated with C-strain and challenged with CSFV Brescia 
strain, cryopreserved at day 21 post-challenge, were stimulated in vitro with CSFV 
or mock-virus supernatant and the IFNy response was interrogated in singlet, live 
lymphocytes. Panel A shows the mean mock-virus stimulation corrected % IFN-y  ^
cells for CDS '^T cells (CD3'"CD4-CD8a^^), ‘naïve’ CD4 T cell (CD3^CD4+CD8a), 
CD8a'°^^' T cells, NK cell populations using the gating strategy illustrated in Figure 
4.1. Panel B shows the mean mock-virus stimulation corrected % IFN-y  ^ cells for 
CDSa^^TcR ô-chain' CD8 T cells and CD8a^ 'TcR 6-chain^ yô-T cells using the 
gating strategy illustrated in Figure 4.3. Means were ealculated from 9 replicate 
cultures (triplicates for 3 pigs) + SD. Values were compared using a two-tailed un­
paired t-test and significance is indicated by ***p<0.001.
4.2.4 Following challenge CSFV C-strain-induced CDS T cell responses are 
polyfunctional and show a putative mixed effector/effector memory phenotype
Phenotypic and fiinctional analysis was performed on PBMC previously 
cryopreserved at the peaks following primary and secondary challenge infections and 
compared to cells collected from pigs 15 days post-vaccination with C-strain. PBMC 
collected at the peaks following primary and secondary challenge infections, day 14 
and 35 post-primary challenge respectively, were stimulated with CSFV or mock 
virus supernatant and analysed by multi-parameter flow cytometry. Due to the 
limited number, of cryopreserved cells, for some parameters (CD25 and CD27) only
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5 randomly chosen vaccinated and challenged pigs out of 8 were analysed. Since 
results showed that CSFV-specific IFN-y"^  cells were located solely in CD3’^ yô-TcR' 
CD4"^CD8a‘°" and CD3>8-TcR'CD4 CD8a“s'' T cell populations, subsequent stains 
were conducted with the omission of CD3 mAh and used only CD4 and CD8a mAbs 
to discriminate these two T cell populations.
On day 15 post-vaccination and days 14 and 35 post-challenge, the majority of IFN-y 
expressing CD8 T cells expressed high levels of the cell adhesion and indicative 
effector memory marker CD44 (Figure 4.8 A) and lacked expression of the peripheral 
lymph node homing receptor, L-selectin/CD62L (Figure 4.8B). Evaluation of the 
expression of CD44 and CD62L at the other time points post-challenge revealed that 
the CD44 '^®^CD62L' was the dominant phenotype throughout (Figure 4.9). In 
contrast, CSFV-specific CD8 T cells from both groups and selected time-points 
displayed variable levels of both CD25, the alpha-ehain of the IL-2 receptor that is 
expressed on the surface of activated lymphocytes (Minami et al, 1993; Piriou et al, 
2003), and CD27, a co-stimulatory receptor that provides a critical survival signal to 
activated T cells (Hendriks et a l, 2003) (Figure 4.8C and 4.8D).
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Figure 4.8 Phenotypic and functional characterization of CSFV-specifîc CDS T 
cells. PBMC from pigs vaccinated with C-strain (vaccinated only) or C-strain vaccinated 
pigs challenged with CSFV Brescia (vaccinated/challenged) were stimulated with CSFV 
and mock-virus supernatant 15 days after vaccination or 14 days after challenge (Day 
14) and 7 days after re-challenge (Day 35), respectively. The expression of CD44 (A), 
CD62L (B), CD25 (C), CD27 (D), and CD 107a (E) on IFN-y  ^singlet, live CD8a'''^CD4- 
T cells was assessed by flow cytometry. Data displayed are representative dot plots of a 
vaccinated/challenged pig. For CD25 and CD27, 5 randomly selected
vaccinated/challenged pigs out of 8 were used. The mean mock-corrected % IFN-y"^  CDS 
T cells for 8 or 10 or 16 replicate cultures (2 replicates for 4 vaccine only pigs and 5 or 8 
vaccinated/challenged pigs, respectively) and error bars represent SD. Values were 
compared using a two-tailed un-paired t-test and significance is indicated by **p<0.01, 
*p<0.05.
125
B
0 .8-1 0 .8-1
■  CD44I0W w
□  CD44high g
“  0 .6 -
00
i
0.4- 0.4-
Z  0.2- Z  0.2-
0.0- I I T r  - T  ■ T
-5 0 7 14 21 28 35 42 49 56
0.0
■5 0 7 14 21 28 35 42 49 56
□  CD62L- 
■  CD62L-H
Days post-challenge Days post-challenge
Figure 4.9 Longitudinal analysis of the expression of CD44 and CD62L on 
CSFV-specifîc CDS T cells. PBMC from three randomly choosen C-strain 
vaccinated and Brescia challenged pigs were collected longitudinally during the 
experiment and cryopreserved till analysis. PBMC were stimulated with CSFV or 
mock-virus supernatant and the expression of CD44 (A), CD62L (B) on IFN-y^ 
singlet, live CD8a^^^CD4' T cells was assessed by flow cytometry. Data display the 
mean mock-corrected % IFN-y^ CDS T cells for 6 replicate cultures (2 replicates for 
three pigs) and error bars represent SD.
The polyfunctionality of CSFV-specific CDS T cells at the peaks of response post­
vaccination (day 15) and vaccination/challenge (day 14 and 35) were again 
investigated by their ability to degranulate and co-express cytokines upon virus 
stimulation. As had been observed in the earlier experiment, only a proportion 
(-50%) of IFN-y^ CDS T cells from the vaccinated only group had mobilised 
CD 107a (Figure 4.SE). In contrast, the majority of cells from vaccinated and 
challenged animals, on both day 14 and 35, showed evidence of degranulation. Co­
expression of TNF-a and IL-2 by CSFV-specific IFN-y"*" CDS T cells was assessed 
using the gating strategy illustrated in Figure 4.10A. Due to the limited number of 
cryopreserved cells, release of CSFV-specific TNF-a and IL-2 was assessed only in 
5 randomly chosen vaccinated and challenged pigs out of S. Interestingly, significant 
variability was observed in the cytokine profile between individual animals, groups
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and time-points (Figure 4.1 OB). In the vaccinated only group, 15 days post­
vaccination the majority of CSFV-specific CDS T cells only secreted IFN-y, with a 
significant minority (19.4-42%) of CSFV-specific IFN-y^ CDS T cells co-expressing 
TNF-a. Only 2 of the 4 vaccinated only pigs were found to have a small proportion 
of CDS T cells expressing all three cytokines (IFN-y, TNF-a and IL-2) (2.9 and 5.1% 
of CSFV-specific IFN-y"^  CDS T cells respectively). Analysis of the vaccinated and 
challenged animals showed that on day 14 post-challenge, cells co-expressing IFN-y 
and TNF-a were the largest population in 2 of the 5 animals analysed (43.6 and 
49.9% of CSFV-specific IFN-y”^ CDS T cells respectively), with the single IFN-y 
expressers being the major population in the other 3 animals. In 4 of the 5 animals 
there was a significant population of cells expressing all three cytokines, which 
ranged from 9.1-29.6% of CSFV-specific IFN-y^ CDS T cells. On day 35 post­
challenge (7 days post-re-challenge), there was an increase in the relative proportion 
of single IFN-y expressers in three animals, while in the other two the greatest 
increase was observed in the triple expressers (pig S) and IFN-y and TNF-a dual 
expressers (pig 10). There were no significant differences in the proportions of TNF- 
a^IFN-y", IL-2^IFN-y" or CD107a^IFN-y" CDS T cells between mock or CSFV 
stimulated conditions (data not shown). Assessment of the relative IFN-y expression 
levels, by comparing fluorescence intensity measurements, revealed that on day 14 
post-vaccination and days 14 and 35 post-challenge, the triple cytokine expressing 
CDS T cells produced significantly larger amounts of IFN-y compared to the single 
and dual expressers (Figure 4.11).
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Figure 4.10 Characterization of polyfunctional cytokine expression by CSFV- 
specific CDS T cells. PBMC from pigs vaccinated with C-strain CSFV (animal 
experiment 3; n=4) or C-strain vaccinated pigs challenged with CSFV Brescia 
(animal experiment 2; n=5) were stimulated with CSFV and mock-virus supernatant 
14 days after vaccination or 14 days after challenge (Day 14) and 7 days after re­
challenge (Day 35), respectively. The expression of TNF-a and IL-2 by CSFV- 
specific IFN-y^ singlet, live CD8a^^^^CD4" T cells were determined by flow 
cytometry. Panel A shows representative dot plots and Panel B presents the mock- 
corrected mean proportions of IFN-y secreting CDS T cells expressing either of the 
two other cytokines, for duplicate cultures/animal.
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Figure 4.11 Characterization of the relative IFN-y expression levels in 
triple/double/single cytokine expressing CSFV-specific CDS T cells. Graphs show 
the mean fluorescence intensity (MFI) of IFN-y staining of each population. Data 
represent the MFI of IFN-y^ CDS T cells for S or 10 replicate cultures (two replicates 
for four vaccinated pigs and five vaccinated and challenged pigs, respectively) and 
error bars represent SD. Statistical analyses were performed using a one-way 
ANOVA followed by a Dunnett’s Multiple Comparison Test against CDS T cells 
secreting only IFN-y; ***p<0.001, **p<0.01.
4.3 DISCUSSION
4.3.1 Introduction
These results provide the first detailed phenotypic and functional analysis of the T 
cell response induced by vaccination with a live attenuated C-strain vaccine followed 
by subsequent challenge infections with virulent CSFV.
4.3.2 Identification of the ‘early’ source of virus-specific IFN-y after C-strain 
vaccination and challenge with virulent CSFV
This study has demonstrated that CDS T cells (CD3^CDSa^‘^ ^CD4‘) are the main 
source of CSFV-specific IFN-y after vaccination with the C-strain vaccine and can 
be detected in the blood as early as S days post vaccination. IFN-y producing CDS T 
cells were detected in all vaccinated groups, independently of the route of vaccine
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administration (i.n. or i.m.). In contrast, infection of unvaccinated animals did not 
result in a detectable T cell IFN-y response against the virus and animals developed 
clinical signs of the disease, leucopenia and viraemia. These results are in accordance 
with previous publications, where it has been reported that a CSFV-specific T cell 
IFN-y response can be identified in the blood as early as 6 or 8 days after C-strain 
vaccination (Suradhat et al, 2001; Graham et al, 2012a, Graham et al, 2012b) and 
confirms the correlation between the T cell IFN-y response and protection against 
CSF. The inability to detect a CSFV-specific IFN-y response in unvaccinated 
challenge control pigs is in accordance with earlier studies conducted utilizing 
moderately virulent CSFV strains (Graham et al, 2012a; Graham et al, 2012b) but 
contrasts to a previous report, where IFN-y producing CD4 and CDS T cells were 
detected in unvaccinated pigs challenged with a virulent strain of CSFV (Suradhat et 
al, 2005). In a study by Suradhat et al, a similar method, based on flow cytometry, 
was used to analyze the phenotype of IFN-y-releasing cells, however the challenge 
was performed with a lower dose of virulent CSFV (2x10"^  TCID50). Pigs developed 
severe leucopenia and the authors were not able to analyze the phenotype of IFN-y- 
producing T cells after 7 days post-challenge (Suradhat et al, 2005). Probably, the 
challenge dose used in the present study (10  ^TCID50) was so strong that the T cells 
started to undergo apoptosis before being able to release detectable CSFV-specific 
IFN-y.
4.3.3 Identification of the long-term source of virus-specific IFN-y after C-strain 
vaccination and challenge with virulent CSFV
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While CDS T cells were detected as the first source of IFN-y produced in response to 
CSFV, they were also shown to be the major producers, with 400-1200 CSFV- 
specific CDS T cells/pl being detected in blood. In comparison, virus-specific CD4 T 
cells were present at 2-6 fold lower numbers, which is in general accordance with an 
earlier study (Graham et al, 2012b). Moreover, re-challenge of animals resulted in a 
significant boosting of specific CDS T cell numbers whilst CSFV-responding CD4 T 
cells remained relatively constant in number. The inability to detect strong CD4 T 
cell responses is rather surprising, given that CSFV is able to infect APCs expressing 
MHC-II, such as monocytes and DCs. A study on the related pestivirus BVDV 
reported that both CD4 and CDS T cell responses are evoked, but CD4 cells produce 
IL-4 in response to this virus, suggestive that their major role is to mediate help for 
the induction of B cell antibody responses (Rhodes et al., 1999). It is possible to 
speculate that CD4 T cells are involved mainly in shaping the humoral and cellular 
immune response to CSFV. As the major source of CSFV-specific IFN-y, this study 
focused on the characterization of CDS T cells, fixture studies should explore CD4 T 
cell responses using other cytokines such as IL-4 as a read-out.
Interestingly, vaccinated/challenged pigs showed an increase in the percentage of 
IFN-y expressing memory CD4 T cells in response to culture with the mock-virus 
supernatant. It might be speculated that this is due to reactivity against an, as yet, 
unidentified antigen present in the PK15 lysate. The presence of CSFV may have 
adjuvanted the response to this antigen, so that it was observed only following 
vaccination and challenge and not seen in control animals inoculated with the mock- 
virus supernatant. '
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4.3.4 Functional and phenotypic characterization of the CSFV-specific CDS T 
cells.
The study next addressed the memory/activation phenotype of the CSFV-specific 
CDS T cells, since it has become apparent in recent years that the efficacy of T cell 
based vaccines is highly dependent upon the quality of the memory population 
induced. CSFV-specific IFN-y^ CDS T cells expressed high levels of the cell 
adhesion glycoprotein, CD44, and lacked expression of the lymph node homing 
receptor CD62L. Based upon current models of CDS T cell differentiation, this 
would classify these cells as either effectors ( T e f f )  or T e m  cells, which traffic via 
non-lymphoid tissues, rather than Tcm cells which express CD62L (Wiesel et al, 
2009).
CD27, a co-stimulatory receptor that provides a critical survival signal to activated T 
cells (Hendriks et al, 2003), is required for CDS memory T cell formation and 
responsiveness. CD27 is a marker of long-term survival and maintenance of T cell 
memory (Mikkelsen et al., 2011) and its expression is lost on human CDS T e f f  cells 
and increases upon differentiation to memory cells with low levels expressed on Tem 
and higher levels on Tcm (Kobayashi et al, 2006; Tomiyama et a l, 2004). A recent 
study of CD27 expression by porcine CD4 T cells has shown that antigen-specific 
IFN-y expressing CD4^CDSa^ T cells may be either CD27' or CD27^ (Reutner et al, 
2013). Compared to CD27'CD4+CDSa^ T cells, CD27^CD4"^CDSa^ T cells respond 
to polyclonal activation with enhanced cytokine production and reduced 
proliferation. They also lack or show reduced expression of lymph node homing 
receptors, and it has therefore been proposed that CD27^ and CD27' porcine CD4 T 
cells may represent Tcm and Tem, respectively. While a comparable analysis of CD27 
expression by porcine CDS T cell is still to be conducted, in a recent study on the
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development of the immune system in young pigs, changes in the expression of 
CD27 on CDS T cells in the blood of pigs from birth to 6 months of age was 
analysed. The results suggested that early effector CDS T cells expressed low levels 
of CD27, which was absent on late effector or memory CDS T cells (Talker et al,
2013). Therefore at this time it may only be hypothesised that the variable level of 
CD27 expression on CSFV-s]pecific CDS T cells reflects a mixture of effector and 
memory phenotypes.
Studies on other viruses belonging to the family Flaviviridae, HCV and YFV, have 
shown an important contribution of effector memory CDS T cells in response to 
infection (Urbani et al, 2002; Akondy et al, 2009). Moreover, in response to a 
yellow fever vaccine, it has been observed that memory CDS T cells passed through 
an effector phase and then gradually down-regulated the expression of activation 
markers, with a following phase characterised by contraction and selection of a pool 
of memory polyfrinctional T cells (Akondy et al, 2009). Perhaps after C-strain 
vaccination CDS T cells pass through different phases and the identified mixed 
population of effector and memory CSFV-specific , CDS T cells might reflect this 
evolution.
Variable expression of CD25, the alpha-chain of the IL-2 receptor, which is 
expressed on the surface of activated lymphocytes (Suradhat et al., 2005; Minami et 
al., 1993; Firiou et al., 2003), was also observed. Heterogeneity in expression of 
CD25 on CDS T cells has been described in an acute murine virus infection model, 
with low CD25 expression associating with generation of long-lived memory and 
high expression with terminal effector differentiation (Kalia et a l, 2010). This 
expression pattern may therefore also imply a mixed CSFV-specific T e f f  and T e m  
population and explain the previously described lack of association between
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enhanced CSFV-specific IFN-y production and up-regulation of CD25 on CDS T 
cells (Suradhat et a/., 2005). Since this analysis was conducted following in vitro 
restimulation of previously cryopreserved PBMC, it remains to be determined 
whether these phenotypes accurately represent those of CSFV-specific CDS T cells 
in vivo. A number of CDS T cell epitopes on CSFV have been recently identified 
(Chapter 5 of this Thesis) and together with the recent development of porcine MHC 
class I tetramers (Patch et ah, 2011), tools could be developed to confirm the 
phenotype of CSFV-specific CDS T cells by direct ex vivo examination.
4.3.5 Polyfunctionality of the CSFV-specific CDS T cells.
The study finally assessed the polyfunctionality of the CSFV-specific CDS T cell 
population since this may be central to their protective capacity. Based on current 
models, CDS Tem cells have been shown to have high ex-vivo cytotoxic potential and 
rapidly produce cytokines upon re-exposure to antigens, whereas CDS Tcm cells 
possess a greater proliferative capacity (Thakur et at.^  2012). Interestingly, it was 
found that early post-challenge or in the absence of challenge, only a proportion of 
CSFV-specific IFN-y CDS T cells mobilised CD 107a, compared to later time-points 
post-challenge, where the majority expressed CD 107a on their surface. CD 107a is 
mobilised to the cell surface following activation-induced degranulation and it has 
been described as a marker for cytotoxic CDS T cell activity, whose expression has 
been associated with loss of perforin following antigen stimulation (Betts et al,
2003). The data presented here suggest that CSFV-specific IFN-y expressing cells 
may also have cytotoxic capacity, and is consistent with previous results that showed 
IFN-y expression was restricted to CDS T cells expressing intracellular perforin 
(Graham et al, 2012b) and other earlier studies that demonstrated CSFV-specific
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cytotoxic activity by T cell cultures isolated from vaccinated pigs (Ceppi et al, 2005; 
Rau et al, 2006; Pauly et al, 1995). While IFN-y secreting Tem have been 
implicated in protection against a variety of intracellular pathogens, simultaneous 
production of IFN-y, TNF-a and IL-2 detected at the single cell level by 
multiparameter flow cytometry has been correlated with enhanced vaccine induced 
protection in cattle (Kaveh et al, 2011), mice (Darrah et al, 2007; Berchtold et al, 
2009; Reyes-Sandoval et al, 2011), humans (Lumsden et a l, 2011), baboons 
(Burgers et al, 2009) and rhesus macaques (Hansen et al, 2011). Moreover, data 
suggest that in humans and mice such polyfunctional CDS T memory cells are 
associated to long-term protection against other viruses belonging to the family 
Flaviviridae (Mikkelsen et a l, 2011; Akondi et a l, 2009). In the present study, the 
majority of CDS T cells produced only IFN-y or IFN-y and TNF-a, with only a small 
percentage co-expressing IFN-y TNF-a, and IL-2. As seen with CD 107a 
mobilisation, there appeared to be a trend towards an increase in functionality 
following challenge although inter-animal variability was observed. Since all animals 
were solidly protected against the challenge infections it was not possible to attribute 
polyfunctionality with enhanced protection. Nevertheless, triple cytokines expressing 
T cells showed the highest ‘quality’ of response by producing the greatest amount of 
IFN-y, followed by the cells co-expressing TNF-a, similar to that observed in other 
systems (Kaveh et al, 2011; Whelan et a l, 2011 ; Seder et al, 2008).
4.4 CONCLUSIONS
Overall, this data supports the hypothesis that CDS T eff /T e m  cells play a key role in 
the protection afforded by C-strain CSFV in the early period preceding the
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appearance of neutralising antibodies. These responses are also readily recalled by 
later challenge. This information and the novel flow cytometric panels developed and 
employed for the first time in the pig to characterise these responses will hopefully 
aid the development and evaluation of next-generation vaccines to CSFV and more 
broadly to other porcine pathogens.
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CHAPTER 5: PROTEOME-WIDE SCREENING REVEALS
IMMUNODOMINANCE IN THE CDS T CELL RESPONSE AGAINST 
CLASSICAL SWINE VIRUS WITH ANTIGEN-SPECIFICITY DEPENDANT 
ON MHC CLASS IHAPLOTYPE
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5.1 INTRODUCTION
As previously described, C-strain vaccine induced IFN-y responses have been 
correlated to rapid protection against CSF (Graham et al., 2012a). As shown in 
Chapter 4 and by earlier studies (Graham et ah, 2012b), CSFV-specific IFN-y 
secreting CDS T cells are the major population induced by C-strain vaccination. 
Determining the viral proteins that are the targets of the CDS T cell response in 
immune animals would provide an important step towards developing a next 
generation marker vaccine capable of providing rapid protection. CSFV has four 
structural proteins (the core protein and the envelope glycoproteins Ems, El and E2) 
and eight non-structural proteins (Npro, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) 
(Thiel et al, 1991). E2 and NS3 have been previously described as targets of the T 
cell response and both proteins may induce IFN-y release (Graham et al, 2012a; 
Ceppi et al, 2005; Rau et al, 2006; Armengol et al, 2002) or cytotoxic activity by T 
cells from vaccinated pigs (Ceppi et al, 2005; Rau et al, 2006; Pauly et al, 1995; 
Armengol et a l, 2002). A T cell epitope was identified on NS4 (Pauly et al, 1995) 
and it was recently reported that NS5B is a putative target of IFN-y secreting T cells 
from C-strain vaccinated pigs (Graham et al, 2012a). Epitopes may be located on 
other viral proteins, since peptides pooled to represent Ems, El, NS2, NS4B and 
NS5A were able to induce PBMC proliferation in vaccinated pigs, but their ability to 
elicit an IFN-y or cytotoxic response was not tested (Armengol et a l, 2002). 
However, most of these studies utilised inbred homozygous pigs, and so were 
focussed on a single haplotype (Ceppi et a l, 2005; Pauly et al, 1995; Armengol et 
al, 2002) and the phenotype of the responding T cells/MHC restriction was not or 
only partially characterized (Graham et a l, 2012a; Ceppi et a l, 2005; Rau et al, 
2006; Pauly er al, 1995; Armengol et a l, 2002).
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Knowledge of epitopes within viral proteins that are targeted by CDS T cells is also 
necessary to ensure that genetically attenuated or sub-unit DIVA vaccines include 
these regions. As the major target of neutralizing antibody responses, the structural 
protein E2 has been used to create subunit or chimeric virus vaccines (Tarradas et al., 
2010; Koenig et al., 2007). Additional evidence that this protein is also able to target 
T cell responses comes from a recent study which showed that a DNA vaccine 
expressing E2 induced a cellular immune response, characterized by IFN-y releasing 
T cells, before the appearance of neutralizing antibodies (Tarradas et al., 2010). 
Moreover, a chimeric vaccine CP7_E2alf, where the E2 protein of the CSFV strain 
Alfort 1S7 is inserted in the backbone of the BVDV strain CP7, can frilly protect pigs 
from challenge before the appearance of neutralizing antibodies (Koenig et al., 
2007). It remains, however, to be determined whether CSFV E2-specific or BVDV 
cross-reactive antigen-specific T cells are involved in mediating this protection.
The ability of subunit vaccines to trigger T cell responses that contribute to 
protection has been observed in other viruses belonging to the family Flaviviridae, 
such as HCV (Schlaphoff et al., 2007; Lang Kush et al., 2012; Mikkelsen et al., 
2011) and dengue virus (DENV) (Costa et al., 2011 ; Gao et al., 200S). Both a HCV 
peptide-vaccine, including 5 MHC-class I and 3 MHC class-II-restricted epitopes, a 
DNA vaccine encoding NS3 and NS4 of HCV and an adenovirus-based vaccine 
expressing HCV NS3 were demonstrated to induce a strong CDS T cell response in 
vaccinated individuals (Schlaphoff et al., 2007; Lang Kush et al., 2012; Mikkelsen et 
al, 2011). DNA vaccines based on the NS3 protein from DENV and an adenovirus 
expressing DENV NSl induced an antigen-specific IFN-y response by CDS T cells 
from vaccinated mice which correlated with protection (Costa et a l, 2011; Gao et a l, 
200S). The analysis of antigen-specific T cell responses that contribute to protection
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against CSFV would provide important information for the development of the next- 
generation of marker vaccines.
With a view to better defining the antigenic targets of the CDS T cell response in 
pigs protected against CSF by vaccination with a live-attenuated C-strain vaccine, a 
peptide library spanning the CSFV proteome was screened for T cell reactivity. Five 
T cell antigens and the corresponding antigenic regions/epitopes were identified and 
characterised and the conservation of these peptides across CSFV strains was 
assessed.
5.2 RESULTS
5.2.1 Summary
In this study the specificity of the CSFV-specific CDS T-cell response was assessed 
by screening a peptide library spanning the CSFV C-strain polyprotein. Initially, 
synthetic peptides were pooled to represent each of the 12 viral proteins and used to 
stimulate PBMC from four pigs rendered immune to CSFV by C-strain vaccination 
and subsequently challenged with the virulent Brescia strain. Then, the antigenic 
peptide pools were dissected and the peptides responsible for the IFN-y induction 
were identified. Conservation of the antigenic regions/epitopes identified across 
CSFV strains and the related pestiviruses BVDV and BDV was assessed. The link 
between variability in the antigen-specificity of CDS T cell responses and the 
expression of distinct MHC class I haplotypes was analysed. Finally, epitope-specific 
CDS T cells were functionally and phenotypically characterized. Initially, CSFV- 
specific IFN-y release was measured using an ELISpot assay, then flow cytometry 
was applied, because this technique allows the phenotypical and functional 
characterisation of the IFN-y-releasing cells.
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5.2.2 Detection of CSFV-specific CDS T cell responses following vaccination and 
challenge
Animals vaccinated in Experiment 1 were solidly protected against both challenge 
infections, at 5 and a further 28 days post-vaccination, with no evidence of 
leukopenia or clinical signs of the disease being observed (Figure 4.5). One week 
after the second challenge inoculation a significant IFN-y response following in vitro 
stimulation with CSFV was observed in PBMC from vaccinated/challenged (V/C) 
animals, but not control pigs (Figure 5.1). Using the flow cytometric gating strategy 
displayed in Figure 5.2A, CSFV-specific IFN-y CDS T cells (CD4'CD8a^‘^ ) and 
‘memory’ CD4 T cells (CD4^CD8a^°^) were detected in PBMC from V/C animals, 
but not control pigs, with the former population dominating the IFN-y response 
(Figure 5.2B). From the 8 V/C pigs, the greatest CDS T cell response was identified 
in pigs AN5, AN7, ANl 1 and AN13, and these animals were selected for an in-depth 
analysis of the specificity of their CDS T cell responses.
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Figure 5.1 Vaccination with C-strain and challenge with virulent CSFV induces 
a virus-specific IFN-y response. Pigs were vaccinated on day -5 and then 
challenged with CSFV Brescia strain on days 0 and 28 post-challenge. Seven days 
after first challenge, PBMC from vaccinated/challenged (V/C) and control animals 
were stimulated in vitro with CSFV or mock virus supernatant and IFN-y release 
measured by ELISpot assay. The mean mock-virus stimulated corrected IFN-y spot- 
forming cells (SFC)/5xlO^ PBMC data for each group are presented and error bars 
represent SD.
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Figure 5.2 Vaccination with C-strain and challenge with virulent CSFV induces 
predominately a virus-specific IFN-y CD8 T cell response. Pigs were vaccinated 
on day -5 and then challenged with CSFV Brescia strain on days 0 and 28 post­
challenge. Seven days after challenge, PBMC from V/C and control animals were 
stimulated with CSFV or mock virus supernatant and IFN-y expression was assessed 
by flow cytometry. Panel A shows the gating strategy used to interrogate responses 
in singlet, live CD8 T cells (CD3^CD8a'’'^ *^ CD4 ) and memory CD4 T cells 
(CD3^CD8a^°^CD4^) for a representative sample. The intracytoplasmic IFN-y 
expression was assessed in each population and panel B shows the mock-virus 
stimulated corrected % IFN-y expressing memory CD4 T cells and CD8 T cells for 8 
V/C animals and 3 control animals. Error bars represent SD. Values of control and 
V/C groups were compared using a two-tailed un-paired t-test and significance is 
indicated by **p<0.01, *p<0.05.
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5.2.3 Screening of a CSFV proteome-wide peptide library to identify CD8 T cell 
antigens
To identify CSFV T cell antigens, PBMC from the four selected V/C pigs were 
incubated for two hours in vitro with pools of overlapping 15mer peptides 
representing the 12 CSFV proteins and CDS T cell reactivity was screened using 
IFN-y detection by flow cytometry (Figure 5.3). Significant IFN-y responses were 
observed in all V/C animals.and each animal reacted against a unique profile of 
antigens. Pig AN5 mounted a significant IFN-y response against NS3 and NS5A 
peptides, pig AN7 reacted significantly against the NS2 peptide pool, pig ANll 
responded to peptides representing the E2 and NS3 proteins and pig AN 13 mounted 
the greatest response to the core peptides with significant reactivity also observed 
against NS 5 A.
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Figure 5.3 CD8 T cells from pigs vaccinated with C-strain and challenged with 
virulent CSFV display distinct profiles of antigen reactivity. Fourteen days after re­
challenge with CSFV Brescia strain, PBMC from four selected pigs were stimulated 
in vitro with synthetic peptide pools representing the 12 CSFV proteins and IFN- 
y expression was assessed by flow cytometry. Graphs show the mean unstimulated- 
corrected % IFN-y^ CDS T cells for each animal in response to peptide pools +/- SD. 
Statistical analyses were performed using a one-way ANOVA followed by a 
Dunnett’s multiple comparison test versus the unstimulated cells; ***p<0.001,
**p<0.01.
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5.2.4 Identification of CD8 T ceil epitopes on CSFV
To identify the peptide targets of these CDS T cell IFN-y responses, a two way 
matrix system was adopted to screen peptides representing the non-structural 
proteins NS5A, NS3, NS2 and the structural protein E2, whereas the peptides 
spanning the core protein were screened individually due to its short length. The 
matrix pools were designed so that each peptide was uniquely present in 2 defined 
pools. An illustration of how peptides were combined into matrix pools and how the 
CDS T cell IFN-y responses to these pools enabled the identification of putative 
antigenic peptides is shown in Table 5.1, using NS2 peptides as example. 
Overlapping peptides were not labelled consecutively, due to the manufacturer’s 
grouping of peptides with identical C-terminal amino acids. PBMC from pigs AN5 
and ANl 3 were stimulated in vitro with the NS5A matrix peptide pools and IFN-y"^  
CDS T cells were identified using flow cytometry (Figure 5.4). Pools C, K, N and Q 
induced a significant IFN-y response in CDS T cells from pig AN5. By analysing the 
peptide constituents of the reacting matrix pools, four potential antigenic 15mers 
were identified for further testing: peptides #25, 33, 58 and 66. Pig ANl3 did not 
mount a significant CDS T cell IFN-y response to any of the NS5A matrix pools. 
PBMC from pig AN7 were stimulated with the NS2 matrix peptide pools and a CDS 
T cell IFN-y response was observed against pools B, I, O, P, identifying 4 putative 
antigenic peptides: #35, 42, 46 and 53. PBMC from pigs AN5 and A N ll were 
stimulated in vitro with the NS3 matrix peptide pools and peptides present in the 
pools D, F, G, X, Y and Z induced a statistically significant CDS T cell IFN-y 
response, which indicated that peptides #134, 136, 137, 147, 149, 150, 160, 162 and 
163 were potentially antigenic. Pig AN5 did not mount a significant response to the 
NS3 matrix pools. E2 matrix peptide pools were screened with PBMC from pig
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ANll leading to the identification of significant reactivity against pools E, G, O and 
P; suggesting reactivity against peptides 45, 47, 55 and 57.
The identified putative antigenic peptides were next screened individually to assess 
their recognition by CDS T cells. PBMC from pig AN5 were found to show 
significant reactivity to overlapping NS5A peptides 33 and 5S, but not 25 and 66, 
suggesting that a single epitope lay in the 1 Imer consensus region LSRVDNALLKF 
(Figure 5.5). Of the four possible antigenic NS2 peptides, overlapping peptides 42 
and 46, with the consensus sequence LISTVTGIFLI, but not 35 and 53, induced a 
statistically significant greater number of IFN-y expressing CDS T cells from pig 
AN7 compared to un-stimulated controls (Figure 5.5). PBMC from pig ANll 
showed significant reactivity against two pairs of overlapping peptides, E2 peptides 
47 and 55 and NS3 peptides 134 and 163 with llm er consensus sequences of 
RYYEPRDSYFQ and VEYSFIFLDEY, respectively (Figure 5.5). Peptides spanning 
the core protein were screened individually using PBMC from pig AN 13 and 
significant CDS T cell IFN-y responses were observed against the peptide 20 
(PESRKKLEKALLAWA) (Figure 5.4).
Table 5.1 Example of the two-way matrix-pooling system used to identify T cell 
reactive peptides from pools representing CSFV proteins.______________
NS2 Matrix pools*
A C D E F G H m m J K
L 1 2 3 4 5 6 7 8 9 10 11
M 12 13 14 15 16 17 18 19 20 21 22
1 N 23 24 25 26 27 28 29 30 31 32 33
34 36 37 38 39 40 41 43 44
a 45 47 48 49 50 51 52 54 55
Q 56 57 58 59 60 61 62 63 64 65 66
R 67 68 69 70 71 72 73 74 75 76 77
S 78 79 80 81 82 83 84 85 86 87 88
;z; T 89 90 91 92 93 94 95 96 97 98 99
U 100 101 102 103 104 105 106 107 108 109 110
*The 110 overlapping 15mer peptides (#1-110) representing CSFV NS2 were pooled using a matrix 
system so that each peptide was uniquely represented in two matrix-pools (Pools A-U).
^Matrix pools B, I, O and P stimulated CDS T cell reactivity from Pig AN7 and so NS2 peptides #35, 
42, 46 and 53 were identified for further testing.
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Figure 5.4 Identification of putative antigenic peptides recognised by CSFV 
specific CDS T cells. Twenty one days after re-ehallenge, PBMC from pigs AN5, 
AN7, ANll and AN 13 were stimulated with synthetic peptides pooled in a 2-way 
matrix for proteins E2 (pig ANll), NS2 (pig AN7), NS3 (pigs AN5 and A N ll) and 
NS5A (pigs AN5 and ANl3). Peptides representing the core protein were screened 
individually (pig ANl3). IFN-y expression by CDS T cells was assessed by flow 
cytometry as described above. The mean unstimulated-eorreeted % IFN-y expressing 
CDS T cells are presented and error bars represent SD. Statistical analyses were 
performed using a one-way ANOVA followed by a Dunnett’s multiple comparison 
test versus unstimulated cells; ***p<0.001, **p<0.01, *p<0.05.
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Figure 5.5 Confirmation of reactivity against defined peptides by CSFV specific 
CDS T cells. PBMC from pigs AN5, AN7 and ANll, cryopreserved at twenty one 
days after re-challenge, were stimulated in vitro with the 15mer antigenie peptides 
identified using the matrix peptide pools (NS5A 25, 33, 58, 66 for pig AN5; NS2 35, 
42, 46, 53 forpig AN7; E2 45, 47, 55, 57 andNS3 134, 136, 137, 147, 149, 150, 160, 
162, 163 for pig ANll). IFN-y expression by CDS T cells was assessed by flow 
cytometry as described above and the mean unstimulated-eorreeted % IFN-y 
expressing CDS T cells are presented and error bars represent SD. Statistical analyses 
were performed using a one-way ANOVA followed by a Dunnett’s multiple 
comparison test versus unstimulated cells; ***p<0.001, **p<0.01, *p<0.05.
The length of CDS T cell epitopes can vary between S and 11 amino acids. However, 
peptides up to 14 amino acids have been reported as binding to MHC class I 
molecules (Burrows et al., 2006). In order to identify the minimal length antigenic 
peptides, which likely represent the natural epitopes for CSFV-speeifie CDS T cells, 
the two possible lOmer, three 9mer and four Smer sequences for each consensus 
llm er sequence of overlapping peptide pairs (NS5A-LSRVDNALLKF NS2- 
LISTVTGIFLI, E2-RYYEPRDSYFQ) were synthesised and tested. Due to a
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limitation in the numbers of PBMC cryopreserved from pigs AN 13 and ANl 1, it was 
not possible to define the minimal length antigenic peptides for NS31902-1912 
VEYSFIFLDEY (pig ANl 1) and core24i_255 PESRKKLEKALLAWA (pig AN13). 
Following stimulation of PBMC from pig AN5 with the NS5A llm er 
LSRVDNALLKF and truncated derivatives (Figure 5.6A), one lOmer, two 9mers 
and the four 8mers induced a statistically significant lower number of IFN-y 
producing CDS T cells than the 1 Imer, suggesting that the 9mer RVDNALLKF was 
the minimal length antigenic peptide. Similar analysis with pig AN7 (Figure 5.6B) 
identified the minimal length antigenic peptide on NS2 to be the Smer STVTGIFL. A 
Smer, YEPRDSYF, located on E2, was identified as being the shortest peptide 
recognised by CDS T cells from pig ANll (Figure 5.6C). Responses to all antigenic 
peptides were all shown to be dose-dependent and the threshold concentration at 
which responses became undetectable was proportional to the frequency of the 
peptide specific T cell population (Figure 5.6D-H).
However, the definition of the minimal length peptides that were recognised by the 
CDS T cells may not mean that they represent the natural epitopes. For example, two 
of the peptides, STVTGIFL and YEPRDSYF, gave weaker responses than longer 
peptides (Fig 5.6B and C). Titrations of the truncated peptides would be most 
informative and would aid the identification of the natural MHC class I epitopes. 
Unfortunately, these experiments were not conducted due to a limitation in the 
nunibers of cryopreserved PBMC.
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Figure 5.6 Identification of minimal length antigenic peptides recognised by 
CSFV specific CD8 T ceils. PBMC from pigs AN5, AN7, ANll and ANl3, 
collected 28 day after re-challenge or cryopreserved at different time-points, were 
stimulated with the identified 15mer or consensus llm er antigenic peptides and the 
truncated derivatives of NS5A LSRVDNALLKF, NS2 LISTVTGIFLI and E2 
RYYEPRDSYFQ. IFN-y expression by CDS T cells assessed by flow cytometry and 
panels A, B and C shows the mean unstimulated-corrected % IFN-y expressing CDS 
T cells +/- SD. Statistical analyses were performed using a one-way ANOVA 
followed by a Dunnett’s multiple comparison test versus the previously identified 
llmer antigenic peptide; ***p<0.001, **p<0.01, *p<0.05. Panels D-H show 
reactivity against a logio dilution series of the identified minimal length antigenic 
peptides (NS5A RVDNALLKF, NS2 STVTGIFL and E2 YEPRDSYF) or antigenic 
regions (core PESRKKLEKALLAWA and NS3 VEYSFIFLDEY).
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5.2.5 CDS T cell epitopes and antigenic peptides are well conserved among 
CSFV strains
Using the Clustal W protein alignment tool, the conservation of the identified CTL 
epitopes/antigenic regions among different CSFV strains was analysed (Table 5.1). 
The NS5A epitope RVDNALLKF was moderately conserved among CSFV isolates: 
the sequence was identical in all the genotype 1.1 strains tested except Shimen, 
where a single amino acid substitution was observed; one or few substitutions were 
detected when that sequence was aligned against the genotype 2.172.3/3.3/3.4 strains 
tested. The NS2 Smer STVTGIFL was conserved in all the CSFV strains analysed 
except the Penevezys isolate, where there was a single amino acid substitution. The 
NS3 llm er VEYSFIFLDEY displayed only one amino acid substitution in the 
Penevezys and UK2000/7.1 isolates (Table 5.2). The epitope YEPRDSYF was 100% 
conserved across all the CSFV strains analysed and the antigenic region 
PESRKKLEKALLAWA, located in the core protein, showed only one amino acid 
mutated in the strain CBR/93 (Table 5.2).
Many substitutions were observed when the epitopes RVDNALLKF (NS5A) and 
STVTGIFL (NS2) were aligned against the related pestivirus BVDV (NADL strain) 
and BDV (BD31 strain), whereas the 1 Imer VEYSFIFLDEY (NS3) showed only the 
same single amino acid substitution as CSFV Penevezys and UK2000/7.1. The E2 
Smer YEPRDSYF had one different substitution in both BVDV and BDV strains, 
instead only the BVDV core sequence showed one amino acid substitution, as 
presented in Table 5.2.
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5.2.6 Differences in CDS T cell response specificity is associated with distinct 
MHC class I haplotype expression
Whether the different specificity of CDS T cell responses between pigs was due to 
them bearing different MHC class I haplotypes was next addressed. The porcine 
swine leukocyte antigen (SLA) genes are highly polymorphic and can influence 
swine immune responses to infectious diseases and vaccines (Luhney et al. 200S). 
The SLA class I (SLA-1, SLA-2 and SLA-3) haplotypes of the four pigs were 
determined using a PCR-SSP-based typing assay. As described in Chapter 2, this 
method relies on 47 discriminatory PCR primer pairs, which amplify products of 
114-316 bp and are designed to amplify the SLA class I alleles by groups that have 
similar sequence motifs (Ho et ah, 2009). Each animal was heterozygous and no two 
haplotypes were shared between these animals (Table 5.3).
To assess the recognition of the five identified antigenic peptides by a larger number 
of C-strain vaccinated pigs (18 animals), PBMC collected during Experiment 3 were 
assayed. In this experiment, pigs were vaccinated with the C-strain and challenged 
after 5 or 3 days with the moderately virulent and divergent CSFV strains 
UK2000/7.1 (n=9) or CBR/93 (n=7). These animals were solidly protected against 
challenge with no evidence of leukopenia, viraemia or clinical signs of the disease 
being observed (Graham et al, 2012b). Four C-strain vaccinated/UK2000/7.1 
challenged pigs (AD53, AD56, AD62 and AD65) and two C-strain
vaccinated/CBR/93 challenged pigs (AE15 and AE17) reacted against the NS2 Smer 
STVTGIFL, with a significantly greater number of IFN-y expressing CDS T cells 
compared to unstimulated controls (Figure 5.6). A significant CDS T cell IFN-y 
response against the NS3 Timer VEYSFIFLDEY was detected in three C-strain 
vaccinated/UK2000/7.1 challenged pigs (AD57, AD64 and AD66) and three C-strain
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vaccinated/CBR/93 challenged pig (AE4, AE8 and AE16) (Figure 5.6). No responses 
were observed in these animals against the core, E2 or NS5A peptides (data not 
shown). To assess whether recognition of the two antigenic peptides was associated 
with the previously identified MHC class I haplotypes, all animals were typed for 
SLA class I using the PCR-SSP-based assay (Table 5.3). No haplotypes were found 
to be shared between these pigs and the animals used to define the antigenic peptides, 
but all pigs that reacted against NS2 8mer STVTGIFL displayed the haplotype Lr-
22.0 and pigs that reacted against the NS3 llm er VEYSFIFLDEY carried the Lr-
01.0 haplotype. Interestingly, three NS3 reactor animals also expressed Lr22.0 but no 
response was detected against NS2.
The amino acid mutation observed in the sequence of NS3 1 Imer VEYSFIFLDEY in 
the CSFV UK2000/7.1 isolate did not affect the peptide binding, since the variant 
peptide (VEYSYIFLDEY) stimulated comparable IFN-y responses in SLA-I Lr-01.0 
pigs challenged with CSFV (Figure 5.8). The substitutions in NS5A 9mer 
RVDNALLKF in UK2000/7.1 and CBR/93 affected MHC binding/T cell reactivity 
since pig AN5 did not show any CD8 T cell reactivity against these variants (Figure 
5.8).
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Figure 5.7 Recognition of the identified epitopes by CD8 T cells from C-strain 
vaccinated pigs challenged with divergent CSFV strains. PBMC from pigs 
vaccinated with C-strain CSFV and challenged with CSFV isolate UK2000/7.1 (A) 
or CBR/93 (B), collected 9 or 12 days post-challenge, were stimulated with antigenic 
peptides NS2 STVTGIFL and NS3 VEYSFIFLDEY. IFN-y expression by CDS T 
cells assessed by flow cytometry and graphs show the mean unstimulated corrected 
% IFN-y expressing CD8 T cells + SD. Statistical analyses were performed using a 
one-way ANOVA followed by a Dunnett’s multiple comparison test versus the un­
stimulated control; **p<0.01, *p<0.05.
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Table 5.3 SLA class I low-resolution (Lr) haplotypes of C-strain vaccinated pigs
Pign°^ SLA-1 SLA-3 SLA-2 Inferredhaplotype
Antigenic
peptide
AN5 04XXBlank
04XX
06XX
04XX/hb06
04XX/hb06
04.0
24.0
NS5A3070-
3078
AN7 IIXX15XX
w09XX
12XX
06XX
04XX/hb06
16.0 mod*
38.0 NS2i223-1230
ANll 08XX09XX
07XX
05XX
07XX
07XX
07.0
28.0
NS3i902-1912
E2996-1003
AN13 07XX07XX
02XX
w09XX
04XX/hb06
05XX
32.0
37.00 eore24i-255
AD53 08XX07XX
06XX(0601)
05XX
12XX
w09XX
22.0
37.0 NS2i223-1230
AD56 08XX07XX
06XX(0601)
05XX
12XX
w09XX
22.0
37.0 NS2i223-1230
AD62 08XX15XX
06XX(0601)
04XX/hb06
12XX
es22
22.0
55.0 NS2i223-1230
AD65 08XX08XX
06XX(0601)
06XX(0601)
12XX
12XX
22.0
22.0 NS2i223-1230
AD57
OIXX
07XX
OIXX
05XX
OIXX
w09XX
01.0
37.0 NS3i902-1912
AD64 OIXX08XX
OIXX
06XX(0601)
OIXX
12XX
01.0 . 
22.0 NS3i902-1912
AD66 OIXX08XX
OIXX
06XX(0601)
OIXX
12XX
01.0
22.0 NS31902-1912
AD52 15XX 07XX 16XX 31.0/63.002XX+15XX OIXX IIXX 36.0
AD55 02XX+15XX OIXX IIXX 36.008XX+CS02 07XX W08XX/10XX 45.0
AE15 08XX07XX
06XX(0601)
05XX
12XX
w09XX
22.0
37.0 NS2i223-1230
AE17 08XX07XX
06XX(0601)
05XX
12XX
w09XX
22.0
37.0 NS2i223-1230
AE04 OIXX08XX
OIXX
06XX(0601)
OIXX
12XX
01.0
22.0 NS3i902-1912
AE08 OIXXOIXX
OIXX
OIXX
OIXX
OIXX
01.0
01.0 NS3i902-1912
AE16 OIXX15XX
OIXX
04XX/hb06
OIXX
es22
01.0
55.0 NS3i902-1912
AE03 Blank 08XX es22/15XX 53.015XX 04XX/hb06 es22 55.0
AE05 15XX 07XX 16XX 31.0/63.015XX 07XX 16XX 31.0/63.0
C-strain vaccinated pigs were challenged with CSFV Brescia (AN), UK2000/7.1 (AD) and 
CBR/93 (AE). *16.0 mod.: SLA-1 *1IXX instead of SLA-1 *04XX. The low-resolution SLA 
haplotypes are designated with a prefix ‘Lr’, a number for the elass I haplotype followed by
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a number for the elass II haplotype separated by à period (e.g. Lr-1.1). The elass II 
haplotypes have not been tested here and have all been designated with the number 0 (Ho et 
al., 2009). Blank: un-typed SLA antigen (Ho et ah, 2009).
PIGAE4
0.20-1
»
0>u 0.16-
1-
00
n
Ü 0.10-
z
u.
o.ool
S
V  0.2
PIG AE8
-mr
y
PIG AE16
/ /
PIGAN5
o>
H
00 1.6QO
^ 0.6 
0^.0
0.10-1
«
s 0.08-
1-
00 0.06-
Q
Ü
0.04-
Z
0.02-
0.00-
V/
Figure 5.8 Effect of the amino acid mutation/s in the sequences of the NS3 
llmer VEYSFIFLDEY and NS5A RVDNALLKF on CD8 T cell reactivity.
PBMC from pigs AE4, AES and AE16 (SLA-I Lr-01.0 pigs challenged with CSFV 
CBR/93) were stimulated in vitro with the NS3 llm er VEYSFIFLDEY or the 
variant peptide VEYSYIFLDEY. PBMC from pig AN5 were stimulated in vzïro with 
NS5A RVDNALLKF or the variant peptides. IFN-y expression by CDS T cells 
assessed by flow cytometry and graphs show the mean % IFN-y expressing CDS T 
cells +/- SD. Statistical analyses were performed using a one-way ANOVA followed 
by a Dunnett’s multiple comparison test versus the un-stimulated control; 
***p<0.001, **p<0.01, *p<0.05.
5.2.7 Functional and phenotypic characterization of peptide-specific CD8 T ceils
The ability of the five identified antigenic peptides to elicit cytotoxic activity was 
investigated by assessment of surface mobilisation of CD 107a, as a marker of 
degranulation, by IFN-y"^  CDS T cells. The gating strategy used to assess CD 107a 
expression by IFN-y expressing CDS T cells was as described in Section 4.2.2. Over
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90% of IFN-y"^  CD8 T cells expressed CD 107a on their surface after peptide 
stimulation, suggesting cytotoxic activity of these cells against the peptide-presenting 
cells (Figure 5.9). To further characterize the epitope-specific CD8 T cell 
populations, the expression of the activation markers CD25 and CD27 on IFN-y^ 
CD8 T cells were investigated using the gating strategy described in Section 4.2.4. 
Interestingly, the majority of peptide-specific IFN-y^ CD8 were CD25' and CD27^ 
(Figure 5.9). However, differences were observed in levels of CD27 expression 
between animals/antigenic peptides, with the majority of CD8 T cells responding to 
NS5-RDNALLKF expressing high levels of CD27, whereas the others showed the 
largest proportion of IFN-y"^  CD8 T cells in the CD27 °^'  ^ population (Figure 5.9). 
Finally, the ability of CD8 T cells to produce other cytokines in response to peptide 
stimulation was assessed. The ability of IFN-y^ CD8 T cells to express IL-2 and 
TNF-a after peptide stimulation was assessed, using the gating strategy illustrated in 
Figure 5.10A. While variability was observed in responses between 
animals/antigenic peptides, the majority of peptide-specific CD8 T cells expressed 
either IFN-y alone or IFN-y and TNF-a (Figure 5.1 OB). Only a small proportion 
expressed IFN-y and IL-2 or all three cytokines, with the largest populations being 
observed in response to the E2 and core peptides. Interestingly, the cells co­
expressing TNF-a or TNF-a/IL-2 expressed incrementally greater amounts of IFN-y 
compared to cells which expressed IFN-y alone or IFN-y and IL-2 (Figure 5.IOC), 
indicative of a greater ‘quality’ of cytokine response.
159
I
&S
CO
o
N^dl
Wdl
^ 5
o
. . .  O
t
‘"V fe
N^dl
s
.dip
B
% I ;i
Wdl
( S
8
I
at-'o
tH
8
I
A
I
+
+
VO
r n
a
oa
fO
iri
" 4 -
o6
m
0Ô
m
l O
I
o
C N
m
-H
m
00
003
00
-H
m
O n
« >
i n
I
O n
Ss
< N  OOs  a
^  dVO
3
oo
I i ^O VO
1 1 1
hJpH
I :00< 8  
2
2
rna
m
vds
dCN
VO
C N
4 4
c n
vd
o
c n
d3
0 Ô
l >
m3
O N
< N
in VO in
vd 00
-H -H -Ht> ON
in in
CO C O
T j-
ÎÎm
f d
C O O n ( N 00
C O VO C O
-H -4 -H -H
< N O n O n 00
CN| C O C O
00
4
5
$
00
3
I
p H ,
p H
1“
C Om
ë til
IÎ
i j
S> 005 8I
I
I
I
I
I
I
Vm
O
(U
1 1  
l i -
8 I
c d  S 
r ~ -  (D 
C )  Æ
iO
p
I
t M
O
§
I - :
I
(UI
I
1
00
8
P% d  c/]
^  
+^I
q - io
Î S
I ^■1o i3i J
M  ( B
• s l
li
I!li
n
4 | .
A s  
o  ' &
- §
SI
c/]
i
I  j
1 8s i
t l
O  CO
I H
m
oo 
^ 8
mg II
O
8
I
Ü
1
Î
A
, T )
I
<D
II
O
V O
St too
0 42  a s  126 1?0 213 2»
FS Lin
=J4 R5
R6 R7
106 10» 10* 1(P 10*
IL-2
B  C
NS 5 A RVDNALLKF  ( Pi g AN5)
C 3  T N F a + I L 2  +
IFNy on ly
N S 2  S T V T G I F L  ( Pi g  AN7)
H  T N F a  + IL2-  
C 3  T N F a  + IL2+ 
^  T N F a - I L 2  + 
a  I F N y o n l y
E2 Y E P R D S Y F  (Pi g AN1 1 )
E 3  T N Fa +I L 2 +  
a  T N Fa - IL 2+  
^ 3  IFNy  o n ly
NS 3  VE Y S F I F L DE Y ( Pi g AN1 1 )
H  T N F a + IL 2 -  
E 3  T N F a - I L 2  + 
^ 3  IFNy on ly
C o r e  P E S R K K L E K A L L A W A  (Pig AN13)
H  T N F a + IL 2 -  
C 3  T N F a  + IL2+ 
TNFa- I L2 +  
C 3  IFNy on ly
N S 5 A  RV DNALLKF (Pi g  A N5 )
250-1 **
WL.
N S 2  STVTGIFL (P ig  A N 7 )
IL .
E2 Y E P R D S Y F  (Pi g  A N 1 1 )
N S 3  V E Y SF iF L D E Y  ( Pi g  A N 1 1 )
■ ■
C o r e  PE SR K K L E K A L L A W A  ( P ig  A N 1 3 )
' t L .
Figure 5.10 Characterization of polyfunctional cytokine expression by CSFV 
peptide-specific CDS T cells. Cryopreserved PBMC from pigs AN5, AN7, ANll 
and AN 13 were stimulated with the identified antigenic peptides and the expression 
of IFN-y, TNF-a and IL-2 by CDS T cells was simultaneously assessed by flow 
eytometry. Panel A shows representative dot plots of the expression of TNF-a and 
IL-2 by peptide specific IFN-y expressing CDS T cells (CDSa^’®^ CD4 ) and Panel B 
shows the relative proportions of IFN-y secreting CDS T cells expressing either of 
the two other cytokines. In panel C, the mean fluorescence intensity (MFI) of IFN-y 
staining in each of the populations is presented. Values represent the mean values for 
triplicate cultures +/- SD. Statistical analyses were performed using a one-way 
ANOVA followed by a Dunnett’s multiple comparison test against IFN-y only 
secreting CDS T cells; ***p<0.001, **p<0.01, *p<0.05.
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5.3 D IS C U S S IO N
5.3.1 Introduction
Despite presenting the porcine immune system with a polyprotein of almost 4000 
amino acids in length, this study has shown that the CDS T cell response to CSFV is 
highly focussed, dominated by only one or two epitopes each located on five 
different viral antigens (core, E2, NS2, NS3 and NS5A).
5.3.2 CDS T cell epitopes and MHC class I restriction
The specificity of the CDS T cell response varied between animals dependent upon 
their MHC class I haplotype, which exhibit a high degree of polymorphism in pigs 
(Lunney et al., 2009). The antigenic sequences identified in this study showed no 
overlap with those previously mapped by Pauly et al (1995) and Armengol et al. 
(2002) and the most likely reason for this is the MHC haplotype of the animals 
studied, which in the case of the two earlier studies were inbred pigs homozygous for 
SLA class I haplotype 4a.O. Interestingly, low resolution SLA class I typing 
suggested that pig AN5 carried haplotype 4.0 and this was confirmed by allele 
specific PCR (data not shown). However, the PCR-SSP-based assay may not 
necessarily detect minor sequence differences in class I alleles, which could still 
result in differential epitope recognition. The 4.0 allele-specific PCR would only be 
definitive if the PCR product was sequenced. Nevertheless, it seems likely that the 
immunodominant response to NS5A was restricted by the Lr-24.0 at the expense of 
peptides restricted by the SLA-1 4a.O alleles. In support of this, the present data 
suggested that responses to N S 2 i223-i230 and NS31902-1912 peptides were additionally 
restricted by the Lr-22.0 and 01.0 haplotypes, respectively, yet three animals that
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were heterozygous for these haplotypes mounted responses solely against NS3. Two 
of the peptides identified in this study, NS31902-1912 and E2996-1003, were orthologous to 
antigenic regions previously identified using BVDV peptides to screen CSFV- 
specific T cell responses (Graham et al, 2012a).
To my knowledge this is only the second report of the definition of minimal length 
antigenic peptides recognised by porcine CDS T cells and it is the first based on an in 
vitro/ex-vivo approach. However, as above stated, the definition of epitopes as the 
shortest peptide that was recognised by the CDS T cells is not necessarily valid. The 
identification of the natural MHC class I epitopes would be aided with titrations of 
the peptides of differing length. The previous report used the NetMHCpan prediction 
algorithm (Hoof et al, 2009) to identify a 9mer peptide (MTAHITVPY) from the FI 
capsid antigen of the foot-and-mouth disease virus (FMDV) that bound the SLA 
allele SLA-1 *0401 (Patch et al, 2011; Pedersen et al, 2013). It was subsequently 
shown that a SLA-1*0401/MTAHITVPY tetramer stained CDS T cells from SLA 
matched FMDV vaccinated pigs and the size of the stained population correlated 
with cytotoxic responses in these animals (Pedersen et a l, 2013). In support of this 
immunoinformatics approach, the CSFV polyprotein was screened for binding to 
potential restricting alleles (based on the SLA class I Lr typing results) and two of 
the peptides NS21223-1230 and NS31902-1912 were predicted by NetMHCpan 
(www.cbs.dtu.dk/services/NetMHCpan/) to bind strongly to at least one of the class I 
alleles potentially present in each of the restricting haplotypes: SLA-2* 12.01 for 
NS2i223-i230 (potentially present in both haplotypes Lr-38.0 and Lr-22.0) and 
NS31902-1912 was predicted to strongly bind SLA-1 *08.01 (Lr-07-0), SLA-3*07.01
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(Lr-28.0); and SLA-2*01.01 and SLA-2*01.02 (Lr-01.0)
(www.cbs.dtu.dk/services/NetMHCpan/).
5.3.3 Immunodominanee of the CD8 T cell response to CSFV
Immunodominance in CD8 T cell responses is thought to arise primarily as a 
consequence of the limitations of peptides to bind with high-affinity to available 
MHC class I molecules, with additional limitations in antigen processing and the 
CD8 T cell receptor repertoire also playing a role. Only approximately 1/2000 of the 
peptides within an antigen can achieve immunodominant status with a given MHC 
class I allele (Yewdell et al., 1999). Immunodominance is thought to be critical for 
immunity since numerically prominent CD8 T cells have been shown to confer more 
effective protection than T cells specific for subdominant epitopes (Oukka et al,
1996). It has also been shown that the efficacy of peptides in providing protection 
against a viral challenge is proportional to their binding affinity for the restricting 
MHC class I molecule (Oukka et al., 1996). In human immunodeficiency virus 
(HIV)-1 infection, it has been shown that immunodominant CD8 T cell responses 
may limit virus replication, but they are primary targets of escape mutant generation 
(Leslie et al, 2004; Ammaranond et a l, 2005). Immunodominance of CD8 T cell 
responses to Flaviviruses has also been described, with disparity in the degree 
depending on the virus/host system studied (Rivino et a l, 2013; Van der Most et al, 
2002). A recent study, utilising a similar strategy to the present one, assessed the 
specificity of human T cell response to DENV. Using a cohort of 25 patients, 21 
novel CD8 T cell epitopes were identified, with NS3 and NS5 being the most 
antigenic and the majority of epitopes being recognised by single patients (Rivino et
164
al., 2013). This study has provided evidence for the importance of 
immunodominance in CDS T cell responses against CSFV, in fact individual 
responses were uniquely focussed on only one or two peptides and were associated 
with the expression of distinct MHC class I haplotypes. There is however still the 
possibility that additional less dominant specificities (subdominant epitopes) exist, 
that were below the limit of detection of the screening method used. In addition to 
peptide-MHC binding, T cell activity could be influenced by other factors, including 
differences in antigen abundance, the composition of the TcR repertoire and the 
affinity of specific TCR for the respective peptide-MHC complex (Yewdell, 2006).
5.3.4 Potential use of the identified T cell epitopes/antigenic regions in a new 
CSFV marker vaccine
The epitopes identified in this study were well conserved amongst CSFV isolates, 
with at most only single substitutions with related amino acids being detected. It 
remains to be empirically determined whether these substitutions could affect T cell 
recognition. NetMHCpan is a method that generates quantitative predictions of the 
affinity of any peptide-MHC class I interaction (Hoof g/ al., 2009). Using 
NetMHCpan, if was predicted that the mutation of tyrosine in place of a 
phenylalanine at position 1906 of the NS3 llm er VEYSFIFLDEY would not affect 
the binding to SLA class I alleles. Moreover, the antigenic corc241-255 peptide and the 
E2996-1003 and NS31902-1912 epitopes are well conserved between CSFV, BVDV and 
BDV. Such conserved T cell epitopes could enhance the efficacy of a BVDV/CSFV 
chimeric vaccine. It has recently been reported that the chimeric vaccine CP7_E2alf 
induces rapid protection, partially comparable to the one observed with C-strain
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(Koenig et al, 2007; Renson et al, 2013). Since this protection precedes the 
appearance of neutralizing antibodies, it may be that T cell responses against 
epitopes conserved between BVDV and CSFV are contributing to the protective 
effect. Support for this hypothesis also stems from recent studies that showed that T 
cells from C-strain vaccinated animals cross-reacted with BVDV derived peptides 
(Graham 2012b). .
Several studies have identified E2 and NS3 as targets of the T cell response against 
CSFV (Graham et al, 2012a; Ceppi et al, 2005; Rau et al, 2006; Pauly et al, 1995; 
Armengol et al, 2002). However, the present results provide strong evidence that at 
least in the context of responses induced by live attenuated CSFV, E2 and NS3 are 
not necessarily the major T cell antigens and other CSFV proteins may be important 
targets of the CDS T cell response. These results however should not be interpreted 
as that the design of a marker vaccine would need to include all potential 
immunodominant antigens. In support of this, a study on the related YFV showed 
that, in case of abrogation of the dominant CDS T cell epitope, the frequencies of T 
cells recognizing the subdominant CDS T cell epitope increased dramatically (Van 
der Most et al, 2002). A previous study showed that vaccination with an IFN-a 
adjuvanted subunit E2 vaccine fully protected pigs against a challenge administered 
only 7 days later, suggesting that a T cell response directed solely against E2 may be 
protective (Toledo et al, 2010). A recent evaluation of dendrimeric peptide 
formulations of linear B cell epitopes from E2 and a CDS T cell antigenic peptide 
from NS3, induced the production of both neutralizing antibodies and IFN-y 
producing cells, which resulted in a degree of protection against CSFV (Monso et al, 
2011). Significantly, the protection achieved was greatest when the T cell antigenic
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peptide was included together with the B cell epitopes (Tarradas et al., 2012). 
However, the MHC class I haplotypes of the recipients in these peptide 
immunization experiments was not assessed and so was not matched to the binding 
specificity of the peptides (Monso et al., 2011; Tarradas et al., 2012). Incorporation 
of T cell epitopes identified in the present study might further enhance the 
development of such a marker vaccine approach. Moreover, to better understand how 
the identified sequences may fianction as epitopes, they could be mapped to the 3D 
structure of the putative restricting MHC class I alleles, using software that predicts 
protein folding and structure.
5.3.5 Polyfunctional T effector memory cells dominate the peptide-specific CD8 
T cell response
All the identified peptides were able to induce CD 107a mobilization in IFN-y^ CDS 
T cells. Translocation of lysosomal-associated membrane protein 1 
(LAMP 1/CD 107a) to the cell membrane has been validated as a marker of cytotoxic 
degranulation by CDS T and NK cells (Betts et al, 2003). This data support previous 
studies, which report the ability of the viral antigens E2 and NS3 to elicit cytotoxic 
activity in vaccinated pigs (Ceppi et al, 2005; Rau et al, 2006; Pauly et al, 1995; 
Armengol et al, 2002) and suggest that these T cells possess cytotoxic activity in 
addition to cytokine release. The polyfunctionality of peptide-specific CDS T cell 
populations was assessed by co-expression of IFN-y, TNF-a and IL-2, since this may 
be central to their protective capacity. Studies on HCV showed that formation of 
specific polyfunctional CDS T cells, induced by vaccination with vectors expressing 
NS3 and NS4a proteins, is associated with protection (Lang Kush et a l, 2012;
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Mikkelsen et al, 2011). However, the majority of peptide-specific CDS T cells 
expressed IFN-y alone or IFN-y and TNF-a with only a small percentage co­
expressing IFN-y, TNF-a, and IL-2. Interestingly, as observed in other systems 
(Whelan et al, 2011; Seder et al, 2008), the subset expressing all three cytokines 
showed the highest ‘quality’ of response producing more IFN-y on a per cell basis. 
Analysis of activation markers showed that the majority of the CDS T cells releasing 
IFN-y after peptide stimulation did not express the alpha chain of the IL-2 receptor 
(CD25). In contrast, previous studies reported variable expression of this marker on 
CSFV-specific IFN-y CDS T cells (Suradhat et al, 2005). It may be speculated that 
the absence of CD25 expression is not indicative of a naive state of CDS T cells, but 
could reflect a memory phenotype of these cells since a previous study reports that 
after antigen stimulation some human CDS T cells express high levels of CD25, 
whereas others display low levels of this marker and the latter preferentially 
differentiate into long-lived functional memory cells (Kalia et a l, 2010). Similar to 
what has been described for human CDS T cell responses to other Flaviviruses, 
variable levels of expression of CD27 were observed on peptide specific CDS T cells 
(Mikkelsen et al, 2011; Tomiyama et al, 2004). Based on data from human CDS T 
cells, this may indicate that the majority of CSFV epitope-specific CDS T cell 
populations may be T effector memory (T em) cells (Tian et a l, 2 0 1 2 ).
The results of this analysis suggest that vaccine strategies should be adopted in order 
to drive the generation of peptide-specific polyfunctional CDS Tem cells. A vaccine 
targeting DCs and enabling stong co-stimulatory signals to naïve CDS T cells should 
be designed, through integration of cytokines (IL-12 and IFN-a) or pathogen- 
associated molecular patterns.
16S
5.4 C O N C L U S IO N S
By utilising a comprehensive approach to determine the antigen specificity of the 
CDS T cell response, this study has provided strong evidence for immunodominance 
in the T cell response to CSFV. CDS T cell responses of individual animals were 
uniquely focussed on only one or two peptides which were mapped on the core, E2 
and non-structural proteins NS2, NS3 and NS5A. The individual responses were 
associated with the expression of distinct MHC class I haplotypes and for two of the 
peptides there was evidence that they are presented by alleles expressed by additional 
haplotypes. The five identified antigenic peptides were highly conserved across 
CSFV isolates, and for some were also well conserved when aligned against the 
related pestiviruses, BVDV and BDV. The responding CDS T cells displayed 
polyfiinctionality, with the majority of IFN-y"^  cells co-expressing the cytotoxicity 
marker CD 107a and populations also releasing TNF-a and/or IL-2. Thus, the 
antigens identified and characterised in this study represent attractive vaccine 
candidates that may be evaluated in the quest to develop the next generation of 
CSFV vaccines.
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CHAPTER 6. GENERAL DISCUSSION AND CONCLUSIONS
170
6.1 INTRODUCTION
C-strain vaccines have contributed greatly to the control of world CSF since their 
introduction, due to their safety and ability to rapidly induce complete protection 
against CSFV. However, their application in non-endemic settings is limited by the 
difficulty of discriminating infected among vaccinated animals (Moennig et al., 
2000). Nevertheless, C-strain vaccines provide an ideal model system with which to 
analyze the immunological mechanisms that underlie rapid protection against CSFV 
and generate, information indispensable for the development of next-generation 
marker CSFV vaccines. While vaccination with C-strain vaccines evokes both 
antibody and cellular immune responses, it is the latter that has been correlated with 
the rapid protection induced by this live attenuated vaccine (Graham et a l, 2012a; 
Suradhat et al., 2001).
6.2 ROLE OF NK AND yô-T CELLS IN THE PROTECTIVE RESPONSE 
AGAINST CSFV
The first part of this study focused on the contribution of NK and yô-T cells 
in the cellular immune response against CSFV. Since C-strain vaccines can induce a 
protective response within several days, it was hypothesised that these two 
populations of the innate immune system could be involved. However, results 
showed that it is unlikely that these cells contribute directly and rather it was found 
that these cells may become only partially activated, a response most likely triggered 
by type I IFN production from CSFV infected pDCs. In vitro experiments showed 
that high levels of IFN-a released by CSFV infected pDCs led to up-regulation of 
MHC-II on NK and yÔ-T cells and a similar phenotype was observed most strikingly
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on cells isolated from animals infected with virulent CSFV. Thus this effect inversely 
correlates with protection and it is not associated with the ability of NK and yô-T 
cells to release antiviral cytokines, such as IFN-y, or express cytolytic proteins, such 
as perforin, which would be effective against CSFV. It has been reported in mice that 
MHC-II ‘dressed’ NK cells can suppress CD4 T-cell responses, since presentation of 
antigen-MHC-II complexes without sufficient co-stimulation can lead to CD4 T cell 
anergy (Nakayama et al., 2011). Also, adoptive transfer of MHC-II-dressed NK cells 
resulted in attenuation of a mouse model of dermal delayed-type hypersensitivity. 
CD4^ T cells were intravenously transferred in mice followed by injection with 
OVA-loaded APCs, in order to induce hypersensivity. Adoptive transfer of MHC-II- 
dressed NK cells in these mice attenuated clinical symptoms and reduced CD4^ T- 
cell accumulation in the draining lymph nodes, suggesting that MHC-II-dressed NK 
cells suppress CD4^ T-cell responses in vivo (Nakayama et al., 2011). Following the 
results of the present study, it may be speculated that MHC-II up-regulation on 
NK/yô-T cells might actually impair the professional DC-induced T cell responses in 
lymphoid tissues, due to competitive antigen presentation, fiirther impeding the 
development of a protective cellular immune response against CSFV.
6.3 EXACERBATED pDC RESPONSE AND OTHER POSSIBLE 
MECHANISMS BEHIND T CELL APOPTOSIS DURING CSFV INFECTION
The exacerbated pDC-mediated type I IFN response against CSFV is likely also 
related to the induction of lymphocyte apoptosis, which further antagonizes the 
development of a protective T cell response. Virulent strains of CSFV induce high 
levels of systemic IFN-a, detectable from two days post infection and reaching
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maximum levels 3-5 days post-infection (250-1300 U/ml) (Summerfield et al., 
2006). This IFN-a response is related to the virulence of the viral strain used, with 
avirulent virus not inducing any detectable level of this cytokine in serum. There is 
also a statistically significant correlation between lymphopenia and serum IFN-a 
levels (Summerfield et al., 2006). Lymphocyte depletion during CSFV infection is 
attributed to induction of apoptosis in non-infected bystander cells (Summerfield et 
al., 1998). Interestingly, Renson et al. (2010) reported that virulent CSFV strains 
strongly up-regulate apoptosis-related IFN stimulated genes (ISG) in lymphocytes, 
with differences between highly and moderately virulent strains, suggesting that the 
IFN-a response leads to bystander apoptosis of lymphocytes (Renson et al., 2010). 
Another study suggested that the induction of the TRAIL by CSFV infected DCs 
may be an alternative mechanism behind CSFV induced lymphopenia (Durand et al., 
2009). Lower replication of live attenuated viruses in target cells, like monocytes and 
DCs, would result in lower release of IFN-a/TRAIL and other pro-apoptotic 
molecules, allowing the host to develop a protective T cell response . In support of 
this hypothesis, in vitro data on monocytes and DCs show that C-strain infects these 
cells less efficiently than the virulent strain Brescia (Graham et al., unpublished 
results). Lower replication of C-strain in vivo would also result in lower levels of 
release of the immunomodulatory structural proteins E™® and core. It has been 
reported that the E™^ glycoprotein can antagonize lymphocyte proliferation and 
protein synthesis, due to its ability to induce lymphocyte apoptosis (Bruschke e/ al.,
1997). Also the core protein may be involved in the inhibition of T cell responses. 
Studies on the related Flavivirus, HCV, showed that this protein can interact with the 
globular domain of the Clq receptor (gClqR), with consequent inhibition of human
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T-cell proliferative responses in vitro (Kittlesen et al., 2000). This observation fits
with previous data that showed that the binding of Clq, the natural ligand for the
' • -  ^
gClqR, to T lymphocytes provides an antiproliferative signal to these cells (Chen et
al, 1994).
6.4 CDS T CELL RESPONSES AGAINST CSFV
The second part of the project aimed to define the T cell populations stimulated by 
vaccination with a C-strairi vaccine. CDS T cells were found to provide the earliest 
source of CSFV-specific IFN-y in vaccinated pigs and also dominated the sustained 
response after challenge and re-challenge with the virulent Brescia strain. CDS T cell 
isolated at the peaks of the response had a putative mixed effector/effector memory 
phenotype, displayed cytotoxicity, with the majority of IFN-y"^  cells co-expressing 
the cytotoxic degranulation marker CD 107a on their surface, and subpopulations co­
expressed TNF-a and IL-2. The characterization of this response is crucial for the 
development of the next generation of CSFV vaccines and new CSFV vaccine 
should be designed in order to activate and maintain this polyfunctional CDS T 
effector/effector memory population. In support of this, it has been shown that 
polyfunctional CDS T memory cells play a critical role in long-term protection 
against other viruses belonging to the family Flaviviridae (Mikkelsen et a l, 2011; 
Akondy et a l, 2009).
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6.5 PROVISION OF DIRECT EVIDENCE OF THE ROLE OF CDS T CELLS 
IN PROTECTION AGAINST CSFV
To consolidate the proposed critical role that C-strain-induced CDS T cells have in 
protection against CSFV, in vivo T cell depletion experiments should be performed. 
Monoclonal antibody-mediated depletion techniques have been successfully applied 
to examine the role of T cell subsets in immunity to various diseases of cattle, 
including tuberculosis (Villareal et a l, 2003), anaplasmosis (Valdez et al, 2002), 
contagious bovine pleuropneumonia (Sacchini et al, 2011) and BVDV {Howard et 
al, 1992). Depletion studies on the related pestivirus BVDV showed that CD4 T 
cells may play an important role in protection against this disease, since depletion of 
these cells, but not CDS T cells, prolonged viraemia (Howard et al, 1992). Also in 
pigs, this method was adopted to determine the role of CDS T cells against African 
swine fever virus (AFSV) and porcine reproductive and respiratory syndrome virus 
(PRRSV) (Oura et al, 2005, Lohse et al, 2004). CDS T cells were shown to play an 
important role in the protective immune response to ASFV infection, since depletion 
of CDS T cells from pigs vaccinated with an avirulent Portuguese ASFV isolate 
OUR/TSS/3 resulted in a loss of protection when challenged (Oura et a l, 2005). In 
contrast, Lohse et al (2004) found that CDS T-cell depletion in the early phase of 
PRRSV infection did not lead to increased disease nor impair the ability of the 
animal to clear PRRSV (Lohse et al, 2004). In order to assess directly the role of 
different T lymphocyte populations in protection against CSFV, their depletion 
should be performed soon after C-strain vaccination and subsequently pigs should be 
challenged with a virulent CSFV strain. A limitation of the AFSV and PRRSV 
studies described above is that anti-CD8 a  antibodies were used to deplete CDS T
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cells. The alpha chain of the CDS is expressed not only on cytotoxic T cells, but also 
on memory CD4 T cell (CD4^CDS^), NK cells and a proportion of yô T cells, 
whereas CDSp is displayed only on CDS T cells. Only with the use of anti-porcine 
CDSp antibodies would the role of CDS T cells against CSFV he defined. A possible 
limitation of the use of depletion techniques in this species is the lack of complement 
fixation of mouse mAbs in pigs. To overcome this limitation, the use of 
immunotoxins (ITs) should be trialled. ITs are hybrid molecules that combine the 
antigen-directed specificity of the immunoglobulin with the activity of the toxin 
(Vitetta et al., 19S3) and can be used for selective cell depletion. Filipovich et al 
(19S4) used ITs (murine monoclonal antibodies covalently linked to ricin) to pre­
treat hone marrow before transplantation and established that the use of 
concentrations of ricin conjugates up to 300 ng/ml/10^ cells were safe (Filipovich et 
al, 19S4). Monoclonal antibodies directed against CD3, CD4 and CDS molecules 
coupled with ricin are highly active and specific reagents and were proposed as 
useful tools for pre-transplant bone marrow purging (Izquierdo et a/., 19SS). It has 
been reported that the combination of anti-murine CD3 (SPV-T3a) and CD7 (WTl) 
monoclonal antibodies, both conjugated to deglycosylated ricin A acted 
synergistically, eliminating approximately 99% of activated T cells at 102S mol/L 
(about l.S mg/mL) (Van Oosterhout Y.V.J.M. et al, 2000). Not only ricin, but also 
saporin has been used as a toxin to conjugate to monoclonal antibodies. MHC-I 
tetramers conjugated to saporin were incubated with polyclonal T-cell populations, 
which resulted in a dramatic reduction in the number of targeted antigen-specific 
CDS T cells with no bystander toxicity in vitro. These ITs were also able to reduced 
liver damage in a model of donor T-cell-mediated hepatic destruction. These data
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provide evidence that MHC tetramers linked to toxins could be adopted for the 
elimination or clinical manipulation of T-cell responses (Penaloza-MacMaster et al., 
2009).
Another system invaluable in providing direct evidence of the role of cell 
populations in protection is the adoptive transfer of lymphocyte populations from 
immune animals into naïve recipients, but due to the size and out-bred nature of 
veterinary species similar studies are rarely conducted. This method has been 
adopted in cattle to provide direct evidence of the protective role of CDS T cells 
against the intracellular parasite Theileria parva. Naïve calves were protected from a 
lethal infection with T. parva by CDS T cells derived from their monozygotic 
immunized twins. Absence of parasite-specific CDS T cells in the adoptively 
transferred cell population resulted in development of the clinical disease in 
challenged only animals (McKeever et al., 1994). For CSFV, the use of in-bred lines 
of miniature swine, originally developed for xenotransplantation research, would 
facilitate the adoptive transfer of T cells without problems of MHC incompatibility. 
Different lymphocyte populations from C-strain vaccinated pigs could he transferred 
into unvaccinated animals before a challenge infection, to confirm their protective 
role against the disease.
6.6 SPECIFICITY OF THE CSFV-SPECIFIC CDS T CELL RESPONSE
The final part of the study aimed to identify the antigenic targets of the C-strain 
induced T cell response. Knowledge of T cell epitopes is necessary to ensure that 
genetically attenuated or subunit DIVA vaccines include these regions. As described
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in Chapter 4, it was observed that T cell responses in individual animals were 
dominated by just 1-2  epitopes, located on different antigenic regions, and that at 
least four CSFV proteins could be potential targets of the CDS T cell response. 
Differences in the specificity of the T cell responses between pigs was associated 
with expression of different MHC class I haplotypes. While it has been shown that 
the efficacy of antigenic peptides in stimulating protective T cell responses against a 
viral challenge is proportional to their binding affinity for the restricting MHC class I 
molecule (Oukka et al, 1996), the results obtained do not exclude that other factors 
may also be involved. The variability in the specificity of the T cell response should 
not limit the design of a marker vaccine based on one/two viral antigen(s), such as 
subunit vaccines or DNA vaccines expressing E2 alone or combined with another 
non-structural protein. In support of this idea, a study on the related yellow fever 
virus showed that, in the case of abrogation of the dominant CDS T cell epitope, the 
fi*equencies of T cells recognizing the subdominant CDS T cell epitope increased 
dramatically (Van der Most et al, 2002). In outbred populations, epitopes that are 
dominant in one individual may be subdominant in other individuals with different 
haplotypes (Betts et al, 2000), but subdominant responses can be enhanced in the 
absence of the dominant epitope (Van der Most et al, 2002). Similar studies could be 
conducted in pigs in the context of responses to CSFV. C-strain mutants could be 
created by inserting a mutation in the area coding for one of the identified T cell 
epitopes, in order to reduce the epitope-binding affinity. These mutants should be 
tested in pigs with the same MHC haplotype, to assess whether subdominant 
responses could he increased in the absence (or alteration) of the dominant epitope.
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6.7 STRATEGIES TO DEVELOP NEW CSFV MARKER VACCINES
Overall, some unanswered questions regarding the mechanisms of immunity to 
CSFV still need to be addressed in order to provide further information for the 
development of the next-generation of CSFV vaccine. The understanding of the role 
of IFN-a in the pathogenesis of CSF and in activating the T cell response could aid 
the design of a successful vaccine. As stated above, some authors have suggested that 
the exacerbated IFN-a response is responsible for the lymphopenia observed in 
infection with virulent CSFV isolates (Renson et al., 2010). However, this cytokine 
induces DC maturation and thus it might be essential in shaping a protective T cell 
response. The ability of CSFV isolates to replicate in target cells is likely related to 
their virulence and, as above stated, in vitro data on monocytes and DCs show that 
C-strain infects these cells less efficiently than the virulent strain Brescia (Graham et 
al., unpublished results). To assess this hypothesis, several CSFV mutants should be 
created and their ability to infect and replicate in target cells assessed. These mutants 
should he tested in naïve pigs, to directly observe their ability to protect or to induce 
CSF. Moreover, the design of an ex vivo organ explant culture system using porcine 
tonsils could re-creates the first site of CSFV infection and facilitate an in-depth 
analysis of the events occurring after CSFV infection with attenuated or virulent 
strains. Understanding how T cell responses are induced, which elements induce the 
required DCs maturation (such as viral PAMPS or cytokines derived by other cell 
populations or low levels of IFN-a released by pDCs), which factors lead to the 
exacerbated pDC response and which ones are linked to T cell apoptosis, would all 
be beneficial to the design an efficient CSFV vaccine.
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To date, many attempts have heen made to develop marker vaccines against CSFV 
and various strategies and methods have been studied (Beer et al., 2007). 
Recombinant chimeric or deletion vaccines carry some concerns over their safety 
because they might revert to virulence in vivo. Safer types of vaccine are the DNA, 
subunit protein and peptide vaccines. Unfortunately, many of them are only able to 
protect pigs against a CSFV letal challenge after at least ten days post-vaccination or 
after multiple administrations, limiting their potential use in the case of a CSF 
outbreak. So far, only the subunit E2 vaccine co-administered with IFN-a (Toledo et 
al., 2010) induced protection one week after a single immunization. Further 
experiments should be developed in order to investigate whether this marker vaccine 
evokes a T cell response comparable to the C-strain vaccine in animals of all MHC 
types.
Co-administration of a subunit vaccine with IFN-a probably ensures early protection 
after vaccination, thanks to the ability of this cytokine to stimulate DC maturation 
and increase their T cell stimulatory capacity (Luft et al, 1998). This approach 
suggests that it is indispensable to create a marker vaccine that target antigens to the 
DCs in order to evoke a strong CD8 T cells response. Not only the co-delivery of 
IFN-a with CSFV antigen, but also other formulations can be adopted in order to 
enhance DC maturation and induce a better T cell response. Inclusion of cytosine- 
guanine (CpG) motifs in a DNA vaccine can enhance its efficacy by triggering DC 
maturation, with up-regulation of their MHC class II and co-stimulatory molecules, 
secretion of IL-12 and induction of type 1 T cell responses (Behhoudi et a l, 2000). A 
DNA vaccine including CpG motifs could be a potential tool to rapidly protect pigs 
against CSFV. Nanoparticles are another system that could be used to deliver CSFV
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antigen to DCs. Antigens can be encapsulated or coated onto nanoparticles and it has 
been reported that use of poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles can 
elicit potent cellular immune responses (Elamanchili et ah, 2007). Another useful 
polymer is chitosan, which induces activation of DCs via a TLR4-dependent 
mechanism (Villiers et al., 2009). Size represents a critical parameter in determining 
whether particulate vaccines can penetrate lymph nodes and reach resident DCs. It 
has been reported that antigen conjugated to nanoparticles with the size of 40-50nm, 
similar to CSFV, can localize to DCs and induce high levels of IFN-y"^  CDS T cells 
and high antibody titres (Fifis et al., 2004). Moreover, induction of antibody and T 
cell responses requires the delivery of antigen together with appropriate ‘danger 
signals’. The binding of pathogen associated moleculars patterns (PAMPs) to 
pathogen-recognition receptors, such as TLRs on APCs, results in their maturation 
and migration to the drining lymph nodes. To ensure the development of a good 
immune response, the antigens should be delivered along with PAMPs to the same 
DC (Stomi et al., 2005). The nature of danger signal received is pivotal in deciding 
the type of immune response generated (Stomi et a l, 2005). Co-encapsulation of 
antigen and PAMPs within a single nanoparticle can increase vaccine potency one 
hundred fold in comparison to administration of PAMPs in soluble form (Tacken et 
al, 2011). The use of nanoparticles against other flavivimses has been reported; 
Domento et al. (2010) formulated PLGA nanoparticles using a recombinant envelope 
protein from West Nile vims, with addition of CpG oligodeoxynucleotides. Particles 
were effectively endocytosed by DCs, with consequent secretion of proinflammatory 
cytokines and up-regulation of co-stimulatory molecules. Mice immunized with this 
formulation developed a strong immune response, characterized by a greater number
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of circulating effector T cells, which offered superior protection against West Nile 
virus encephalitis compared with animals immunized using the adjuvant aluminium 
hydroxide (Demento et al., 2010). A similar strategy could he evaluated to see if it 
might form the basis of an effective marker vaccine against CSFV.
6.8 CONCLUSIONS
Overall, this study has provided an improved understanding of the cellular immune 
responses induced by à live attenuated CSFV vaccine, which may be crucial for 
providing rapid protection. The data suggested that NK and yô-T cells do not directly 
contribute to the cellular effector mechanisms induced by live attenuated CSFV, but 
rather they are modulated by the type I IFN response triggered by CSFV infected 
pDCs. Instead, IFN-y secreting CDS T cells with the capacity for cytotoxic 
degranulation dominated the cellular response following vaccination and subsequent 
challenge infections with virulent CSFV. A striking immunodominance was 
observed in this CDS T cell response to CSFV, with antigen-specificity dependant on 
MHC class I haplotype expression. It is hoped that this data will aid the development 
of the next generation of CSFV vaccines, which are urgently required to improve 
disease outbreak control.
182
REFERENCES
1. Abbas, A.K., Lichtman. A.H.: Cellular and Molecular Immunology. 5th ed. 
Philadelphia, USA: Elsevier Saunders, 2005.
2. Akondy, R.S., Monson, N.D., Miller, J.D., Edupuganti, S., Teuwen, D., Wu, H., 
Quyyumi, F., Garg, S., Altman, J.D., Del Rio, C., Keyserling, H.L., Ploss, A., 
Rice, C.M., Orenstein, W.A., Mulligan, M.J., Ahmed, R. 2009. The yellow fever 
virus vaccine induces a broad and polyfunctional human memory CD8+T cell 
response. Journal o f Immunology 183, 7919-7930.
3. Ammaranond, P., Zaunders, J., Satchell, C., van Bockel, D., Cooper, D.A., 
Kelleher, A.D. 2005. A new variant cytotoxic T lymphocyte escape mutation in 
HLA-B27-positive individuals infected with HIV type \. AIDS Research and 
Human Retroviruses 21, 395-397.
4. Andrew, M., Morrissy, C., Leghaus, C., Oke, P., Sproat, K., Hodgson, A., 
Johnson, M., Coupar, B. 2000. Protection of pigs against classical swine fever 
with DNA-delivered gp55. Vaccine 18, 1932-1938.
5. Armengol, E., Wiesmüller, K., Wienhold, D., Büttner, M., Pfaff, E., Jung, G., 
Saalmüller, A. 2002. Identification of T-cell epitopes in the structural and non- 
structural proteins of classical swine fever virus. Journal o f General Virology 83, 
551-560.
6 . Banchereau, J., Steinman M. 1998. Dendritic cells and the control of immunity. 
Nature 392, 245-252.
7. Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, 
J., Huddart, R., Smith, K., Townsend, R., Brown, A., Antrobus, R., Ammendola,
183
V., Naddeo, M., O’Hara, G., Willberg, C., Harrison, A., Grazioli, F., Esposito, 
M.L., Siani, L., Traboni, C., Go, Y., Adams, D., Hill, A., Colloca, S., Nicosia, A., 
Cortese, R., Klenerman, P. 2012. Novel Adenovirus-based vaccines induce broad 
and sustained T cell responses to HCV in man. Science Translational Medicine 4, 
115ral.
8 . Bauhofer, O., Summerfield, A., Sakoda, Y., Tratschin, J.D., Hofinann, M.A., 
Ruggli, N. 2007. Classical swine fever virus Npro interacts with interferon 
regulatory factor 3 and induces its proteasomal degradation. Journal o f Virology 
81,3087-3096.
9. Beer, M., Reimann, I., Hoffinann, B., Depner, K. 2007. Novel marker vaccines 
against classical swine fever. Vaccine 25, 5665-5670.
10. Behhoudi, S., Chao, D., Klenerman, P., Austyn, J. 2000. The effect of DNA 
containing CpG motif on dendritic cells. Immunology 99, 361-366.
11. Berchtold, C., Panthel, K., Jellbauer, S., Kohn, B., Roider, E., Partilla, M., 
Heesemann, J., Endres, S., Bourquin, C., Russmann, H. 2009. Superior protective 
immunity against murine Listeriosis by combined vaccination with CpG DNA 
and recombinant Salmonella enteric Serovar Typhimurium. Infection and 
Immunity 77, 5501-5508.
12. Betts, M. R., Casazza, J. P., Patterson, B. A., Waldrop, S., Trigona, W., Fu, T.M., 
Kern, F., Picker, L. J., Koup, R. A. 2000. Putative immunodominant human 
immunodeficiency virus-specific CD8 T-cell responses cannot be predicted by 
major histocompatibility complex class I haplotype. Journal o f Virology 74, 
9144-9151.
184
13. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douke, D.C., Roeder, 
M., Koup, R.A. 2003. Sensitive and viable identification of antigen-specific 
CD8+T cells by a flow cytometric assay for degranulation. Journal o f 
Immunoogicall Methods 281, 65-78.
14. Bonneville, M., O'Brien, R., Bom, W. 2010. yô T cell effector functions: a blend 
of innate programming and acquired plasticity. Nature Reviews Immunology 10, 
467-478.
15. Bouma, A., de Smit, A., de Jong, M, de Kluijver, B., Moormann, R. 2000. 
Determination of the onset of the herd-immunity induced by the E2 sub-unit 
vaccine against classical swine fever vims. Vaccine 18, 1374-81.
16. Brandes, M., Willimann, K., Moser, B. 2005. Professional antigen-presentation 
function by human yôT cells. Science 309, 264-268.
17. Bmschke, C., Hulst, M.M., Moormann, R.J., van Rijn, P.A., van Oirschot, J.T. 
1997. Glycoprotein Ems of pestivimses induces apoptosis in lymphocytes of 
several species. Journal o f Virology 71, 6692-6696.
18. Bukowski, J.F., Welsh, R.M. 1986. Enhanced susceptibility to cytotoxic T 
lumphovytes of target cells isolated from vims-infected or interferon-treated 
micQ. Journal o f Virology 59,135-739.
19. Burgers, W.A., Chege, G.K., Muller, T.L., van Hannelen, J.H., Khoury, G., 
Shephard, E.G., Gray, C M,, Williamson, C., Williamson, A.L. 2009. Broad, 
high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited 
by a DNA and modified vaccinia Ankara vaccine containing human 
immunodeficiency vims type I subtype C genes in baboons. Journal o f General 
Virology 90, 468-480.
185
20. Burrows, S.R., Rossjohn, J., McCluskey, J. 2006. Have we cut ourselves too 
short in mapping CTL epitopes? Trends in Immunology 27, 11-6.
21. Chen, A., Gaddipati, S., Hong, Y., Volkman, D.J., Peerschke, E.I., Ghebrehiwet, 
B. 1994. Human T cells express specific binding sites for Clq. Role in T cell 
activation and proliferation. Journal o f Immunology 153, 1430-40.
22. Ceppi, M., de Bruin, M.G., Seuherlich, T., Balmelli, C., Pascolo, S., Ruggli, N., 
Wienhold, D., Tratschin, J.D., McCullough, K.C., Summerfield, A. 2005. 
Identification of classical swine fever virus protein E2 as a target for cytotoxic T 
cells by using mRNA-transfected antigen presenting cells. Journal o f General 
Virology 8 6 , 2525-2534.
23.Colonna, M., Trichieri, G., Liu, Ÿ.J. 2004. Plasmacytoid dendritic cells in 
immunity. Nature Immunology 5, 1219-1226.
24. Costa, S.M., Yorio, A.P., Goncalves, A.J., Vidale, M.M., Costa, E.C., Mohana- 
Borges, R., Motta, M.A., Freire, M.S., Alves, A.M. 2011. Induction of a proctive 
response in mice by the dengue virus NS3 protein using a DNA vaccine. PLoS 
One 6 , e25685.
25.Crotta, S., Stilla, A., Wack, A., D'Andrea, A., Nuti, S., D'Oro, U., Mosca, M., 
Filliponi, F., Brunetto, R., Bonino, F., Abrignani, S., Valiante, N. 2002. 
Inhibition of natural killer cells through engagement of CD81 by the major 
hepatitis C virus envelope protein. Journal o f Experimental Medicine 195, 35-41.
26. Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W., Davey, D.F., Flynn, 
B.J., Hoff, S.T., Andersen, P., Reed, S.G., Morris, S.L., Roederer, M., Seder, 
R.A. 2007. Multifunctional THl cells define a correlate of vaccine-mediated 
protection against Leishmania. Nature Medicine 13, 843-850.
186
27. de Smith, A., Bouma, A., van Gennip, H., de Kluijver, E., Moormann, R. 2001. 
Chimeric (marker) C-strain viruses induce clinical protection against virulent 
classical swine fever virus (CSFV) and reduce transmission of CSFV between 
vaccinated pigs. Vaccine 19, 1467-1476.
28. Demento, S.L., Bonafé, N., Cui, W., Kaech, S.M., Caplan, M.J., Fikrig, E., 
Ledizet, M., Fahmy, T.M. 2010. TLR9-targeted biodegradable nanoparticles as 
immunization vectors protect against West Nile encephalitis. Journal o f 
Immunology 1^5,29^9-2991,
29. Denyer, M., Wileman, T., Stirling, C., Zuher, B., Takamatsu, H. 2006. Perforin 
expression can define CD8 positive lymphocyte subsets in pigs allowing 
phenotypic and functional analysis of Natural Killer, Cytotoxic T, Natural Killer 
T and MHC un-restricted cytotoxic T-cells. Veterinary Immunology and 
Immunopathology 110, 279-292.
30. Devilder, M., Allain, S., Dousset, C., Bonneville, M., Scotet, E. 2009. Early 
triggering of exclusive IFNy responses of human Vy9V52 T cells by TLR 
activated myeloid and plasmacytoid dendritic cells. Journal o f Immunology 183, 
3625-3633.
31. Dewulf, J., Laevens, H., Koenen, F., Mintiens, K., de Kruif, A. 2001. An E2 sub­
unit marker vaccine does not prevent horizontal or vertical transmission of 
classical swine fever virus. Vaccine 20, 86-91.
32. Dewulf, J., Laevens, H., Koenen, F., Mintiens, K., de Kruif, A. 2004. Efficacy of 
E2-suh-unit marker and C-strain vaccines in reducing horizontal transmission of 
classical swine fever virus in weaner pigs. Preventive Veterinary Medicine 65, 
121-133.
187
33. Dong, X., Chen, Y., Wu, Y., Chen, Y. 2005. Candidate multi-peptide-vaccine 
against classical swine fever virus induced potent immunity with serological 
marker. Vaccine 23, 3630-3633.
34. Dong, X., Chen, Y. 2007. Marker vaccine strategies and candidate CSFV marker 
vaccines. Vaccine 25, 205-230.
35. Drew, T.W.: Classical swine fever (hog cholera). In OIE Manual, of Diagnostic 
Test and Vaccines for Terrestrial Animals (mammals, birds and bees) Sixth ed. 
Paris, France: World Organization for Animal Health (OIE). 2008. 1092-1106.
36. Durand, S.V., Hulst, M.M., de Wit, A.A., Mastehroek, L., Loeffen, W.F. 2009. 
Activation and modulation of antiviral and apoptotic genes in pigs infected with 
classical swine fever viruses of high, moderate or low virulence. Archives o f  
Virology 154, 1417-1431.
37. Eblè, P.L., Geurts, Y., Quak., S., Moonen-Leusen, H.W., Blome, S., Hofinann, 
M.A., Koenen., F., Beer, M., Loeffen, W.L. 2013. Efficacy of chimeric pestivirus 
vaccine candidates against classical swine fever: protection and DIVA 
civàmcXonsiics. Veterinary Microbiology \62,A31-A6.
38. Edwards, S., Fukusho, A., Lefevre, P., Lipowski, A., Pejsak, Z., Roehe, P., 
Westergaard, J. 2000. Classical swine fever: the global situation. Veterinary 
Microbiology 73, 103-119.
39. Elamanchili, P., Lutsiak, C.M., Hamdy, S., Diwan, M., Samuel, J. 2007. 
‘Pathogen-mimicking’ nanoparticles for vaccine delivery to dendritic cells. 
Journal o f Immunotherapy 30, 378-395.
188
40. Elbers, K., Tautz, N., Becher, P., Stoll, D., Rumenapf, T., Thiel, H. 1996. 
Processing in the pestivirus E2-NS2 region: identification of proteins p7 and 
E l^ l. Journal o f Virology 10, Al3\-43\5.
41. Eloranta, M.L., Lovgren, T., Finke, D., Mathsson, L., Ronnelid, J., Kastner, B., 
Aim, G.V., Ronnblom, L. 2009. Regulation of the interferon-alpha production 
induced by RNA-containing immune complexes in plasmacytoid dendritic cells. 
Arthritis & Rheumatism 60, 2418—2427.
42. Essler, S.E., Ertl, W., Deutsch, J., Ruetgen, B.C., Groiss, S., Stadler, M., 
Wysoudil, B., Gemer, W., Ho, C.S., Saalmueller, A. 2013. Molecular 
characterization of swine leukocyte antigen gene diversity in purebred Pietrain 
pigs. Animal Genetics 44, 202-205.
43. Everett, H.E., Salguero, F.J., Graham, S.P., Haines, F.J., Johns, H., Clifford, D., 
Nunez, A., La Rocca, S.A., Parchariyanon, S., Steinbach, F., Drew, T.W., 
Crooke, H. 2010. Characterization of experimental infection of pigs with 
genotype 2.1 and 3.3 isolates of classical swine fever virus. Veterinary 
Microbiology 142, 26-33.
44. European Union (1980). EU Council Directive 80/217/EEC of 22 January 1980 
introducing Community measures for the control of classical swine fever (last 
amended 14 June 1993). Official Journal of the European Communities, pp. 11 -
23.
45. Fehniger, T, Caligiuri, M. 2001. Interleukin 15: biology and relevance to human 
disease. Blood 97, 14-32.
46. Femandez-Sainz, I., Holinka, L., Gavrilov, B.V., Prarat, M., Gladue, D., Lu, Z., 
Risatti, G.R., Borca, M.V. 2009. Alteration of the N-linked glycosylation
189
condition in El glycoprotein of Classical Swine Fever Virus strain Brescia alters 
virulence in swine. F/ro/ogy 386, 210-216.
47. Femandez-Sainz, I., Gladue, D., Holinka, L., O’Donnell, V., Gudmundsdottir, I., 
Prarat, M., Patch, J., Golde, W., Lu, Z., Zhu, J., Carrillo, C., Risatti, G.R., Borca, 
M.V. 2010. Mutations in Classical Swine Fever vims NS4B affect vimlence in 
swine. Jowrwfl/o/ F/ro/ogy 84, 1536-1549.
48.Fiebach, A.R., Guzylack-Piriou, L., Python, S., Summerfiled, A., Ruggli, N. 
2008. Classical swine fever vims N(pro) limits type I interferon induction in 
plasmacytoid dendritic cells by interacting with interferon regulatory factor 7. 
Journal ofVirolosv 85. 8002-8011.
49. Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G.A., Li, J., Mottram, P.L., 
McKenzie, I.F.C., Plehanski, M. 2004. Size-Dependent Immunogenicity: 
Therapeutic and Protective Properties of Nano-Vaccines against Tumors. Journal 
o f Immunology 113, 31 A%-3\5 A.
50. Filipovich, A.H., Vallera, D.A., Youle, R.J., Quinones, R.R., Neville, D.M. Jr, 
Kersey, J.H. 1984. Ex-vivo treatment of donor hone marrow with anti-T-cell 
immunotoxins for prevention of graft-versus-host disease. Lancet 1, 469-472.
51. Floegel, G., Wehrend, A., Depner, K., Fritzemeier, J., Waberski, D., Moennig, V. 
2000. Detection of classical swine fever in semen of infected boars. Veterinary 
Microbiology 11, \09-l\6.
52. Francki, R., Fauquet, C., Knudson, D., Brown, F. 1991. Classification and 
nomenclature of vimses. Fifth report of the intemational committee on the 
taxonomy of vimses. Archives o f Virology 2, 223-233.
190
53. Fray, M. D., G. E. Mann, and B. Charleston. 2001. Validation of an Mx/CAT 
reporter gene assay for the quantification of hovine type-I interferon. Journal o f 
Immunological Methods 249, 235-244.
54. Frey, C., Bauhofer, O., Ruggli, N., Summerfield, A., Hofinann, M., Tratschin, J.
2006. Classical swine fever virus replicon particles lacking the E™^ gene: a 
potential marker vaccine for intradermal application. Veterinary Research 37, 
655-670.
55. Fritzemeieij, J., Teuffert, J., Greiser-Wilke, I., Staubach, C., Schlter, H., 
Moennig, V. 2000. Epidemiology of classical swine fever in Germany in the 
mnQiiQS. Veterinary Microbiology 11,29-Al.
56. Ganges, L., Barrera, M , Nunez, J., Blanco, I., Frias, M., Rodriguez, F., Sobrino,
F. 2005. A DNA vaccine expressing the E2 protein of classical swine fever virus 
elicits T cell responses that can prime for rapid antibody production and confer 
total protection upon viral challenge. Vaccine 23, 3741-3752.
57. Gao, G., Wang, Q., Dai, Z., Calcedo, R., Sun, X., Li, G., Wilson, J.M. 2008. 
Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NSl 
from dengue virus that are present in all major serotypes. Humany Gene Therapy 
19, 927-936.
58. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., Trinchieri,
G. 2002. Reciprocal Activating Interaction between Natural Killer Cells and 
Dendritic Cells. Journal o f Experimental Medicine 195, 327-333.
59. Gemer, W., Kaser, T., Saalmuller, S. 2009. Porcine T lymphocytes and NK cells 
-  an update. Developmental and comparative immunology 33, 310-320.
191
60. Gibbens, J., Mansley, S., Thomas, G., Morris, H., Paton, D., Drew, T. Sandwick, 
T., Wilesmith, J. 2000. Origins of the CSFV outbreak. Veterinary Record 147, 
310.
61. Gladue, D.P., Holinka, L.G., Femandez-Sainz, I.J., Prarat, M.V., O’Donell, V., 
Vepkhvadze, N., Lu, Z., Rogers, K., Risatti, G.R., Borca, M.V. 2010. Effects of 
the interactions of classical swine fever vims Core protein with proteins of the 
SUMOylation pathway on vimlence in swine. Virology 407, 129-136.
62. Gladue, D.P., Holinka, L.G., Largo, E., Femandez-Sainz, I., Carrillo, O’Donell, 
V., Baker-Branstetter, R., Lu, Z., Amhroggio, X., Risatti, G.R., Nieva, J.L., 
Borca, M.V. 2012. Classical Swine fever vims protein p7 is a viroporin involved 
in vimlence in swine. Journal o f Virology 86, 6778-6791.
63. Golden-Mason, L., Rosen, H. 2006. Natural killer cells: primary target for 
hepatitis C vims immune evasion strategies. Liver transplantation 12, 363-372.
64. Graham, S.P., Everett, H.E., Johns, H., Haines, F.J., La Rocca, S.A., Khatri, M., 
Wright, I., Drew, T.W., Crooke, H.R. 2010. Characterisation of vims-specific 
peripheral blood cell cytokine responses following vaccination or infection with 
classical swine fever vimses. Veterinary Microbiology 142, 34-40.
65. Graham, S.P., Everett, H.E., Haines, F.J., Johns, H.,L, Sosan, O.A., Salguero, 
F.J., Clifford, D.J., Steinbach, F., Drew, T.W., Crooke, H.R. 2012a. Challenge of 
pigs with Classical swine fever vimses after C-strain vaccination reveals 
remarkably rapid protection and insights into early immunity. PLoS One 7, 
e29310.
66. Graham, S.P., Haines, F.J., Johns, H., Sosan, O.A., La Rocca, S.A., Lamp, B., 
Rumenapf, T., Everett, H.E., Crooke, H.R. 2012h. Characterization of vaccine-
192
induced, broadly cross-reactive IFN-y secreting T cell responses that correlate 
with rapid protection against classical swine fever virus. Vaccine 30, 2742-2748.
67. Greiser-Wilke, I., Moenning, V. 2004. Vaccination against classical swine fever 
virus: limitations and new strategies. Animal Health Research Review 5, 223-226.
68. Hammond, J., McCIy, R., Jansen, E., Morrissy, C., Hodgson, A., Johnson, M. 
2000. Vaccination with a single dose of a recombinant porcine adenovirus 
expressing the classical swine fever virus gp55 (E2) gene protects pigs against 
classical swine fever. Vaccine 18, 1040-1050.
69. Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne- 
Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, 
A.W., Chiuchiolo, M.J., Parks, C.L., Axthelm, M.K., Nelson, J.A., Jarvis, M.A., 
Piatak, M., Lifson, J.D., Picker, L.J. 2011. Profound early control of highly 
pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527.
70. Helwig, D.M., Keast, J.C. 1966. Viability of virulent swine fever virus in cooked 
and uncooked ham and sausage casings. Austrian Veterinary Journal 42, 131-
135.
71. Hendriks, J., Xiao, Y., Borst, J. 2003. CD27 promotes survival of activated T 
cells and complements CD28 in generation and establishment of the effector T 
cell pool. Journal o f Experimental Medicine 198, 1369-1380.
72. Herzer, K., Falk, C., Encke, J., Eichhorst, S., Ulsenheimer, A., Seliger, B., 
Krammer, P. 2003. Upregulation of major histocompatibility complex class I on 
liver cells by Hepatitis C virus core protein via p53 and TAPI impairs natural 
killer cells cytotoxicity. Jowrwfl/o/F/ro/ogy 77, 8299-8309.
193
73. Ho, C.S., Lunney, J.K., Franzo-Romain, M.H., Martens, G.W., Lee, Y.J., Lee, 
J.H., Wysocki, M., Rowland, R.R., Smith, D.M. 2009. Molecular characterization 
of swine leucocyte antigen class I genes in outbred pig populations. Animal 
Genetics 40, 468-78.
74. Hofhnan, B., Beer, M., Schelp, C., Schirrmeier, H., Depner, K. 2005. Validation 
of a real-time RT-PCR assay for sensitive and specific detection of classical 
swine fever. Journal ofVirologicalMethods 130, 36-44.
75. Hoof, I., Peters, B., Sidney, J., Pedersen, L.E., Sette, A., Lund, O., Buus, S., 
Nielsen, M. 2009. NetMHCpan, a method for MHC class I binding prediction 
beyond h u m a n s . 61, 1-13.
76. Howard, C.J., Clarke, M.C., Brownlie, J., Sopp, P. 1992. Immunity to bovine 
virus diarrhoea virus in calves: the role of different T-cell subpopulations 
analysed by specific depletion in vivo with monoclonal antibodies. Veterinary 
Immunology Immunopathology 32, 303-314.
77. Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, 
R.P., Lamer, A.C., Finbloom, D.S. 1999. Interleukin-10 inhibits expression of 
both interferon alpha- and interferon gamma-induced genes by suppressing 
tyrosine phosphorylation of STATl. Blood 93, 1456-1463.
78. Izquierdo, M., Balboa, M.A., Figuera, A., Lopez-Botet, M. 1988. Selective T cell 
subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins. Clinical 
Expert Immunology 74, 300-304.
79. Jamin, A., Gorin, S., Cariolet, R., Le Potier, M., Kuntz-Simon, G. 2008. Classical 
swine fever vims induces activation of plasmacytoid and conventional dendritic 
cells in tonsil, blood and spleen of infected pigs. Veterinary Research 39, 07.
194
80. Johns, H.L., Bensaude, E., La Rocca, S.A., Seago, J., Charleston, B., Steinbach, 
P., Drew, T.W., Crooke, H., Everett, H. 2010. Classical swine fever virus 
infection protects aortic endothelial cells from plpC-mediated apoptosis. Journal 
o f General Virology 91, \03^-\046.
81. Kaech, S.M., Wherry, E.J., Ahmed, R. 2002. Effector and memory T-cell 
differentiation: implications for vaccine development. Nature Review
Immunology 2,251-261.
82. Kalia, V., Sarkar, S., Suhramaniam, S., Haining, W.N., Smith, K.A., Ahmed, R.
2010. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells 
favours terminal-effector differentiation in vivo. Immunity 32, 91-103.
83. Kaveh, D.A., Bachy, V.S., Hewinson, R.G., Hogarth, P.J. 2011. Systemic BCG 
immunization induces persistent lung mucosal multifunctional CD4 TEM cells 
which expand following virulent mycobacterial challenge. PLoS One 6, e21566.
84. Kawai, T., and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen 
recognition. Internal Immunology 21,317-337.
85. Kittlesen, D.J., Chianese-Bullock, K.A., Yao, Z.Q., Braciale, T.J., Hahn, Y.S. 
2000. Interaction between complement receptor gClqR and hepatitis C virus core 
protein inhibits T-lymphocyte proliferation. Journal o f Clinical Investigation 
106, 1239-1249.
86. Kobayashi, N., Kondo, T., Takata, H., Yokota, S., Takiguchi, M. 2006. 
Functional and phenotypic analysis of human memory CD8+ T cells expressing 
CXCR3. Journal o f Leukocyte Biology 80, 320-329.
195
87. Koenig, P., Lange, E., Reimann, I., Beer, M. 2007. CP7_E2alf: a safe and 
efficient marker vaccine strain for oral immunization of wild boar against 
Classical swine fever virus (CSFV). Vaccine 25, 3391-3399.
88. Krey, T., Himmelreich, A., Heimann, M., Menge, C., Thiel, H.J., Maurer, K., 
Rumenapf, T. 2006. Function of hovine CD46 as a cellular receptor for bovine 
viral diarrhea virus is determined by complement control protein 1. Journal o f 
Fzm/ogy 80, 3912-3922.
89. La Rocca, A., Herbert, R., Crooke, H., Drew, T., Wileman, T., Powell, P. 2005. 
Loss of Interferon Regulatory Factor 3 in Cells Infected with Classical Swine 
Fever Virus Involves the N-Terminal Protease, Npro. Journal o f Virology 79, 
7239-7247.
90. Laddomada, A. 2000. Incidence and control of classical swine fever in European 
wild boar. Veterinary Microbiology 73, 121-130.
91. Laevens, H., Koenen, F., Deluyker, H., De Kruif, A. 1999. Experimental 
infection of slaughter pigs with classical swine fever virus: transmission of the 
virus, course of the disease and antibody response. Veterinary Record 145, 243- 
248.
92. Lanier, L. 2005. NK cell recognition. Annual review o f immunology 23, 225-274.
93. Lang Kush, K.A., Ginsberg, A.A., Van, J., Wiseman, R.W., Khan, A.S., Sardesai, 
N.Y., O’ConnOr, D.H., Weiner, D.B. 2012. Hepatitis C virus NS3/NS4A DNA 
vaccine induces multiepitope T cell responses in rhesus macaques mimicking 
human immune responses. Molecular Therapy 20, 669-678.
196
94. Larsen, M., Sauce, D., Arnaud, L., Fastenackels, S., Appay, V. 2012. Evaluating 
cellular polyfunctionality with a novel polifunctionality index. PLoS One 7, 
e42403.
95. Leslie, A.J., Pfafferott, K.J., Chetty, P., Draenert, R., Addo, M.M., Feeney, M., 
Tang. Y., Holmes, E.C., Allen, T., Prado, J.G., Altfeld, M., Brander, C., Dixon. 
C., Ramduth, D., Jeena, P., Thomas, S.A., St John, A., Roach, T.A., Kupfer, B., 
Luzzi, G., Edwards, A., Taylor, G., Lyall, H., Tudor-Williams, G., Novelli, V., 
Martinez-Picado, J., Kiepiela, P., Walker, B.D., Goulder, P.J. 2004. HIV 
evolution: CTL escape mutation and reversion after transmission. Nature 
Medicine 10, 2S2-2S9.
96. Li, W., Mao, L., Yang, L., Zhou, B., Jiang, J. 2013. Development and partial 
validation of a recombinant E2-based indirect ELISA for detection of specific 
IgM antibody responses against classical swine fever virus. Journal o f 
VirologicalMethods 191, 63-68.
97. Liu, Y. 2005. IPC: Professional type 1 interferin-producing cells and 
plasmacytoid dendritic cell precursors. Annual Review o f Immunology 23, 275- 
306.
98. Lohse, L., Nielsen, J., Eriksen, L. 2004. Temporary CD8+ T-cell depletion in 
pigs does not exacerbate infection with porcine reproductive and respiratory 
syndrome virus (PRRSV). Viral Immunology 17, 594-603.
99. Luft, T., Pang, K.C., Thomas, E., Hertzog, P., Hart, D.N., Trapani, J., Cebon, J.
1998. Type I IFNs enhance the terminal differentiation of dendritic cells. Journal 
o f Immunology 161, 1947-1953.
197
100. Lumsden, J.M., Schwenk, R.J., Rein, L.E., Moris, P., Janssens, M., Ofori- 
Anyinam, O., Cohen, J., Rester, K.E., Heppner, D.G., Krzych, U. 2011. 
Protective immunity induced with the RTS, S/AS vaccine is associated with IL-2 
and TNF-a producing effector and central memory CD4 T cells. PLoS One 6, 
e20775.
101. Lunney, J.K., Ho, C.S., Wysocki, M., Smith, D.M. 2009. Molecular genetics 
of the swine major histocompatibility complex, the SLA complex. 
Developmental & Comparative Immunology 33, 362-374.
102. Mandelhoim, O., Lieberman, N., Lev, M., Paul, L., Amon, T. I., Bushkin, Y., 
Davis, D. M., Strominger, J. L., Yewdell, J. W., Porgador, A. 2001. Recognition 
of haemagglutinins on vims-infected cells by NKp46 activates lysis by human 
NK cells. 409:1055-1060.
103. McKeever, D.J., Taracha, E.L., Innes, E.L., MacHugh, N.D., Awino, E., 
Goddeeris, B.M., Morrison, W.L 1994. Adoptive transfer of immunity to 
Theileria parva in the CD 8+ fraction of responding efferent lymph. Proceedings 
o f the National Academy o f Sciences 91, 1959-1963.
104. Meyers, G., Saalmüller, A., Büttner, M. 1999. Mutations Abrogating the 
RNase Activity in Glycoprotein E™® of the Pestivims Classical Swine Fever 
Vims Lead to Vims Attenuation. Journal o f Virology 73, 10224-10235.
105. Mikkelsen, M., Holst, P.J., Bukh, J., Thomsen, A.R., Christensen, J.P. 2011. 
Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based 
hepatitis C vims vaccine encoding NS3 linked to the MHC class II chaperone 
protein invariant chain. Journal o f Immunology 186, 2355-2364.
198
106. Minami, Y., Kono, T., Miyazaki, T., Taniguchi, T. 1993. The IL-2 receptor 
complex: its structure, fimction and target genes. Annual Review o f Immunology 
11,245-267.
107. Moennig, V. 2000. Introduction to classical swine fever: virus, disease and 
control policy. Veterinary Microbiology 73, 93-102.
108. Moennig, V., Floegel-Niesmann, G., Greiser-Wilke, I. 2003. Clinical signs 
and epidemiology of classical swine fever: a review of new knowledge. 
Veterinary Journal 165, W-20.
109. Monso, M., Tarradas, J., de la Torre, B., Sohrino, F., Ganges, L., Andreu, D. 
2011. Peptide vaccine candidates against classical swine fever virus: T cell and 
neutralizing antibody responses of dendrimers displaying E2 and NS2-3
Journal o f Peptide Science \1, 24-31.
110. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffinan, R.L, 
1986. Two types of murine helper T cell clone. I. Definition according to profiles 
of lymphokine activities and secreted proteins. Journal o f Immunology 136, 
2348-2357.
111. Moormann, R.J.M, van Rijn, P.A., de Smith, H.J., Wensvoort. G., Terpstra, 
C. 1996. Recent developments in pig vaccinology. In: Proceeding o f the 
International Pig Veterinary Society (IPVS) congress, pp. 25-29.
112. Nakayama, M., Takeda, K., Kawano, M., Takai, T.,Ishii, N., Ogasawara, K.
2011. Natural killer (NK)-dendritic cell interactions generate MHC class II- 
dressed NK cells that regulate CD4+ T cells. Proceedings o f the National 
Academy o f Sciences l0'3>,\^360-\'3>365.
113. Newman, K., Riley, E. 2007. Whatever turns you on: accessory-cell-
199
dependent aetivation of NK cells by pathogens. Nature Reviews Immunology 7, 
279-291.
114. Oukka, M., Manuguerra, J.C., Livaditis, N., Tourdot, S., Riche, N., Vergnon,
I., Cordopatis, P., Kosmatopoulos, K. 1996. Protection against lethal viral 
infection by vaccination with nonimmunodominant peptides. Journal o f 
Immunology 157, 3039-3045.
115. Oura, C.A., Denyer, M.S., Takamatsu, H., Parkhouse, R.M. 2005. In vivo 
depletion of CD8+ T lymphocytes abrogates protective immunity to African 
swine fever virus. Journal o f General Virology 86, 2445-2450.
116. Parchariyanon, S., Inui, K., Damrongwatanapokin, S., Pinyoehon, W., 
Rowings, P., Paton, D. 2000. Sequence analysis of E2 glycoprotein genes of 
classical swine fever viruses: identification of a novel genogroup in Thailand. 
Dtsch Tierarztl Wochenschr 107, 236-238.
117. Patch, J.R;, Pedersen, L.E., Toka, F.N., Moraes, M., Grubman, M.J., Nielsen, 
M., Jungersen, G., Buus, S., Golde, W.T. 2011. Induction of foot-and-mouth 
disease virus-specific cytotoxic T cell killing by vaccination. Clinical Vaccine 
Immunolology 18, 280-288.
118. Paton, D., McGoldrick A., Greiser-Wilke, L., Pareharity-Anon, S., Song, J., 
Liou, P., Stadejek, T., Rowings, J., Bjorklund, H., Belak, S. 2000. Genetic typing 
of classical swine fever virus. Veterinary Microbiology 73, 137-157.
119. Paton, J., Greiser-Wilke, I. 2003. Classical swine fever -  an update. Research 
in Veterinary Science 75, 169-178.
200
120. Pauly, T., Elbers, K., Kônig, M., Lengsfeld, T., A. Saalmüller, A., Thiel, H. 
1995. Classical swine fever virus-specific cytotoxic T lymphocytes and 
identification of a T cell epitope. Journal o f General Virology 76, 3039-3049.
121. Pedersen, L.E., Hamdahl, M., Nielsen, M., Patch, J.R., Jungersen, G., Buus,
S., Golde, W.T. 2013. Identification of peptides from foot-and-mouth disease 
virus structural proteins bound by class I swine leukocyte antigen (SLA) alleles, 
SLA-1*0401 and SLA-2*0401. Genetics 44, 251-258.
122. Peeters, B., Bienkowska-Szewczyk, K., Hulst, M., Gielkens, A., Kimman, T. 
1997. Biologically safe, non-transmissible pseudorabies virus vector vaccine 
protects pigs against both Aujeszky’s disease and classical swine fever. Journal 
o f General Virology 78, 3311-3315.
123. Penaloza-MaeMaster, P., Masopust, D., Ahmed, R. 2009. T-cell 
reconstitution without T-cell immunopathology in two models of T-cell-mediated 
tissue destruction. 128, 164-171.
124. Pestova, T.V., Shatsky, I.N., Fletcher, S.P., Jackson, R.J., Hellen, C.U. 1998. 
A prokaryotic like mode of cytoplasmic eukaryotic ribosome binding to the 
initiation codon during internal translation initiation of hepatitis C and classical 
swine fever virus RNAs. Genes & Development 12, 67-83.
125. Pintaric, M., Gemer, W., Saalmuller, A. 2008. Sinergistie effects of IL-2, IL- 
12 and IL-18 and cytolytic activity, perforin expression and IFN-gamma 
production of porcine natural killer cells. Veterinary Immunology 
Immunopathology 121, 68-82.
201
126. Piriou, L., Chevallier, S., Hutet, E., Charley, B., Le Potier, M.F., Albina, E.
1999. Humoral and cell-mediated immune responses of d/d histoeompatible pigs 
against classical swine fever (CSF) virus. Veterinary Research 34, 389-404.
127. Phyton, S., Gerber, M., Suter, R., Ruggli, N., Summerfield, A. 2013. Efficient 
sensing of infected cells in absence of virus particles by plasmaeytoid dendritic 
cells is blocked by the viral ribonuclease E(ms). PLoS Pathogen 9, el 003412.
128. Qiu, H., Lang, H., Wang, Z. 1999. Studies on field isolates of classical swine 
fever virus. Experimental immunization of pregnant sows with lapinized hog 
cholera virus. In: Proceeding o f China Institute o f Veterinary Drug Control 
(1995-1999), 14, pp. 54-56, (in Chinese).
129. Qiu, H., Tong, G., Shen, R. 2006. The Lapinized Chinese Strain Vaccine 
against Classical Swine Fever Virus: A Retrospective Review Spanning Half A 
Century. Agricultural Sciences in China 5, 1-14.
130. Rangelova, D., Nielsen, J., Strandbygaard, B., Koenen, F., Blome, S., 
Uttenthal, A. 2012. Efficacy of marker vaccine candidate CP7 E2 alf in piglets 
with maternally derived C-strain antibodies. Vaccine 30, 6376-6381.
131. Rasmussen, T., Uttenthal, A., Nielsen, J., Beer, M., Depner, K., Reimann, I.
2005. Viruence, immunogenicity and vaccine properties of a novel chimeric 
pesti virus. In: Abstracts o f the sixth ESWpestivirus symposium, P5-6, p 83.
132. Ran, H., Reverts, H., Balmelli, C., McCullough, K., Summerfield, A. 2006. 
Immunological properties of recombinant classical swine fever virus NS3 protein 
in vitro and in vivo. Veterinary Research 37, 155-168.
2 0 2
133. Reimann, L, Depner, K., Trapp, S., Beer, M. 2004. An avirulent chimeric 
Pestivirus with altered cell tropism protects pigs against lethal infection with 
classical swine fever virus. Virology 322, 143-157.
134. Renson, P., Blanchard, Y., Le Dimna, M., Felix, H., Cariolet, R., Jestin, A., 
Le Potier, M.F. 2010. Acute induction of cell death-related IFN stimulated genes
• (ISG) differentiates highly from moderately virulent CSFV strains. Veterinary 
Research 41, 7.
135. Renson, P., Dimna, M., Keranflee, H.A., Cariolet, R., Koenen, F., Potier, 
M.F. 2013. CP7_E2alf oral vaccination confers partial protection against early 
classical swine fever virus challenge and interferes with pathogeny-related 
cytokine responses. Veterinary Research 44, 9.
136. Reutner, K., Leitner, J., Essler, S.E., Witter, K., Patzl, M., Steinberger, P., 
Saalmuller, A., Gemer, W. 2012. Porcine CD27: Identification, expression and 
functional aspects in lymphocyte subset in swine. Developmental and 
Comparative Immunology 38, 321-331.
137. Reutner, K. Leitner,, J., Müllebner, A., Ladinig, A., Essler, S.E., Duvigneau, 
J.C., Ritzmann, M., Steinberger, P., Saalmüller, A., Gemer,W. 2013. CD27 
expression discriminates porcine T helper cells with functionally distinct 
properties. Veterinary Research 44, 18.
138. Reyes-Sandoval, A., Wyllie, D.H., Bauza, K., Milieic, A., Forbes, E.K., 
Rollier, C.S., Hill, A.V. 2011. CD8+ T effector memory cells protect against 
liver-stage malaria. Journal o f Immunology 187, 1347-57.
139. Riedel, C., Lamp, B., Heimann, M., Konig, M, Blome, S., Moennig, V., 
Schuttler, C., Thiel, H.J., Rumenapf, T. 2012. The core protein of classical swine
203
fever virus is dispensable for virus propagation in vitro. PLoS Pathogens 8, 
e l002598.
140. Risatti, G., Borca, M., Kutish, G., Lu, Z., Holinka, L., French, R., Tulman, E., 
Rock, D. 2005. The E2 glycoprotein of classical swine fever virus is a virulence 
determinant in swine. Journal o f Virology 79, 3787-3796.
141. Risatti, G., Holinka, L., Fernandez, Sainz, I., Carrillo, C., Kutish, G., Lu, Z., 
Zhu, J., Rock, D., Borca, M. 2007. Mutations in the carboxyl terminal region of 
E2 glycoprotein of classical swine fever virus are responsible for viral attenuation 
in swine. F/ro/ogy 364, 371-382.
142. Risatti, G., Holinka, L.G., Fernandez, Sainz, I., Carrillo, C., Lu, Z., Borca, M.
2007. N-linked glycosylation status of classical swine fever virus strain Brescia 
E2 glycoprotein influences virulence in swine. Journal o f Virology 81, 924-933.
143. Rivino, L., Kumaran, E.A., Joyanovic, V., Nadua, K., Teo, E.W., Pang, S.W., 
Teo, G.H., Gan, V.C., Lye, D.C., Leo, Y.S., Hanson, B.J., Smith, K.G., 
Bertoletti, A., Kemeny, D.M., MaeAry, P.A. 2013. Differential Targeting of 
Viral Components by CD4+ versus CD8+ T Lymphocytes in Dengue Infection. 
Journal o f Virology ?>1,269?>-2106.
144. Rhodes, S.G., Cocksedge, J.M., Collins, R.A., Morrison, W.I. 1999. 
Differential cytokine responses of CD4+ and CD8+ T cells in response to bovine 
viral diarrhoea virus in cattle. Journal o f General Virology, 80, 1673-9.
145. Ruggli, N., Bird, B., Liu, L., Bauhofer, O., Tratschin, J., Hofmann, M. 2005. 
N(pro) of classical swine fever virus is an antagonist of double-stranded RNA- 
mediated apoptosis and IFN-alpha/beta induction. Virology 340, 265-276.
204
146. Rumenapf, T., Stark, R., Meyers, G., Thiel, H. 1991. Structural proteins of 
hog cholera virus expressed by vaccinia virus: further characterization and 
induction of protective immunity. Journal o f Virology 65, 589-597.
147. Rumenapf, T., Unger, G., Strauss, J., Thiel, H. 1993. Processing of the 
envelope glycoproteins of pestiviruses. Journal o f Virology 67,3288-3294.
148. Rumenapf T. and Thiel H. ‘Molecular Biology of Pestivirus’, in. Animal 
Viruses: Molecular Biology, Caister Academic Press, 2008, pp 44-55.
149. Saalmuller, A., Pauly, T., Hohlieh, B.J., Pfaff, E. 1999. Characterization of 
porcine T lymphocytes and their immune response against viral antigens. Journal 
o f Biotechnology 73, 223-233.
150. Sacchini, F., Naessens, J., Awino, E., Heller, M., Hlinak, A., Haider, W., 
Stemer-Koek, A., Jores, J. 2011. A minor role of CD4+ T lymphocytes in the 
control of a primary infection of cattle with Mycoplasma mycoides subsp. 
mycoides. Veterinary Research 42, 77.
151. Sainz, I.E., Holinka, E.G., Lu, Z., Risatti, G.R., Borca, M.V. 2008. Removal 
of a N-linked glycosylation site of classical swine fever virus strain Brescia Ems 
glycoprotein affects virulence in swine. Virology 370, 122-129.
152. Sandwik, T., Drew, T., Paton, D. 2000. CSF virus in East Anglia: where 
froml Veterinary Record \41,25\.
153. Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecehia, A. 1992. Two 
subset of memory T lymphocyte with distinct homing potentials and effector 
functions. Ah/wrc 401, 708-712.
154. Saulmon, E. 1973. Hog cholera eradication: dream or reality. Journal o f 
American Veterinary Medical Association 163, 1003-1005.
205
155. Schlaphoff, V., Klade, C.S., Jilma, B., Jelovcan, S.B., Comberg, M., Tauber, 
E., Manns, M.P., Wedemeyer, H., IC41 Study Group. 2007. Functional and 
phenotypic characterization of peptide-vaecine-induced HCV-speeific CDS T 
cells in healthy individuals and chronic hepatitis C patients. Vaccine 25, 6793- 
6806.
156. Schroeder, S., von Rosen, T., Blome, S., Loeffen, W., Haegeman, A., 
Koenen, F., Uttenthal, A. 2012. Evaluation of classical swine fever virus 
antibody detection assays with an emphasis on the differentiation of infected 
from vaccinated animals. Revue scientifique et technique 31, 997-1010.
157. Schweinitz, E., Dorset, M. 1904. New facts concerning the etiology of hog 
cholera. In: 20^  ^annual report o f the bureau o f animal industry. US Department 
of Agriculture, p. 157-162.
158. Seder, R.A., Darrah, P.A., Roederer, M. 2008. T-cell quality in memory and 
protection: implications for vaccine design. Nature Review Immunology 8, 247- 
258.
159. Sene, D., Levasseur, F., Abel, M., Lambert, M., Camous, X., Hernandez, C., 
Pene, V., Rosenberg, A., Jouvin-Marche, E., Marche, P., Cacoub, P., Caillat, Z. 
2010. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses 
through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathogens 
6,1-15.
160. Sheng, C., Wang, J., Xiao, J., Chen, Y., Jia, L., Zhi, Y., Li, G., Xiao, M.
2012. Classical swine fever virus NS5B protein suppresses the inhibitory effect 
of NS5A on viral translation by binding to NS5A. Journal o f General Virology 
93, 939-950.
206
161. Smith, H.R., Heusel, J.W., Mehta, I.K., Kim, S., Domer, B.G., Naidenko, 
O.V., lizuka, K., Fumkawa, H., Beekman, D.L., Pingel, J.T., Sealzo, A.A., 
Fremont, D.H., Yokoyama, W.M. 2002. Recognition of a virus-encoded ligand 
by a natural killer cell activation receptor. Proceedings o f the National Academy 
o f Sciences 99, 8826-8831.
162. Stageman, A., Elbers, A. de Smit, H., Moser, H., Smak, J., Pluimers, F. 2000. 
The 1997-1998 epidemic of classical swine fever in the Netherlands. Veterinary 
Microbiology 13, IS3-196.
163. Stomi, T., Kundig, T.M., Senti, G., Johansen, P. 2005. Immunity in response 
to particulate antigen-delivery systems. Advanced Drug Delivery Reviews 57, 
333-355.
164. Summerfield, A., Hofinann, M.A., McCullough, K.C. 1998. Low density 
blood granulocytie eells induced during classical swine fever are targets for virus 
infection. Veterinary Immunology Immunophatology 63, 289-301.
165. Summerfield, A., Knoetig, S.M., McCullough, K.C. 1998. Lymphocyte 
apoptosis during Classical Swine Fever: implication of activation-induced eell 
death. Journal o f Virology 72, 1853-1861.
166. Summerfield, A., McNeilly, F., Walker, I., Allan, G., Knoetig, S.M., 
McCullough, K.C. 2001. Depletion of CD4(+) and CD8(high+) T-eells before the 
onset of viremia during classical swine fever. Veterinary Immunology 
Immunophatology 1^, 3-10.
167. Summerfield, A., Alves, M., Ruggli, N., de Bruin, M.G., McCullough, K.C.
2006. High IFN-alpha responses associated with depletion of lymphocytes and
207
natural IFN-producing cells during classical swine fever. Journal o f Interferon 
and Cytokine Research 26, 248-255.
168. Sun, Y., Yang, Y., Zheng, H., Xi, D., Lin, M., Zhang, X., Yang, L., Yan, Y., 
Chu, X., Bi, B. 2013. Co-expression of Ems and E2 genes of classical swine 
fever vims by replication-defective recombinant adenovims completely protect 
pigs against vimlent challenge with classical swine fever vims. Research 
Veterinary Science 94, 354-60.
169. Suradhat, S., Intrakamhaeng, M., Damrongwatanapokin, S. 2001. The 
correlation of vims-specific interferon-gamma production and protection against 
classical swine fever vims infection. Veterinary Immunology and 
Immunopathology ^3,111-1^9.
170. Suradhat, S., Sada, W., Buranapraditkun, S., Damrongwatanapokin, S. 2005. 
The kinetics of cytokine production and CD25 expression by porcine lymphocyte 
subpopulations following exposure to classical swine fever vims (CSFV). 
Veterinary Immunology and Immunopathology \06,\91-20^.
171. Taeken, P.J., Zeelenberg, I.S., Cmz, L.J., van Hout-Kuijer, M.A., van de 
Gling, G., Fokkink, R.G., Lambeck, A.J., Figdor, C.G. 2011. Targeted delivery 
of TLR ligands to human and mouse dendritic cells strongly enhances 
adjuvanticity. Blood 118, 6836-6844.
172. Takamatzu, H.H., Denyer, M.S., Stirling, C., Cox, S., Aggarwal, N., Dash, P., 
Willeman, T.E., Bamett, P.V. 2006. Porcine gammadelta T eells: possible roles 
on the innate and adaptive immune responses following vims infection. 
Veterinary Immunology and Immunopathology 112, 49-61.
208
173. Talker, S.C., Kâser, T. Reutner, K., Sedlak, C., Mair, K.H., Koinig, H., 
Graage, R., Viehmann, M., Klingler, E., Lading, A., Ritzmann, M., Saalmüller, 
A, Gemer, W. 2013. Phenotypic maturation of porcine NK- and T-cell subsets. 
Developmental and Comparative Immunology 40, 51-68.
174. Tam, J.P. 1988. Syntetic peptide vaceine design: synthesis and properties of a 
high-density multiple antigenic peptide system. Proceedings o f the National 
Academy o f Sciences 85, 5409-5413.
175. Tamura, T., Sakoda, Y., Yoshino, P., Nomura, T., Yamamoto, N., Sato, Y., 
Okamatsu, M., Ruggli, N., Kida, H. 2012. Selection of classical swine fever vims 
with enhanced pathogenicity reveals synergistic vimlent determinants in E2 and 
NS4B. Journal o f Virology 86, 8602-8613.
176. Tang, Q., Guo, K., Kang, K., Zhang, Y., He, L., Wang, J. 2011. Classical 
swine fever vims NS2 protein promotes interleukin-8 expression and inhibits 
MG132-induced apoptosis. Virus Genes 42, 355-362.
177. Tarradas, J., Argilaguet, J., Rosell, R., Nofrarias, M., Crisei, E., Cordoba, L., 
Perez-Martin, E., Diaz, L, Rodriguez, F., Domingo, M., Montoya, M., Ganges, L. 
2010. Interferon-gamma induction correlates with protection by DNA vaccine 
expressing E2 glycoprotein against classical swine fever vims infection in 
domestic pigs. Veterinary Microbiology 142, 51-58.
178. Tarradas, J., Monso, M., Fraile, L., de la Torre, B.G., Munoz, M., Rosell, R., 
Riquelme, C., Pérez, L.I., Nofrarias, M., Domingo, M., Sobrino, F., Andreu, D., 
Ganges, L. 2012. A T-cell epitope on NS3 non-stmetural protein enhances the B 
and T cell responses elieide by dendrimeric constmetions against CSFV in 
domestic pigs. Veterinary Immunology Immunopathology 150, 36-46.
209
179. Terpstra, C., Tielen, M. 1976. Antibody response against swine fever 
following vaeeination with the C-strain virus. Zentralblattfur Veterinarmedizin 
ReiheB 23, S09-S21.
180. Terpstra, C., Krol, B. 1976. Effect of heating on the survival of swine fever 
virus in pasteurized canned ham from experimentally infected animals. Tijdschr 
Diergeneeskd\0\,\231-\2A\.
181. Terpstra, C., Bloemraad, M., Gielkens, A.L. 1984. The neutralizing 
peroxidase-linked assay for detection of antibody against swine fever virus. 
Veterinary Microbiology 9, 113-120.
182. Terpstra, C., Wensvoort, G. 1988. The protective value of vaeeine-induced 
neutralizing antibody titres in swine fever. Veterinary Microbiology 16, 123-128.
183. Terpstra, C., Woortmeyer, R., Barteling, S. 1990. Development and 
properties of a cell culture produced vaccine for hog cholera based on the 
Chinese strain. Deutsche Tierarztliche Wochenschrift 91, 77-79.
184. Terpstra, C., de Smit, A.J. 2000. The 1997/1998 epizootic of swine fever in 
the Netherlands: control strategies under a non-vaccination regimen. Veterinary 
Microbiology 77, 3-15.
185. Thakur, A., Pedersen, L., Jungersen, G. 2012. Immune markers and correlates 
of protection for vaccine induced immune responses. Vaccine 30, 4907-4920.
186. Thiel, H., Stark, R., Welland, E., Rumenapf, T., Meyers, G. 1991. Hog 
cholera virus: molecular composition of virions from a pestivirus. Journal o f 
Virology 65, 4705-4712.
187. Tian, J., Zeng, G., Pang, X., Liang, M., Zhou, J., Fang, D., Liu, Y., Li, D., 
Jiang, L. 2012. Identification and immunogenicity of two new HLA-A*0201-
210
restricted CDS T-cell epitopes on dengue NSl protein. International Immunology 
24,207-218.
188. Toka, F.N., Nfon, C., Dawson, H., Golde, W.T. 2009. Natural killer eell 
dysfunction during acute infection with foot-and-mouth disease virus. Clinical 
Vaccine Immunology \6, 1738-1749.
189. Toledo, J., Barrera, M., Famos, O., Gomez, S., Rodriguez, M., Aguero, F., 
Ormazabal, V., Parra, N., Suarez, L., Sanchez, O. 2010. Human alFN co­
formulated with milk derived E2-CSFV protein induce early fully protection in 
vaccinated pigs. Vaccine 2^,1901-191 A.
190. Tomiyama, H., Takata, H., Matsuda, T., Takiquchi, M. 2004. Phenotypic 
classification of human CD8+ T cells reflecting their function: inverse correlation 
between quantitative expression of CD27 and cytotoxic effector function. 
European Journal o f Immunology 34, 999-1010.
191. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and 
adaptive immunity. Nature Reviews Immunology 3, 133-146.
192. Tseng, C., Miskovly, E., Houghton, M., Kimpel, G. 2001. Characterization of 
liver T-cell receptor gammadelta T eells obtained from individuals chronically 
infected with hepatitis C virus (HCV): evidence for these T eells playing a role in 
the liver pathology associated with HCV infections. Hepatology 33, 1312-1320.
193. Urbani, S., Boni, C., Missale, G., Elia, G., Cavallo, C., Massari, M., 
Raimondo, G., Ferrari, C. 2002. Virus-specific CD8+ lymphocytes share the 
same effeetor-memory phenotype but exhibit funetional differences in acute 
hepatitis B and C. Journal o f Virology 76, 12423-12434.
211
194. Van der Most, R.G., Harrington, L.E., Giuggio, V., Mahar, P.L., Ahmed, R. 
2002. Yellow fever virus 17D envelope and NS3 proteins are major targets of the 
antiviral T cell response in mice. Virology 296, 117-124.
195. van Gennip, H., van Rijn, P., Widjojoatmodjo, M., de Smit, A., Moormann, 
R. 2000. Chimerie elassical swine fever viruses containing envelope protein 
E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with 
CSFV and induce a distinguishable antibody response. Vaccine 19, 447-459.
196. van Gennip, H., Bouma, A., van Rijn, P., Widjojoatmodjo, M., Moormann, R. 
2002. Experimental non-transmissible marker vaecines for classical swine fever 
(CSF) by trans-complementation of E(ms) or E2 of CSFV. Vaccine 20, 1544- 
1556.
197. van Oirsehot, J.T. 2003. Vaceinology of elassical swine fever: from lab to 
field. Veterinary Microbiology 96, 361
198. Van Oosterhout, Y.V.J.M., van Emst, L., Schattenberg, A.V.M.B., Tax, 
W.J.M., Ruiter, D.J., Spits, H., Nagengast, F.M., Masereeuw, R., Evers, S., de 
Witte, T., Preijers, F.W.M.B. 2000. A combination of anti-CD3 and anti-CD7 
ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. 
R W  95, 3693-3701.
199. Valdez, R.A., McGuire, T.C., Brown, W.C., Davis, W.C., Jordan, J.M.m 
Knowles, D.P. 2002. Selective in vivo depletion of CD4(+) T lymphoeytes with 
anti-CD4 monoclonal antibody during acute infeetion of calves with Anaplasma 
marginale. Clinical Diagnostic Laboratory Immunology 9, 417-424.
212
200. Villarreal-Ramos, B., McAulay, M., Chance, V., Martin, M., Morgan, J., 
Howard, C.J. 2003. Investigation of the role of CD8+ T cells in bovine 
tuberculosis in vivo. Infection and Immunity 71, 4297-4303.
201. Villiera, C., Chevallet, M., Diemer, H., Couderc, R., Freitas, H., Van 
Dorsselaer, A., Marche, P.N., Rabillound, T. 2009. From seeretome analysis to 
immunology: chitosan induces major alterations in the activation of dendritic 
cells via a TLR4-dependent meehanism. Molecular and Cellular Proteomics 8, 
1252-1264.
202. Vitetta, E.S., Krolick, K.A., Miyama-Inaba, M., Cushley, W., Uhr, J.W. 
1983. Immunotoxins: a new approach to cancer therapy. Science 219, 644-650.
203. Wang, Z. 1996. Retrospect and prospect of the eontrol of classical swine 
fever. In: Progress in Immunogical Prevention o f Important Infectious Diseases 
of Animals, China Agriculture Press, Beijing, pp. 64-71 (in Chinese).
204. Weiland, E., Stark, R., Haas, B., Rumenapf, T., Meyers, G., Thiel, H. 1990. 
Pestivirus glycoprotein whieh induces neutralizing antibodies forms part of a 
disulfide-linked heterodimer. Journal o f Virology 64, 3563-3569.
205. Weiland, F., Weiland, E., Unger, G., Saalmuller,, A., Thiel, H. 1999. 
Loealization of pesti viral envelope proteins E*^® and E2 at the cell surface and on 
isolated particles. Journal o f General Virology 80, 1157-1165.
206. Whelan, A.O., Villarreal-Ramos, B., Vordermeier, H.M., Hogart, P.J. 2011. 
Development of an antibody to bovine IL-2 reveals multifunctional CD4 Tem 
cells in cattle naturally infected with bovine tuberculosis. PLoS One 6, 1-8.
207. Widjojoatmodjo, M., van Gennip, H., Bouma, A., van Rijn P., Moormann, R.
2000. Classical swine fever virus E(ms) deletion mutants: trans-complementation
213
and potential use as nontransmissible, modified, live-attenuated marker vaceines. 
Journal o f Virology 74, 2973-2980.
208. Wienhold, D., Armengol, E., Marquardt, A., Marquardt, C., Voigt, H., 
Buttner, M., Saalmuller, A., Pfaff, E. 2005. Immunomodulatory effeet of 
plasmids co-expressing cytokines in classieal swine fever virus subunit gp55/E2- 
DNA vaeeination. Veterinary Research 36,51 \-5^1.
209. Wiesel, M., Walton, S., Richer, K., Oxenius, A. 2009. Virus-specific CD8 T 
cells: activation, differentiation and memory formation. APMIS 117, 356-381.
210. Xiao, M., Bai, Y., Xu, H., Geng, X., Chen, J., Wang, Y, Chen, J, Li, B. 2008. 
Effect of NS3 and NS5B proteins on classieal swine fever internal ribosome 
entry site-mediated translation and its host cellular translation. Journal o f 
General Virology 89, 994-999.
211. Xiao, M., Wang, Y., Zhu, Z., Yu, J., Wan, L., Chen, J. 2009. Influenee of 
NS5A protein of classieal swine fever virus (CSFV) on CSFV internal ribosome 
entry site-dependent translation. Journal o f General Virology 90, 2923-2928.
212. Xu, J., Mendez, E., Caron, P., Lin, C., Murcko, M., Collett, M. 1997. Bovine 
viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor 
requirements, and molecular model of an enzyme essential for pestivirus 
replication. Journal o f Virology 71, 5312-5322.
213. Yang, H., Parkhouse, R. 1996. Phenotypic classification of porcine 
lymphocyte subpopulations in blood and lymphoid tissues. Immunology 89, 76-
83.
214. Yewdell, J.W. 2006. Confronting eomplexity: real world immunodominance 
in antiviral CD8  ^T eell responses. Immunity 25, 533-543.
214
215. Yewdell, J.W., Bennink, J.R. 1999. Immunodominance in major 
histocompatibility complex class I-restricted T lymphocyte responses. Annual 
Review o f Immunology 17, 51-88.
215
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
